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Summary 
Advances in psychiatric genetics are providing opportunities to investigate underlying 
pathogenic mechanisms. Rare loss of function (LoF) variants that have large effects 
on risk are of particular interest because they unequivocally implicate LoF of a single 
gene and are expected to have prominent phenotypic effects. The first LoF variants 
to be identified for schizophrenia were in the SETD1A gene. SETD1A catalyses 
methylation of lysine residue 4 on histone 3 (H3K4) and its pathogenic role is 
consistent with convergent evidence implicating disrupted H3K4 methylation in 
schizophrenia and other neurodevelopmental disorders. However, understanding of 
the biological mechanisms underlying the association between SETD1A LoF and 
psychopathology is lacking. This thesis investigated the functional consequences of 
Setd1a haploinsufficiency using a mouse model. 
Setd1a haploinsufficiency resulted in modest transcriptomic changes in the 
developing mouse brain that were enriched for mitochondrial annotations (Chapter 
3). However, there was no enrichment for schizophrenia common variant association. 
Additionally, placental weight was reduced in Setd1a+/- mice and sexually dimorphic 
changes in placental gene expression and postnatal growth were observed in 
Setd1a+/- males but not females (Chapter 4). 
Behavioural phenotyping revealed that constitutive Setd1a haploinsufficiency caused 
heightened emotional reactivity and aberrant sensorimotor gating (Chapter 5). The 
effects on sensorimotor gating were robust and could not be rescued by established 
antipsychotics (haloperidol and risperidone) (Chapter 6). However, male (but not 
female) Setd1a+/- mice showed an insensitivity to the startle-inhibiting effects of 
risperidone, potentially indicating 5-HT2A receptor dysfunction. Finally, behavioural 
phenotyping of a conditional knockout with Setd1a haploinsufficiency constrained to 
the nervous system revealed evidence for a degree of convergence with the 
constitutive model (Chapter 7). 
In conclusion, this thesis provides novel insights into the diverse effects of Setd1a 
haploinsufficiency. These findings warrant further investigation to establish the 
pathophysiological relevance of effects on the developing brain, placenta, and adult 
brain function. 
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Chapter 1: General Introduction 
1.1. Unmet clinical need of schizophrenia 
Schizophrenia is a chronically disabling and extremely distressing neuropsychiatric 
disorder. Mortality rates are high in people with schizophrenia, with a reduction in life 
expectancy of between 10 and 20 years (Chesney, Goodwin, & Fazel, 2014; Hjorthøj, 
Stürup, McGrath, & Nordentoft, 2017). High mortality in schizophrenia has been 
attributed to increased risk of suicide or medical conditions caused by poor lifestyle 
factors, such as heavy smoking, inadequate diet, and reduced physical activity 
(Laursen, Nordentoft, & Mortensen, 2014). Despite a relatively low prevalence 
(McGrath, Saha, Chant, & Welham, 2008), schizophrenia is ranked among the top 20 
causes of disability worldwide (Spencer et al., 2018). The economic burden of 
schizophrenia is substantial, both in terms of the direct costs of care (Mangalore & 
Knapp, 2007) and indirect costs caused by high levels of unemployment (Marwaha & 
Johnson, 2004), homelessness (Folsom et al., 2005), and loss of family caregiver 
work productivity (Mangalore & Knapp, 2007). Recent meta-analyses suggest that 
recovery rates are low; respectively, only 30 % and 13 % of people with first-episode 
and multi-episode schizophrenia meet criteria for recovery (Jääskeläinen et al., 2013; 
Lally et al., 2017). 
Symptoms of schizophrenia can be broadly classified into three categories; i) positive 
or psychotic (detachment from reality, comprising hallucinations and delusions), ii) 
negative (anhedonia, motivational deficits, and social withdrawal), and cognitive 
(impairments in executive function, attention, and memory) (Arango & Carpenter, 
2011). Onset typically occurs in late adolescence or early adulthood but is usually 
preceded by a prodromal phase characterised by less severe symptomatology 
(Lewandowski, Cohen, & Öngur, 2011; Lieberman et al., 2001). As with all other 
mental disorders, there are currently no clinically viable biomarkers or diagnostic tests 
for schizophrenia (Owen, Sawa, & Mortensen, 2016). Consequently, diagnosis relies 
on an assessment of symptom presentation and history, as outlined by the Diagnostic 
and Statistical Manual of Mental Disorders 5 (American Psychiatric Association, 
2013) and International Classification of Diseases (World Health Organization, 1993). 
However, it is being increasingly recognised that these discrete diagnostic categories 
do not accurately reflect the underlying pathophysiology or genetic architecture of 
psychiatric disorders, which may hinder research aimed at understanding their 
biology (Owen, 2014). The Research Domain Criteria initiative was developed in 
response to these limitations, with the aim of refocussing research efforts on 
2 
investigating the neurobiological substrates of continuous dimensions of 
psychopathology that span current diagnostic boundaries (Cuthbert, 2015). 
There are currently no disease-modifying treatments for schizophrenia (Millan et al., 
2016). Limited progress has been made in the development of new treatments since 
the original discovery of the therapeutic properties of highly specific D2 receptor 
antagonists, so called first-generation (typical) antipsychotics, over 60 years ago 
(Creese, Burt, & Snyder, 1976; Seeman, Lee, Chau-Wong, & Wong, 1976). Although 
second-generation (atypical) antipsychotics target a wider range of receptors, they 
share this fundamental mechanism of D2 receptor blockade (Kapur & Remington, 
2001). The purported advantages of atypical over typical antipsychotics are 
questionable (Cunningham Owens & Johnstone, 2018), with limited evidence for 
increased efficacy or tolerability due to adverse side-effects, such as motor 
disturbance, weight gain, and cardiometabolic symptoms (Geddes, Freemantle, 
Harrison, & Bebbington, 2000; Huhn et al., 2019; Leucht et al., 2013). Current 
antipsychotics are also ineffective for treating negative symptoms (Krause et al., 
2018) and cognitive symptoms (Buchanan, Freedman, Javitt, Abi-Dargham, & 
Lieberman, 2007), which are the most disabling (Bowie, Reichenberg, Patterson, 
Heaton, & Harvey, 2006; Rabinowitz et al., 2012). In addition, approximately 30 % of 
patients do not respond to antipsychotic treatment (Meltzer, 1997), of which between 
70 – 84 % are treatment resistant from illness onset (Demjaha et al., 2017; Lally et 
al., 2016). Thus, there is a great need for novel therapeutics that are based on a better 
understanding of pathogenic mechanisms.  
1.2. Neurobiology of schizophrenia 
A comprehensive understanding of the neurobiological underpinnings of 
schizophrenia remains elusive and the search for neuroimaging biomarkers to aid 
diagnosis is ongoing (Abi-Dargham & Horga, 2016; Fusar-Poli & Meyer-Lindenberg, 
2016). This section reviews current understanding of the neuroanatomical and 
functional brain changes that occur in schizophrenia. 
1.2.1. Neuroanatomical abnormalities 
A number of neuroanatomical changes have been consistently reported in 
schizophrenia. Post-mortem brain weight is consistently reduced in patients with 
schizophrenia (Harrison, Freemantle, & Geddes, 2003) and volumetric neuroimaging 
measures indicate that reduced overall brain volume and enlarged ventricles are 
recurrently observed (Steen, Mull, Mcclure, Hamer, & Lieberman, 2006). Large-scale 
meta-analyses of neuroimaging studies conducted by the ENIGMA consortium have 
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shown reduced grey matter volume in the cerebellum (Moberget et al., 2018), 
hippocampus, and several subcortical structures, including the amygdala, thalamus, 
and nucleus accumbens (van Erp et al., 2016). Moreover, decreased cortical 
thickness and surface area have also been reported, with largest effects in frontal and 
temporal cortices (van Erp et al., 2018). Post-mortem evidence implicates several of 
the same brain regions, with marked neuropathology in the dorsolateral prefrontal 
cortex (PFC), thalamus, and hippocampal formation (Harrison, 2008) that are thought 
to underlie abnormalities in functional connectivity (Harrison, 1999a). Whole-brain 
estimates of white matter integrity are also reduced in schizophrenia (Kelly et al., 
2018; Klauser et al., 2016), suggesting widespread structural dysconnectivity.  
Interpreting how these structural changes relate to pathophysiological mechanisms 
is challenging. Several studies show a moderating effect of cumulative antipsychotic 
medication on grey matter volume (Moncrieff & Leo, 2010; van Erp et al., 2016) and 
cortical thickness (van Erp et al., 2018) but not white matter integrity (Kelly et al., 
2018). These effects could also be attributed to natural disease progression, although 
a longitudinal study has shown that antipsychotic treatment (but not illness duration 
or severity) correlates with grey matter volume reductions over time (Fusar-Poli et al., 
2013). However, preclinical studies suggest that antipsychotics do not produce the 
hallmark neuropathological changes observed in schizophrenia (Harrison, 1999b). 
Some of the neuroanatomical alterations observed in chronic schizophrenia are 
present in unmedicated individuals with first-episode psychosis (Samartzis, Dima, 
Fusar-Poli, & Kyriakopoulos, 2014; Shah et al., 2017) and individuals at high genetic 
risk for schizophrenia (Fusar-Poli et al., 2011), possibly suggesting that these 
changes precede illness onset and may have a genetic basis. However, there is 
mixed evidence regarding whether common variant genetic risk for schizophrenia 
predicts changes in brain morphometry (van der Merwe et al., 2019). One study has 
shown that schizophrenia-associated copy number variants (CNVs) are associated 
with decreased volume of some of the subcortical regions previously shown to be 
reduced in schizophrenia (Warland, Kendall, Rees, Kirov, & Caseras, 2019). Thus, 
the extent to which neuroanatomical alterations reflect core aspects of schizophrenia 
pathogenesis and how these changes relate to psychopathology remains unknown. 
1.2.2. Functional brain alterations 
Functional magnetic resonance imaging (fMRI) studies have shown that patients with 
schizophrenia exhibit aberrant resting-state and task-related activity in several of the 
brain regions implicated by structural neuroimaging, including prefrontal, cingulate 
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and temporal cortices, hippocampus, striatum, thalamus, and cerebellum (McGuire, 
Howes, Stone, & Fusar-Poli, 2008). Meta-analyses of fMRI studies have shown 
reduced functional connectivity between these brain regions in schizophrenia (Dong, 
Wang, Chang, Luo, & Yao, 2018; Li et al., 2019), supporting the view that disruption 
of brain network dynamics contributes to pathogenesis (Friston, Brown, Siemerkus, 
& Stephan, 2016). However, there is a large degree of heterogeneity in the affected 
brain regions, effect sizes, and directionality of activity changes across studies, which 
could be due to differences in patient symptomatology and/or unreliable fMRI 
measures (Fröhner, Teckentrup, Smolka, & Kroemer, 2019).  
Findings from molecular imaging studies have yielded support for the prevailing 
theory of the neurochemical substrate of schizophrenia. The dopamine hypothesis 
initially proposed that elevated dopaminergic transmission was central to 
schizophrenia pathophysiology (Meltzer & Stahl, 1976). This theory has undergone 
several refinements since its conception, such that it now focuses on the role of 
dopamine dysregulation in the striatum in relation to positive symptoms (Howes & 
Kapur, 2009). The nature of this striatal dopaminergic dysfunction comprises 
increased presynaptic dopamine synthesis (Fusar-Poli & Meyer-Lindenberg, 2013) 
and elevated dopamine release (Abi-Dargham, van de Giessen, Slifstein, Kegeles, & 
Laruelle, 2009; Breier et al., 1997; Laruelle et al., 1996), with little evidence for 
differences in D2/D3 receptor density (Howes et al., 2012). Recent evidence suggests 
that these effects are larger in the dorsal than limbic striatum (McCutcheon, Beck, 
Jauhar, & Howes, 2018). These findings challenge the longstanding assumption of 
dopaminergic dysfunction in mesolimbic pathways, leading to the proposal that 
nigrostriatal dysfunction may contribute more to pathophysiology (McCutcheon, Abi-
Dargham, & Howes, 2019).  
The dopamine hypothesis has also been extended to explain cognitive symptoms of 
schizophrenia as a result of hypodopaminergic function in the PFC (Davis, Kahn, Ko, 
& Davidson, 1991). There is mixed evidence to support this hypothesis; a meta-
analysis of the molecular imaging literature suggests that differences in D1 receptor 
availability in the PFC of schizophrenia are inconclusive (Kambeitz, Abi-Dargham, 
Kapur, & Howes, 2014). Conversely, a subsequent study found evidence for deficient 
dopamine release following amphetamine challenge in the dorsolateral PFC of 
schizophrenia patients (Slifstein et al., 2015).  
Convergent evidence also implicates abnormal glutamatergic signalling in the 
pathophysiology of schizophrenia (Howes, McCutcheon, & Stone, 2015), particularly 
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in the hippocampus (Harrison, 2004). Glutamate binds to several receptors, including 
the N-methyl-D-aspartate (NMDA) receptor (Meldrum, 2000). Initial evidence for a 
pathophysiological role for NMDA receptor hypofunction was provided by preclinical 
studies showing that administration of NMDA receptor antagonists recapitulates 
neuropathological changes and behavioural endophenotypes of schizophrenia (Lee 
& Zhou, 2019; Olney & Farber, 1995). Moreover, NMDA receptor antagonists induce 
psychotic-like symptoms in healthy controls (Krystal et al., 1994; Lahti, Weiler, 
Michaelidis, Parwani, & Tamminga, 2001).  
There is also evidence that NMDA receptor hypofunction may be caused by a 
deficiency in D-serine levels. D-serine is the main co-agonist that binds to glycine 
modulatory sites on synaptic NMDA receptors and is required for receptor opening 
(Papouin et al., 2012). Reduced D-serine levels have been consistently reported in 
serum of schizophrenia patients (Cho, Na, Cho, & Kang, 2016). Moreover, decreased 
expression of the D-serine transporter in the PFC and cerebellum of schizophrenia 
patients has been suggested to reflect a compensatory mechanism for reduced 
synaptic availability of D-serine (Burnet et al., 2008a). Several lines of evidence 
suggest that D-amino acid oxidase (DAO) hyperactivity, an enzyme that metabolises 
D-serine, may contribute to NMDA receptor hypofunction in schizophrenia by 
reducing D-serine levels (Burnet et al., 2008b; Verrall, Burnet, Betts, & Harrison, 
2010). Two randomised-controlled trials indicate that DOA inhibitors show therapeutic 
potential in schizophrenia as adjunctive treatments (Lane et al., 2013; Lin et al., 2018) 
but several questions remain regarding their mechanism of action (Harrison, 2018).  
Neuroimmunological evidence also implicates the involvement of the NMDA receptor 
in schizophrenia pathogenesis (Coutinho, Harrison, & Vincent, 2014). Serum 
autoantibodies to the NMDA receptor have been reported in patients with first-episode 
psychosis (Lennox et al., 2017; Pathmanandavel et al., 2015; Scott et al., 2018; 
Steiner et al., 2013; Zandi et al., 2011) and psychosis is present in 67 % of patients 
with NMDA receptor antibody encephalitis (Al-Diwani et al., 2019). It has been 
suggested that this autoimmune response may contribute to pathogenesis by 
affecting NMDA receptor membrane trafficking (Jézéquel, Johansson, Leboyer, & 
Groc, 2018).  
A meta-analysis of proton magnetic spectroscopy studies has shown that levels of 
glutamatergic metabolites are elevated in the basal ganglia, thalamus, and medial 
temporal lobe in schizophrenia (Merritt, Egerton, Kempton, Taylor, & McGuire, 2016). 
This paradoxical increase in glutamatergic transmission is thought to be caused by 
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disinhibition of pyramidal neurons as a result of NMDA receptor hypofunction on 
inhibitory gamma-aminobutyric acid (GABA)-ergic interneurons (Cohen, Tsien, Goff, 
& Halassa, 2015; Homayoun & Moghaddam, 2007). Interestingly, striatal dopamine 
synthesis is negatively correlated with glutamate levels in the hippocampus (Stone et 
al., 2010) and anterior cingulate cortex (Jauhar et al., 2018) in the early stages of 
schizophrenia, suggesting downstream effects of dysregulated glutamatergic 
transmission on striatal dopaminergic function. Consistent with this, genetic ablation 
of the NMDA receptor subunit Grin1 in parvalbumin-positive GABAergic neurons 
leads to an enhancement and attenuation of amphetamine-induced dopamine 
release in the striatum and medial PFC, respectively (Nakao et al., 2019). These 
findings resemble the effects of amphetamine challenge observed in schizophrenia 
patients (Abi-Dargham et al., 2009; Breier et al., 1997; Laruelle et al., 1996; Slifstein 
et al., 2015) and support the hypothesis that dopaminergic dysfunction in 
schizophrenia is secondary to NMDA receptor hypofunction (Howes et al., 2015). 
A more general role for GABAergic dysfunction in schizophrenia (Lewis, Hashimoto, 
& Volk, 2005) is supported by post-mortem studies showing reduced PFC expression 
of the GABA-synthesising enzyme glutamic acid decarboxylase 67 (GAD67) in 
patients (Akbarian et al., 1995; Hashimoto et al., 2003; Volk, Austin, Pierri, Sampson, 
& Lewis, 2000). In addition, upregulation of GABAA receptors is consistently observed 
in post-mortem studies (Benes, Vincent, Marie, & Khan, 1996; Benes, Vincent, 
Alsterberg, Bird, & SanGiovanni, 1992), suggesting post-synaptic changes that 
compensate for deficient GABA synthesis. Molecular imaging studies have yielded 
inconsistent findings regarding whole-tissue GABA concentration and GABAA 
receptor availability (Egerton, Modinos, Ferrera, & McGuire, 2017). However, there is 
evidence from one study using a technique that directly measures GABA levels in the 
synapse for impaired GABA neurotransmission in the dorsolateral PFC of 
antipsychotic naïve schizophrenia patients (Frankle et al., 2015). Convergent 
evidence also implicates GABAergic dysfunction as contributing to hippocampal 
hyperactivity in schizophrenia (Heckers & Konradi, 2015), which has been suggested 
to lead to dysregulation of the dopamine system (Grace, 2016). Genetic evidence has 
shown convergence of schizophrenia CNVs on the GABAA receptor complex that is 
independent of an association with the NMDA receptor (Pocklington et al., 2015). 
Together, these findings suggest a primary role for GABAergic dysfunction in 
schizophrenia pathogenesis that is distinct from the effects of NMDA receptor 
hypofunction described above. 
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Serotonergic dysfunction has also been suggested to contribute to schizophrenia 
pathogenesis (Geyer & Vollenweider, 2008). Consistent with this, the hallucinogenic 
drugs lysergic acid diethylamide (LSD) and psilocybin induce psychomimetic states 
via agonism of the serotonin (5-HT) 2A receptor (Halberstadt & Geyer, 2011). 
Conversely, many atypical antipsychotics exhibit antagonistic effects at 5-HT2A 
receptors (Meltzer & Massey, 2011). The role of serotonergic dysfunction in 
schizophrenia pathogenesis is unclear and could involve modulation of midbrain 
dopaminergic projections to the limbic system and PFC (Abi‐Dargham, 2007) and/or 
functional interaction between the 5-HT2A receptor and metabotropic glutamate 
receptor 2 (González-Maeso & Sealfon, 2009). Post-mortem studies consistently 
report elevated 5-HT1A and reduced 5-HT2A receptor densities in frontal cortex 
(Burnet, Eastwood, & Harrison, 1996; Harrison, 1999c) and there is evidence for 
abnormal 5-HT2A receptor expression in cerebellum of schizophrenia patients 
(Eastwood, Burnet, Gittins, Baker, & Harrison, 2001). However, a schizophrenia-
associated polymorphism in the 5-HT2A receptor gene does not influence mRNA 
expression levels of this receptor in post-mortem cortical regions (Bray, Buckland, 
Hall, Owen, & O’Donovan, 2004). In addition, findings from molecular imaging studies 
demonstrating abnormal serotonergic transmission in schizophrenia are inconsistent 
(Selvaraj, Arnone, Cappai, & Howes, 2014).  
In summary, schizophrenia is associated with widespread neuroanatomical and 
functional alterations in several brain regions. The neurochemical substrates of 
functional alterations are complex and involve several interacting neurotransmitter 
systems that are not well understood. 
1.3. Schizophrenia aetiology 
The aetiology of schizophrenia is complex, comprising a myriad of environmental 
factors and genetic variants. Understanding how these factors interact to ultimately 
result in the emergence of psychopathology remains a major challenge for research 
(van Os et al., 2014). This section provides an overview of known environmental risk 
factors for schizophrenia and current understanding of the genetic architecture. 
1.3.1. Environmental risk factors 
Epidemiological studies have identified several sociodemographic factors that are 
associated with increased risk for schizophrenia (van Os, Kenis, & Rutten, 2010). For 
example, incidence of schizophrenia is higher in urban areas (Vassos, Pedersen, 
Murray, Collier, & Lewis, 2012). Several explanations for this relationship have been 
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proposed, including social stress and exposure to other putative environmental risk 
factors that are more common in urban areas (e.g., pollution, higher rates of infection 
transmission, and illicit drug use) (Kirkbride, Keyes, & Susser, 2018). Immigration has 
also been repeatedly linked with an increased risk of schizophrenia, particularly in 
ethnic minority groups (Jongsma, Turner, Kirkbride, & Jones, 2019; Selten, van der 
Ven, & Termorshuizen, 2019) and has been suggested to be mediated, in part, by the 
effects of social exclusion (Selten, van der Ven, Rutten, & Cantor-Graae, 2013). 
However, the underlying mechanisms linking these sociodemographic factors with 
risk of schizophrenia are poorly understood (Plana-Ripoll, Pedersen, & McGrath, 
2018). Moreover, the extent to which these associations reflect causal effects on 
schizophrenia risk is questionable due to the possibility of genetic confounding and 
reverse causation. 
Other environmental risk factors for schizophrenia that occur during early life are 
thought to increase risk by influencing brain development during sensitive periods 
(Owen, O’Donovan, Thapar, & Craddock, 2011). The human brain undergoes 
protracted development throughout early life, characterised by profound 
neurogenesis and neuronal migration in utero, followed by gliogenesis, myelination, 
and synaptogenesis later in gestation and extending into childhood, and extensive 
synaptic pruning during late childhood and adolescence (Silbereis, Pochareddy, Zhu, 
Li, & Sestan, 2016). Several prenatal risk factors for schizophrenia have been 
identified, including nutritional insufficiency (Brown & Susser, 2008; Xu et al., 2009), 
maternal stress (Khashan et al., 2008; van Os & Selten, 1998) and infection (Brown 
& Derkits, 2010; Khandaker, Zimbron, Lewis, & Jones, 2013), and obstetric 
complications (Cannon, Jones, & Murray, 2002). The causative nature of these 
relationships is supported by animal studies showing that many neurobiological and 
behavioural endophenotypes of schizophrenia are recapitulated by prenatal stressors 
(Meyer & Feldon, 2010). Childhood trauma is also linked with increased risk for 
schizophrenia (McGrath et al., 2017; Varese et al., 2012). Although the complexities 
of childhood adversity are difficult to model in vivo, maternal deprivation and isolation 
rearing are widely used developmental models of schizophrenia (Fone & Porkess, 
2008; Marco et al., 2015). Cannabis use during adolescence has also been 
suggested to increase risk for schizophrenia (Mustonen et al., 2018) and this is 
supported by animal models (Renard, Rushlow, & Laviolette, 2016). However, a 
genetic predisposition for schizophrenia also increases the likelihood of cannabis use 
(Power et al., 2014), which may suggest some degree of genetic confounding. 
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1.3.2. Genetic architecture 
Preliminary evidence that genetic factors contribute to schizophrenia liability was 
provided by twin studies showing that up to 80 % of the variance in liability is explained 
by genetic variance (Sullivan, Kendler, & Neale, 2003). Progress in understanding the 
genetic architecture of schizophrenia was initially slow, with many findings from 
linkage and candidate gene studies not being reproducible (Farrell et al., 2015). 
Recent advances in genomic technologies and formation of international consortia, 
notably the Psychiatric Genomics Consortium (Sullivan et al., 2018), have enabled 
the large-scale studies that are needed to detect genetic variants at stringent 
genome-wide significance levels (Bray & O’Donovan, 2018). It is hoped that these 
genetic discoveries will provide insights into the biology of schizophrenia, ultimately 
facilitating the development of more effective treatments (Harrison, 2015a).  
1.3.2.1. Common variants 
Genome-wide association studies (GWASs) compare single nucleotide 
polymorphism (SNP) arrays between cases and controls, enabling an unbiased 
investigation of genomic regions associated with schizophrenia risk. These studies 
have confirmed the highly polygenic nature of schizophrenia, involving the 
contribution of many SNPs that are common in the population (frequency > 5 %). To 
date, 145 risk loci have been robustly associated with schizophrenia (Pardiñas et al., 
2018; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), 
some of which corroborate the involvement of dopaminergic (DRD2) and 
glutamatergic (GRIN2A, GRIA1, GRM3, and SRR) mechanisms, and implicating 
voltage-gated calcium channels (CACNA1C, CACNB2, and CACNA1I) in 
pathogenesis. However, the DRD2 risk allele does not affect mRNA levels in post-
mortem striatum (Toste et al., 2019), raising questions about the pathophysiological 
mechanism underlying this association. 
It is predicted that several thousand common variants contribute to schizophrenia risk 
(Ripke et al., 2013) and that the number of SNPs that reach genome-wide significance 
will increase as sample sizes become larger. Individual SNPs have a small effect on 
risk (odds ratio < 1.2) but cumulatively account for 23 % of the variance in 
schizophrenia liability (Cross-Disorder Group of the Psychiatric Genomics 
Consortium, 2013). Such SNP heritability estimates are considerably lower than 
heritability estimates from twin studies, which is thought to reflect non-additive genetic 
effects (epistasis), gene-environment interactions, and the contribution of rare 
variants (Maher, 2008).  
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There is a high degree of overlap in common variants associated with schizophrenia 
and other neuropsychiatric disorders, particularly bipolar disorder and major 
depressive disorder (Brainstorm Consortium, 2018; Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013; International Schizophrenia Consortium, 
2009). This genetic pleiotropy reflects clinical overlap and has important implications 
for understanding pathophysiology (O’Donovan & Owen, 2016). Pathway analysis of 
common variant association for schizophrenia, bipolar disorder, and major depressive 
disorder has shown enrichment for genes involved in histone methylation, synaptic 
signalling, and immune and neurotrophic factors (Network and Pathway Analysis 
Subgroup of Psychiatric Genomics Consortium, 2015). Notably, the strongest 
association across all three disorders was observed for histone methylation and this 
remained significant when data were analysed separately for schizophrenia.  
Recent evidence, perhaps surprisingly, suggests that common variant risk for 
schizophrenia also affects placental function (Ursini et al., 2018). The placenta 
mediates maternal-foetal nutrient transfer and is a source of endocrine signals that 
are essential for prenatal development (Bronson & Bale, 2016; Jansson & Powell, 
2007). Interestingly, polygenic risk for schizophrenia predicts the occurrence of 
obstetric complications and schizophrenia common variants that are differentially 
expressed in the placenta following early-life complications are enriched for metabolic 
and cellular stress pathways (Ursini et al., 2018). Obstetric complications are 
generally regarded as an environmental risk factor for schizophrenia (Cannon et al., 
2002). However, these findings may suggest that this relationship might be an indirect 
consequence of genetic risk for schizophrenia and raise the possibility that genetic 
risk for schizophrenia has pathogenic effects on in utero brain development by 
affecting placental function. 
Uncovering molecular insights into pathogenesis from common variant association is 
challenging (Harrison, 2015b). Linkage disequilibrium of SNPs within a GWAS 
discovery locus means that there are several potential candidate genes that could be 
responsible for the signal at a given locus. Moreover, most SNPs are in non-coding 
regions of the genome, suggesting that these risk variants impact on regulation of 
gene expression by altering regulatory element sequences (Bray, 2008). Elucidating 
the functional consequences of these non-coding SNPs requires integration with 
functional genomics data and consideration of potential cell-type specific effects 
operating at particular points in development (Bray & Hill, 2016; Sullivan & 
Geschwind, 2019). 
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Work is ongoing to generate brain-specific functional genomics data for this purpose 
(PsychENCODE Consortium, 2018). Initial findings indicate an over-representation of 
schizophrenia risk loci in foetal brain regulatory elements (de la Torre-Ubieta et al., 
2018; Hannon et al., 2016; Li et al., 2018; O’Brien et al., 2018; Won et al., 2016), 
suggesting a role for common variants in neurodevelopmental processes. Consistent 
with this, patterns of differential DNA methylation observed in PFC of patients with 
schizophrenia are enriched for genes with neurodevelopmental roles and CpG sites 
at which DNA methylation changes occur during foetal brain development (Pidsley et 
al., 2014). In addition, single-cell transcriptomics approaches have revealed 
enrichment for striatal medium spiny neurons, cortical interneurons, and cortical and 
hippocampal pyramidal neurons in the adult brain (Skene et al., 2018), particularly 
excitatory neurons (Li et al., 2018; Wang et al., 2018).  
1.3.2.2. Rare variants 
1.3.2.2.1. Copy number variants 
CNVs are structural variants (i.e., chromosomal deletions or duplications) that range 
in size from 1 kb to several megabases (Malhotra & Sebat, 2012). Many benign CNVs 
are present throughout the human genome (Sebat et al., 2004). Pathogenic CNVs 
are rare (< 1 % frequency) but tend to be large (> 500 kb), gene-rich, and occur de 
novo at recurrent genomic locations via non-allelic homologous recombination (Kirov, 
2015). 11 CNVs have been robustly linked with risk of schizophrenia, including 5 
duplications (1q21.1, 7q11.23, 15q11.2-q13.1, 16p13.1, and proximal 16p11.2) and 
6 deletions (22q11.2, 1q21.1, 2p16.3, 3q29, 15q11.2, and 15q13.3) that have a 
substantial effect on liability (odds ratios 2 - 60) (Rees et al., 2014a). 8 of these CNVs 
meet criteria for genome-wide significance in the largest study to date (Marshall et 
al., 2017). The burden of large CNVs in schizophrenia is increased even after 
exclusion of known schizophrenia CNVs (Rees et al., 2014b), suggesting that 
additional, as yet unidentified, CNVs contribute to schizophrenia.  
Schizophrenia-associated CNVs also increase risk for other neurodevelopmental 
disorders, such as autism spectrum disorders and developmental delay, with greater 
penetrance (Kirov et al., 2014). It is important to note that these CNVs are not fully 
penetrant, with recent evidence highlighting that common variants play a role in 
determining phenotypic expression (Bergen et al., 2019; Tansey et al., 2016). 
Nevertheless, all CNVs that increase risk for schizophrenia are associated with 
cognitive impairment, even in individuals without a neuropsychiatric diagnosis 
(Kendall et al., 2019a). It has been suggested that the relative enrichment of 
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deleterious CNVs across neurodevelopmental and neuropsychiatric disorders reflects 
the degree of neurodevelopmental aberration and consequent cognitive impairment 
(Owen & O’Donovan, 2017). Consistent with this, the burden of large CNVs in 
neuropsychiatric disorders with less of a neurodevelopmental component, such as 
bipolar disorder (Green et al., 2016) and depression (Kendall et al., 2019b), is lower 
than for schizophrenia. In addition, there is an increased burden of CNVs associated 
with intellectual disability in schizophrenia (Rees et al., 2016). 
With the exception of deletions at 2p16.3 which selectively affect the NRXN1 gene, 
all CNVs encompass multiple genes (Kirov, 2015). Generating mechanistic insights 
from CNVs therefore requires a pathway analysis approach to identify whether the 
genes hit by CNVs are over-represented in particular biological processes. In a 
landmark study, Kirov et al. (2012) demonstrated that genes in de novo CNV loci are 
enriched for the post-synaptic density. Moreover, this effect was principally driven by 
genes encoding the NMDA receptor complex and, to a lesser extent, activity-
regulated cytoskeleton-associated protein. These findings are consistent with prior 
hypotheses regarding NMDA receptor hypofunction in schizophrenia and support a 
pathophysiological role for aberrant synaptic plasticity (Hall, Trent, Thomas, 
O’Donovan, & Owen, 2015; Harrison & Owen, 2003; Harrison & Weinberger, 2005). 
Subsequent work in a larger sample replicated the over-representation of genes in 
schizophrenia-associated CNVs in the NMDA receptor complex and provided the first 
genetic evidence that GABAA receptors play an independent role in schizophrenia 
pathogenesis (Pocklington et al., 2015). Interestingly, enrichment was also observed 
for neurodevelopmental processes (e.g., abnormal neural plate morphology and 
neuronal differentiation). 
1.3.2.2.2. Loss of function variants 
Recent advances in next generation sequencing technologies have facilitated gene 
discovery efforts aimed at the identification of rare point mutations, such as single 
nucleotide variants and insertions or deletions (indels), that are highly penetrant for 
schizophrenia and, consequently, extremely rare in the population (< 0.1 %). Unlike 
SNPs and CNVs, rare variants identified by whole exome sequencing unequivocally 
implicate a single protein-coding gene and the functional consequence of the 
mutation for gene function can be determined more easily. The majority of exome 
sequencing studies have not been powered to detect specific variants at exome-wide 
significance but have shown an increased burden of protein-altering mutations in 
schizophrenia (Genovese et al., 2016; Singh et al., 2017) that are enriched for 
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synaptic signalling (Curtis, Coelewij, Liu, Humphrey, & Mott, 2018; Fromer et al., 
2014; Purcell et al., 2014), voltage-gated calcium and sodium channels (Purcell et al., 
2014; Rees et al., 2019), and histone modifications (Curtis, 2016).  
De novo loss of function (LoF) variants in the SETD1A (SET Domain Containing 1A) 
gene were first reported in two schizophrenia cases (Takata et al., 2014). Subsequent 
work confirmed the pathogenic contribution of SETD1A LoF variants in the largest 
exome sequencing study of schizophrenia to date (Singh et al., 2016). The effect size 
of SETD1A LoF was high (odds ratio = 37.6), with mutations being observed in 10 out 
of 7,776 schizophrenia cases (4 of which occurred de novo), whereas only 2 were 
observed in 58,404 controls. Several of the SETD1A LoF carriers had impaired 
intellectual functioning and 6 additional carriers (2 de novo) were observed in children 
with a range of neurodevelopmental phenotypes, suggesting a role for SETD1A LoF 
in neurodevelopmental disorders more generally. Consistent with this, recent 
evidence also implicates de novo mutations in SETD1A in language disorders (Eising 
et al., 2019) and epilepsy (Yu et al., 2019).  
In the Singh et al. (2016) paper, LoF variants were distributed throughout the SETD1A 
gene (Figure 1.1) but all occurred before the catalytic SET domain (exons 16 - 19). 
Notably, 7 of these variants were the same two-base deletion at the exon 16 splice 
acceptor site. Transfecting this variant into a human cell line was associated with 
reduced expression of a fused GFP reporter, which was shown using Sanger 
sequencing to be a result of aberrant splicing leading to a premature stop codon and 
truncated protein. The remaining LoF variants were either stop-gain mutations, splice 
acceptor site point mutations, or frameshifting indels that are predicted to lead to 
haploinsufficiency.  
 
Figure 1.1. Summary of SETD1A LoF mutations observed in schizophrenia and 
other neurodevelopmental disorders. Taken from Singh et al. (2016). 
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1.3.2.3. Summary of genetic findings 
In summary, the genetic architecture of schizophrenia is highly polygenic, comprising 
a large number of common variants (SNPs) with small, but cumulative, effects on risk, 
and several CNVs that are rare in the population but increase risk considerably. 
These have led to several important mechanistic insights regarding schizophrenia 
pathogenesis and a better understanding of genetic pleiotropy with other 
neuropsychiatric and neurodevelopmental disorders. Exome sequencing is starting 
to identify highly damaging, rare LoF variants in specific genes (SETD1A) with 
predictable effects on gene function (haploinsufficiency) that have considerable 
potential for investigating pathogenic mechanisms using model systems. 
1.4. SETD1A: utility for disease modelling 
SETD1A is an attractive candidate for disease modelling for several reasons. First, 
the LoF mutations observed in human carriers are predicted to cause 
haploinsufficiency, which can be recapitulated in model systems to investigate 
biologically relevant mechanisms contributing to pathogenesis. Second, SETD1A LoF 
mutations are highly penetrant and, consequently, haploinsufficiency is expected to 
have substantial phenotypic effects, making it a biologically tractable target. Finally, 
SETD1A encodes a subunit of a histone methyltransferase complex involved in 
methylation of lysine residue 4 on histone 3 (H3K4) (see section 1.4.4). The 
convergence of common and rare variants on H3K4 methylation may suggest that 
studying SETD1A could serve as a window into more general biological pathways 
underlying pathogenesis.  
1.4.1. Histone modifications 
Nucleosomes are the repeating unit making up chromatin, each comprising 146 bp of 
DNA wrapped around a histone octamer with two of each histone protein (H2A, H2B, 
H3, and H4) (Kornberg & Lorch, 1999). Histones are highly conserved proteins, 
comprising a globular domain, which interacts with other histones and DNA to form 
the nucleosome, and protruding N-terminal tails (Luger, Mäder, Richmond, Sargent, 
& Richmond, 1997). Post-translational modifications of histone tails, such as 
methylation, acetylation, phosphorylation, and ubiquitylation, change higher-order 
chromatin structure by affecting interactions between histones and DNA within a 
nucleosome or between histones of adjacent nucleosomes (Kouzarides, 2007). 
Histone modifications are broadly classified as either activating (correlated with 
euchromatin formation and gene expression) or repressive (correlated with 
heterochromatin formation and gene silencing) (Bannister & Kouzarides, 2011). The 
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observation that distinct histone modifications correlate with gene expression 
prompted the proposal that these modifications form the basis of a histone code that 
lead to the recruitment of transcriptional regulators affecting gene expression (Strahl 
& Allis, 2000).  
1.4.2. H3K4 methylation 
H3K4 methylation is generally considered an activating histone mark on the basis that 
broad H3K4 methylation peaks are observed at regions of euchromatin (Noma, Allis, 
& Grewal, 2001). There are three types of H3K4 methylation: mono- (H3K4me1), di- 
(H3K4me2), and tri-methylation (H3K4me3). These marks are all found at 
transcription start sites of active genes (Barski et al., 2007; Ernst et al., 2011). H3K4 
methylation marks serve as binding sites for ‘reader’ enzymes that bring about 
downstream changes (e.g., chromatin remodelling and recruitment of transcription 
factors) that lead to transcriptional activation (Ruthenburg, Allis, & Wysocka, 2007). 
For example, Transcription factor II D recognises and binds H3K4me3, illustrating its 
role as a docking site for transcription initiation (Vermeulen et al., 2007). The different 
forms of H3K4 methylation are also differentially distributed throughout the genome, 
with enhancers showing enrichment of H3K4me1 (Heintzman et al., 2007; 2009), 
whereas promoters are marked with H3K4me2 and H3K4me3 (Kim et al., 2005; 
Mikkelsen et al., 2007).  
H3K4 methylation is a labile epigenetic mark that can be removed by lysine 
demethylases (KDMs). There are 6 mammalian KDMs that have been shown to 
remove H3K4 methylation (Hyun, Jeon, Park, & Kim, 2017), providing an additional 
layer of regulatory complexity. Interestingly, H3K4 methylation co-occurs with the 
repressive H3K27 mark at bivalent domains in embryonic stem cells (ESCs), which 
is thought to keep genes involved in differentiation in a “poised” state, permitting rapid 
transcriptional activation by removal of the repressive mark (Bernstein et al., 2006). 
It is important to note, however, that the causative role of H3K4 methylation in 
transcriptional activation has recently been questioned (Howe, Fischl, Murray, & 
Mellor, 2017), raising the possibility that these marks are a consequence of gene 
expression. 
1.4.3. H3K4 methylation in the brain 
The work described above suggesting a role for H3K4 methylation in transcriptional 
activation has mostly been conducted in cell lines. Similar findings have been 
reported in post-mortem human brain tissue, with positive correlations between levels 
of promoter H3K4me3 and mRNA levels (Huang & Akbarian, 2007; Stadler et al., 
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2005). Notably, H3K4me3 peaks in PFC are enriched for genes involved in putative 
biological mechanisms of schizophrenia, such as glutamatergic and dopaminergic 
transmission (Dincer et al., 2015). Moreover, reduced H3K4me3 has been reported 
at the Gad1 promoter in post-mortem brain of schizophrenia patients (Huang et al., 
2007), which may contribute to previously described GABAergic dysfunction. Single-
cell analysis has shown that neuronal H3K4me3 peaks are enriched for schizophrenia 
common variant association (Girdhar et al., 2018), suggesting a degree of molecular 
convergence between common and rare variant genetic risk. Consistent with this, 
knockdown of SETD1A in a human neuroblastoma cell line leads to transcriptomic 
changes that are enriched for schizophrenia common variants (Cameron, Blake, 
Bray, & Hill, 2019).  
The landscape of H3K4 methylation in human brain undergoes dramatic remodelling 
during the early years of life (Cheung et al., 2010; Shulha, Cheung, Guo, Akbarian, & 
Weng, 2013), implicating an important role for dynamic regulation of H3K4 
methylation in neurodevelopment (Roidl & Hacker, 2014). Indeed, mutations in many 
other genes from the H3K4 methyltransferase gene family (KMT2) and readers and 
erasers of H3K4 methylation have been linked with a variety of neurodevelopmental 
disorders and intellectual disability (Vallianatos & Iwase, 2015). Based on these 
findings, it might be predicted that SETD1A LoF causes disturbed neurodevelopment 
with downstream consequences for later brain function that contribute to the 
emergence of psychopathology. 
In addition to its role in neurodevelopment, changes in H3K4 methylation contribute 
to adult brain function. Animal studies have shown that knockout of KMT2A (Gupta et 
al., 2010; Kerimoglu et al., 2017) and KMT2B (Kerimoglu et al., 2013; Kerimoglu et 
al., 2017) cause memory impairments. Both of these genes are involved in regulating 
H3K4me3 in the hippocampus at promoters of learning-associated genes (Collins, 
Sweatt, & Greer, 2019). KMT2A is also involved in regulating H3K4me3 in the 
hippocampus and anterior cingulate cortex during memory retrieval (Webb et al., 
2017). In addition, conditional knockout of KMT2A in the PFC or ventral striatum 
causes deficient synaptic plasticity (Jakovcevski et al., 2015; Shen et al., 2016). 
These findings illustrate the involvement of H3K4 methylation in biological processes 
underlying learning and memory and suggest that the link between SETD1A LoF and 
cognitive impairment might involve similar pathogenic mechanisms. 
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1.4.4. SETD1A biochemical function 
SETD1A (also known as KMT2F) is a member of the KMT2 family of genes that 
specifically catalyse H3K4 methylation. In mammals, this gene family contains five 
other KMTs: KMT2A (MLL1), KMT2B (MLL2), KMT2C (MLL3), KMT2D (MLL4), and 
KMT2G (SETD1B) (Shilatifard, 2008). Each of these enzymes contain a 130-140 
amino acid SET (Suppressor of variegation 3-9 (Su(var)3-9), Enhancer of zeste 
(E(z)), and Trithorax) domain that catalyses the transfer of methyl groups from the 
cofactor S-adenosylmethionine to H3K4 in non-redundant COMPASS (Complex 
Proteins Associated with Set1) complexes (Miller et al., 2001). There are five common 
subunits observed in all COMPASS complexes (ASH2L, RBBP5, WDR5, DPY30, and 
HCFC1) plus complex-specific subunits; in the SETD1A complex, these are CXXC1 
and WDR82 (Shilatifard, 2012).  
The SETD1A complex is capable of catalysing H3K4me1, H3K4me2, and H3K4me3 
(Lee & Skalnik, 2005). However, knockdown of SETD1A in ESCs results in reduced 
bulk H3K4me3, without affecting levels of H3K4me1 or H3K4me2 (Wu et al., 2008). 
The genomic targeting of H3K4me3 by the SETD1A complex involves coordinated 
activity of the CXXC1 and WDR82 subunits. The CXXC1 subunit of the SETD1A 
complex recognises non-methylated CpG islands, restricting H3K4 methylation 
activity of the SETD1A complex to euchromatin regions (Clouaire et al., 2012; Tate, 
Lee, & Skalnik, 2010). The deposition of H3K4me3 at transcription start sites by the 
SETD1A complex is facilitated by the WDR82 subunit, which is bound to the RNA 
recognition motif of SETD1A and recruits the complex to the Ser-5 phosphorylated 
C-terminal domain of RNA polymerase II, which is associated with transcription 
initiation (Lee & Skalnik, 2008).  
1.4.5. Setd1a and embryonic development 
Homozygous knock-out of Setd1a is embryonically lethal (Bledau et al., 2014), 
highlighting its essential role in embryogenesis. However, its precise role remains 
unclear with one study suggesting that it is necessary for inner cell mass formation in 
the blastocyst (Fang et al., 2016), while another suggests that it is required during 
gastrulation, after inner cell mass formation (Bledau et al., 2014). Setd1a plays a role 
in maintenance of ESC pluripotency through its interaction with Oct4, leading to 
H3K4me3 at the promoters of Oct4 target genes (Bledau et al., 2014; Fang et al., 
2016). This interaction may be mediated indirectly through Uhrf1, which binds with 
both Setd1a and Oct4 to maintain H3K4me3 at bivalent domains in ESCs, particularly 
at the promoters of genes involved in specifying neuroectodermal lineages (Kim et 
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al., 2018). Ablation of the catalytic SET domain in ESCs is associated with impaired 
differentiation but has no effect on self-renewal (Sze et al., 2017). These findings 
suggest that the aforementioned role of Setd1a in ESC maintenance does not depend 
on its methyltransferase activity but that this is critical for cell-fate specification during 
differentiation. 
There is also evidence to suggest that Setd1a plays a role in placental function. 
Knockdown of Setd1a in mouse ESCs leads to transcriptomic changes that are 
enriched for placental development (Fang et al., 2016). Moreover, Setd1a expression 
is reduced in the mouse placenta following a prenatal high-fat diet (Gabory et al., 
2012), a manipulation that is associated with schizophrenia endophenotypes in 
animal models (Sullivan, Riper, Lockard, & Valleau, 2015). These findings suggest 
that Setd1a LoF may exert pathogenic effects by influencing placental function during 
prenatal development. 
1.4.6. Setd1a and neurogenesis 
Embryonic neurogenesis involves the asymmetric division of neuronal progenitor 
cells (NPCs) in the ventricular zone of the developing telencephalon to produce two 
daughter cells: a self-renewing NPC and a differentiating cell that will terminally 
differentiate into a post-mitotic neuron (Paridaen & Huttner, 2014). This asymmetric 
division is essential for maintaining a sufficient pool of NPCs for the production of the 
vast number of neurons of manifold subtypes and at the right stage of development. 
A role for Setd1a in neurogenesis is supported by evidence for impaired proliferation 
of NPCs in primary cultures derived from Setd1a deficient mice (Bledau et al., 2014). 
Subsequent work has shown that Setd1a is recruited by the histone chaperone HIRA 
to deposit H3K4me3 at the promoter of the β-catenin gene, leading to increased β-
catenin expression and NPC self-renewal (Li & Jiao, 2017). β-catenin is a component 
of the canonical Wnt signalling pathway that regulates cell-fate decisions (Zechner et 
al., 2003). Li and Jiao (2017) also report that knockdown of Setd1a results in 
premature neuronal differentiation and a reduction in markers of NPC proliferation in 
the embryonic mouse brain. Setd1a is also recruited by Nap1|1 to deposit H3K4me3 
at the promoter of RassF10, which has a similar effect on maintaining NPC 
pluripotency (Qiao et al., 2018). Together, these findings provide convergent 
evidence for a role for Setd1a in regulating the balance between NPC proliferation 
and differentiation, suggesting that perturbations to this balance may play a role in 
pathogenic mechanisms of Setd1a LoF in neurodevelopmental disorders. 
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1.4.7. Summary: current understanding of Setd1a function 
Setd1a is a promising candidate for investigating schizophrenia pathogenesis 
because it implicates LoF of a single gene of large effect that can be recapitulated in 
model systems. Convergent evidence supports a role for disrupted H3K4 methylation 
in schizophrenia and other neurodevelopmental disorders, a process that is important 
for neurodevelopment and brain function. Setd1a is known to be essential for prenatal 
development, with strong evidence to support a role in embryonic neurogenesis and 
suggestive evidence for a role in placental function. However, very little is known 
about the precise biological mechanisms underlying the association between Setd1a 
LoF and risk for psychopathology. 
1.5. Thesis aims 
The aim of this thesis was to investigate the functional consequences of Setd1a 
haploinsufficiency using a mouse model to reproduce the predicted effects of LoF 
variants on gene function in human carriers. An integrative approach was adopted to 
assess the effects of Setd1a LoF on; i) behavioural endophenotypes of relevance to 
schizophrenia and other neurodevelopmental disorders, and ii) candidate pathogenic 
mechanisms, spanning prenatal development and adult brain function. The specific 
aims of each chapter were as follows: 
 Chapter 3: assess the regulatory role of Setd1a in the embryonic mouse brain 
using RNA-seq to determine transcriptomic changes in a constitutive 
heterozygous knockout mouse line (Setd1a+/-). 
 Chapter 4: investigate effects of Setd1a haploinsufficiency on the placenta 
(i.e., placental weight and gene expression) and growth curves of Setd1a+/- 
mice. 
 Chapter 5: perform a comprehensive behavioural characterisation of the 
Setd1a+/- mouse line (i.e., anxiety, activity levels, sensorimotor gating, motoric 
functioning, and object recognition memory). 
 Chapter 6: determine whether sensorimotor gating impairments observed in 
Setd1a+/- mice in Chapter 5 can be rescued using antipsychotics with different 
pharmacological profiles to probe underlying neurochemical mechanisms. 
 Chapter 7: explore the extent to which behavioural effects of Setd1a 
haploinsufficiency observed in Chapter 5 are attributable to effects in the 
nervous system alone using a Nestin-Cre driver to create a conditional 
knockout. 
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Chapter 2: General Methods 
2.1. Animal lines 
2.1.1. Knockout strategy 
Heterozygous Setd1a knockout mice were generated using a 'knockout-first' strategy, 
as shown in Figure 2.1 (Skarnes et al., 2011). This approach combines the Flp/FRT 
and Cre-LoxP systems to create a reporter-tagged allele with conditional potential. 
C57BL/6NTac-Setd1atm1a(EUCOMM)Wtsi/WtsiCnrm knockout-first mice were produced by 
EUCOMM. The tm1a allele was created by insertion of a FRT-flanked LacZ/neomycin 
reporter cassette into the intronic region between exons 3 and 4 of the Setd1a gene, 
disrupting gene function by splicing to the LacZ cassette. In addition, a critical exon 
present in all transcript variants (i.e., exon 4) was flanked by LoxP sites, conferring 
conditional knockout potential. The tm1a allele was converted to a conditional (tm1c) 
allele by crossing Setd1atm1a mice with a FlpO driver line, leading to excision of the 
LacZ/neomycin cassette and restoration of gene function. Mice heterozygous for the 
‘floxed' Setd1atm1c allele were generated and supplied by the Mary Lyon Centre (MRC 
Harwell) and subsequently crossed with a Cre driver line. Recombination and deletion 
of the floxed exon by Cre recombinase causes a frameshift mutation in the deleted 
(tm1d) allele, resulting in loss of Setd1a function via nonsense mediated decay. 
 
Figure 2.1. Depiction of the ‘knock-out first’ strategy used to generate the 
heterozygous Setd1a knockout mouse. A: The LacZ/neomycin cassette in the 
tm1a allele disrupts gene function. B: Removal of the LacZ/neomycin cassette by Flp 
recombinase restores gene function and converts the tm1a allele into a conditional 
tm1c allele. C: Excision of the floxed exon by Cre recombinase causes a frameshift 
mutation, leading to nonsense mediated decay of the tm1d allele. Adapted from: 
https://www.mousephenotype.org/data/genes/MGI:2446244. 
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2.1.2. Animal husbandry 
Offspring were separated from their mothers on postnatal day 28 and an ear biopsy 
collected for genotyping. Mice were subsequently group housed (2-5 per cage) in 
single sex cages containing the same environmental enrichment and were cleaned 
out weekly. Standard chow and water were available ad libitum in home cages. 
Temperature- (21 + 2 °C) and humidity- (50 + 10 %) regulated holding rooms were 
maintained on a 12-hour light-dark cycle (lights on from 08:00-20:00). All procedures 
were conducted in accordance with the requirements of the UK Animals (Scientific 
Procedures) Act 1986 (PPL 30/3375). 
2.2. Genotyping 
2.2.1. DNA extraction  
Tissue biopsies were digested in lysis buffer (0.1 M Tris-HCl pH 8.5, 5 mM EDTA pH 
8.0, 0.02 % SDS, 0.2 M NaCl) containing either 100 μg/mL (ear biopsies) or 200 
μg/mL (embryo biopsy) Proteinase K (Promega, UK) at 55 °C overnight. Samples 
were centrifuged at 13,000 rpm for 10 minutes to pellet debris and the supernatant 
was transferred to a sterile Eppendorf. Samples were treated with an equal volume 
of phenol (Sigma, UK) to purify nucleic acids, thoroughly mixed by shaking for 10 
minutes, centrifuged at 13,000 rpm for 10 minutes and the upper aqueous phase 
transferred to a new Eppendorf. An equal volume of ice-cold isopropanol (Thermo-
Fisher Scientific, UK) was added to all samples and mixed thoroughly to precipitate 
DNA. DNA was pelleted by centrifugation at 13,000 rpm for 10 minutes at 4 °C. The 
supernatant was removed and the pellet was washed in 70 % (v/v) ethanol. Samples 
were vortexed briefly to resuspend the pellet and centrifuged at 13,000 rpm for 5 
minutes. Following removal of the supernatant, the pellet was left to air dry and then 
resuspended in TE buffer (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0). Samples were 
stored at -20 °C until required. 
2.2.2. PCR 
Animals were genotyped using two separate PCRs to identify the presence of the 
mutant Setd1a allele and the Cre transgene. Tables 2.1 and 2.2 show the contents 
for the mutant Setd1a and Cre PCR reactions, respectively. The cycling conditions 
for the Setd1a PCR were; i) 94 °C for 15 minutes, ii) 94 °C for 30 seconds, iii) 60 °C 
for 30 seconds, iv) 72 °C for 60 seconds, v) repeat ii-iv 34 times, vi) 72 °C for 2 
minutes. The cycling conditions for the Cre PCR were; i) 95 °C for 10 minutes, ii) 94 
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°C for 30 seconds, iii) 51.7 °C for 30 seconds, iv) 72 °C for 60 seconds, v) repeat ii-iv 
34 times, vi) 72 °C for 2 minutes. 
Table 2.1. PCR reaction contents for the mutant Setd1a PCR. 
Reagent Volume per reaction (μL) 
10 X PCR buffer (Qiagen, UK) 2.0 
dNTPs (10 mM) 0.4 
Forward primer (20 μM) 
AATGATAGCGGCTCCCCAAT 1.0 
Mutant reverse primer (20 μM) 
GAACTTCGGAATAGGAACTTCG 1.0 
WT reverse primer (20 μM) 
GAGACAAGACAGAGCCGAGT 1.0 
Hot Start Taq DNA polymerase (Qiagen, UK) 0.2 
DNA template 1.0 
Nuclease-free H2O 13.4 
 
Table 2.2. PCR reaction contents for the Cre PCR. 
Reagent Volume per reaction (μL) 
10 X PCR buffer (Qiagen, UK) 3.0 
dNTPs (10 mM) 0.6 
Cre forward primer (20 μM) 
GCGGTCTGGCAGTAAAAACTATC 1.5 
Cre reverse primer (20 μM) 
GTGAAACAGCATTGCTGTCACTT 1.5 
Internal control forward primer (20 μM) 
CTAGGCCACAGAATTGAAAGATCT 1.5 
Internal control reverse primer (20 μM) 
GTAGGTGGAAATTCTAGCATCATCC 1.5 
Hot Start Taq DNA polymerase (Qiagen, UK) 0.2 
DNA template 2.0 
Nuclease-free H2O 18.2 
 
Following completion of the reaction, an appropriate volume of 5X DNA loading buffer 
(Bioline, UK) was added to PCR products. 20 μL of each reaction and 4 μL of 100 bp 
HyperladderTM (Bioline, UK) were loaded onto an agarose gel (3.0 % or 1.5 % for Cre 
and Setd1a PCRs, respectively), which was then run at 100 V for 50 minutes. The gel 
was visualised under ultraviolet light following separation of the DNA. Mice 
heterozygous for the Setd1a mutant allele were identified by the presence of a mutant 
band at 143 bp and a WT band at 204 bp (Figure 2.2A). The presence of the Cre 
transgene was indicated by a band at 100 bp (Figure 2.2B).  
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Figure 2.2. Examples of the mutant Setd1a and Cre PCRs. A) Amplification of wild 
type Setd1a (204 bp) and mutant Setd1a (143 bp). B) Amplification of the Cre 
transgene (100 bp) and internal control gene (324 bp). 
An additional PCR was used to identify the presence of the Setd1atm1d allele to 
demonstrate correct recombination and deletion of the floxed exon. The cycling 
conditions and reaction contents were identical to the Setd1a mutant PCR except for 
the primers; a forward primer was located in the selection cassette 
(AAGGCGCATAACGATACCAC) and two reverse primers, one in the LoxP site 
(ACTGATGGCGAGCTCAGACC) and the other in the floxed exon 
(GAGACAAGACAGAGCCGAGT). The 174 bp amplicon from the forward primer and 
LoxP site primer is specific to the tm1d allele because the product is too large for 
amplification in the tm1c allele (Figure 2.3). In addition, a 259 bp band from the 
forward primer and floxed exon reverse primer will only be observed in the tm1c allele 
because this region is excised from the tm1d allele following recombination.  
 
Figure 2.3. Example of Setd1atm1d PCR. Amplification of deleted Setd1a allele at a 
band size of 174 bp. 
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2.2.3. Embryonic sex determination 
Embryo sex was determined by a multiplex PCR for a Y-linked family of genes (Ssty) 
and an autosomal control gene (Om1a). Table 2.3 shows the PCR reaction contents. 
The PCR conditions for the reaction were; i) 94 °C for 10 minutes, ii) 94 °C for 45 
seconds, iii) 61 °C for 45 seconds, iv) 72 °C for 45 seconds, v) repeat ii-iv 34 times, 
vi) 72 °C for 5 minutes. Gels were visualised as described above. A single band at 
245 bp (Om1a) indicated female sex and an additional band at 343 bp (Ssty) indicated 
male sex (Figure 2.4). 
Table 2.3. PCR reaction contents for the sex determination PCR. 
Reagent Volume per reaction (μL) 
10 X PCR buffer (Qiagen) 2.5 
MgCl2 (25 mM) 2.0 
dNTPs (10 mM) 0.5 
Ssty forward primer (10 μM) 
CTGGAGCTCTACAGTGATGA 1.0 
Ssty reverse primer (10 μM) 
CAGTTACCAATCAACACATCAC 1.0 
Om1a forward primer (40 μM) 
TTACGTCCATCGTGGACAGCAT 0.25 
Om1a reverse primer (40 μM) 
TGGGCTGGGTGTTAGTCTTAT 0.25 
Hot Start Taq DNA polymerase (Qiagen) 0.25 
DNA template 1.0 
Nuclease-free H2O 16.25 
 
 
Figure 2.4. Example of the sex determination PCR. Amplification of the autosomal 
control gene Om1a (245 bp) and Y-linked gene family Ssty (343 bp).  
2.3. Behavioural methods 
Animals were handled daily for at least seven days prior to behavioural testing. 
Testing started when the animals were 8 weeks old. All animals underwent 
behavioural tests in the order described here. The time of day that each test was 
conducted was counterbalanced across genotypes. 
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2.3.1. Elevated plus maze 
The elevated plus maze (EPM) was constructed from white Perspex. The apparatus 
comprised four arms (19 x 8 cm) arranged in the shape of a cross. Two of the 
opposing arms were open platforms extending outwards from the centre of the 
apparatus (‘open arms’). The other two opposing arms were enclosed by opaque, 15 
cm high walls (‘closed arms’). The maze was elevated 50 cm from the floor and evenly 
illuminated by a 60 watt lamp positioned above the apparatus and oriented upwards. 
Mice were placed in the same closed arm at the beginning of the trial and allowed to 
freely explore the apparatus for five minutes. A camera was positioned above the 
maze and connected to a computer to record each trial. Ethovision software (Version 
XT, Noldus, Netherlands) was used to track the animals’ position in the maze (track 
rate = 17 frames per second), which was divided into five virtual zones; two open 
arms, two closed arms, and the central region. Measures of anxiety were the 
proportion of time spent on either of the open arms (relative to the amount of time 
spent on either of the closed arms), latency of first entry onto an open arm, and the 
number of entries onto the open arms summed across each arm.  
2.3.2. Open field test 
The open field test (OFT) was conducted under the same conditions as the EPM. The 
apparatus comprised a square-shaped arena (75 cm x 75 cm) with 45 cm high walls 
constructed from white Perspex. Animals were placed in the same corner of the arena 
and allowed to freely explore for ten minutes. The arena was subdivided into two, 
concentric virtual zones in Ethovision software for tracking: the central 60 cm x 60 cm 
region ('inner zone') and the surrounding 15 cm ('outer zone'). The amount of time 
spent in the inner zone, the number of entries into the inner zone, and the latency of 
first entry into the inner zone were calculated as indices of anxiety.  
2.3.3. Locomotor activity 
Locomotor activity levels were assessed using clear Perspex boxes (21 x 36 x 20 cm) 
fitted with two transverse infrared beams. The beams were equally spaced (0.3 cm 
from either end of the box) and positioned 0.1 cm from the floor of the box. The 
apparatus was connected to a computer and the number of beam breaks during the 
120 minute sessions were recorded in 30 minute quartiles using a custom programme 
(BBC BASIC Version 6). Activity levels were assessed in the dark and at the same 
time of day over three consecutive days. The primary outcome measures were; i) 
spontaneous activity levels (i.e., number of beam breaks) in a novel environment and 
27 
ii) habituation to a novel environment, indicated by a reduction in activity levels over 
time both within a session and across consecutive days.  
 
2.3.4. Sensorimotor gating 
Acoustic startle response (ASR) and prepulse inhibition (PPI) were measured in a 
single test session using apparatus from SR-Lab (San Diego Instruments, USA). Mice 
were placed in a clear Perspex tube (35 mm diameter) mounted on a Perspex plinth 
in a sound-attenuating chamber. A 70 dB (A scale) white noise stimulus was 
continuously played during the whole session via a loudspeaker positioned 12 cm 
above the tube. Each session started with a five minute habituation period. This was 
followed by two blocks of acoustic stimuli with an average intertrial interval of 16 
seconds (pseudorandomly varied between 6 and 24 seconds). In block 1, 6 pulse-
alone trials were presented at 120 dB above background, followed by 7 additional 
pulse-alone trials interspersed with 18 prepulse trials (either 4 dB, 8 dB or 16 dB 
above background, 6 of each prepulse amplitude) and three no stimulus trials. Three 
additional no stimulus trials were presented at the end of the block. In block 2, a range 
of pulse alone trials were presented (80 – 120 dB in 10 dB increments), with three 
trials of each amplitude in a pseudorandom order with two no stimulus trials at the 
end of the block. Each pulse-alone trial consisted of a 40 ms acoustic startle stimulus. 
Prepulse trials comprised a 20 ms acoustic prepulse stimulus followed by a 40 ms 
acoustic startle stimulus 80 ms after prepulse offset.  
The whole-body startle response on each trial was detected by a piezoelectric sensor 
attached to the plinth, which transduced flexion in the plinth into a digitised signal. 
The average startle response (Vavg) was recorded in arbitrary startle units using SR-
Lab software over the 65 ms period following stimulus onset. Startle data were weight-
adjusted by dividing Vavg by body weight. PPI was calculated as the percentage 
reduction in startle amplitude between prepulse and pulse alone trials (excluding the 
first 3 pulse-alone trials).  
2.3.5. Rotarod performance test 
Motor coordination and motor learning were assessed using the Rotarod performance 
test (Ugo Basile, Italy). The apparatus comprised a circular rod (6 cm diameter) 
coated with rubber grooves. Mice were placed on the rotating rod, which was 
suspended 16 cm above levers that triggered a timer to stop and record the latency 
to fall on each trial. Motor learning was assessed across five accelerating trials lasting 
300 seconds each (three trials on day one and two trials the next day). On each 
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accelerating trial, the speed of rotation increased from 5 rpm to 50 rpm at a constant 
rate of 0.15 rpm per second. Motor coordination was assessed on day two at 10 fixed 
rotation speeds. Mice completed two 120 second trials at each speed (20 trials in 
total). The speed of rotation increased across the test session in 5 rpm increments 
from 5 rpm to 50 rpm. 
2.3.6. Novel object recognition 
Recognition memory was assessed using the novel object recognition paradigm. 
Testing was conducted under dimmed lighting in a white Perspex arena (30 x 30 cm) 
with 30 cm high walls. Ethovision software was used to manually code object 
exploration (defined as when the head was within 2 cm of and oriented towards the 
object) using the keyboard. Prior to testing, mice were habituated to the empty arena 
for 10 minutes per day over three consecutive days to overcome anxiety associated 
with being in a novel environment and promote object exploration.  
Each test session comprised three phases. First, mice were refamiliarised to the 
empty arena for 10 minutes (‘habituation phase’). Second, two identical objects were 
placed in diagonally opposite quadrants of the arena (10.5 cm from the corners) and 
mice explored the objects for up to 15 minutes (‘acquisition phase’). To control for 
differences in propensity to explore the objects that could contribute to subsequent 
memory performance, the total amount of object exploration was timed during the trial 
by the experimenter. The trial was ended once 40 seconds of object exploration had 
been reached. Finally, the ‘test phase’ was conducted after a retention interval of 
either 30 minutes or 24 hours (within-subjects). Mice were placed back in the arena 
for 5 minutes with one of the objects that the animals had been exposed to during 
acquisition (‘familiar’) and another object that had not been encountered previously 
(‘novel’). The objects were presented in the same locations as the acquisition phase 
and object exploration was recorded.  
At least 24 hours elapsed between the mice being re-tested at the other retention 
interval. For the second test session, different objects that had not been encountered 
previously were placed in the quadrants of the arena that were unoccupied in the 
previous session. The order of the retention interval, location of the objects, and 
allocation of objects to retention interval were counterbalanced.  
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2.4. Molecular methods 
2.4.1. Timed-matings and dissections 
Pairings were always set up in the late afternoon. For embryonic timepoints, males 
were separated from females early the following morning and females were inspected 
for a vaginal plug to confirm mating. Pregnant dams were culled by cervical 
dislocation and either whole heads (E11.5) or whole brains (E13.5 and E18.5) were 
dissected. For postnatal timepoints, day of birth was designated as postnatal day zero 
(P0). Animals were culled by cervical dislocation and dissected tissue was snap 
frozen using dry ice and stored at -80 °C until required. 
2.4.2. RNA extraction 
Tissue was homogenized in an appropriate volume of TRI reagent (Sigma, UK) using 
Lysing Matrix D tubes (MP Biomedicals, UK). Homogenisation was performed three 
times for 10 seconds at 6 m/second in a Fast Prep 120 Homogeniser (Thermo Fisher 
Scientific, UK). Samples were centrifuged for 10 minutes at 13,000 rpm to pellet 
debris and the supernatant was transferred to a fresh RNase-free Eppendorf. RNA 
was extracted and DNase treated according to manufacturer’s instructions using a 
Direct-zolTM RNA Miniprep kit (Zymo, UK). RNA purity was assessed using a 
NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, UK). RNA 
concentration was quantified using a QubitTM RNA HS Assay Kit and Qubit 2.0 
Fluorometer (Invitrogen, UK). Samples were stored at -80 °C until required. 
2.4.3. cDNA synthesis 
RNA to cDNA conversion was performed using RNA to cDNA EcoDryTM Premix 
(double-primed) kits (Clontech, UK). 1 μg RNA per sample was reverse transcribed 
according to manufacturer's instructions. cDNA was diluted 1:10 in nuclease-free 
water and stored at -20 °C until required. 
2.4.4. RT-qPCR 
Intron-spanning primers (annealing temperature = 58 °C) were designed for Setd1a 
and three housekeeping genes (Hprt, Dynein, and B2m; Table 2.4). Samples were 
run in triplicate and the same biological replicate was used for amplification of Setd1a 
and all three housekeeping genes. A nuclease-free water no-template control was 
included on each run. The contents of each 25 μL reaction were: 12.5 μL 2X SensiMix 
SYBR No-ROX (Bioline, UK), 1.75 μL forward primer, 1.75 μL reverse primer, 5.0 μL 
template, 4.0 μL nuclease-free H2O. Reactions were performed using a Corbett Rotor 
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Gene 6000 Real-Time PCR Machine with the following conditions; i) 95 °C for 10 
minutes, ii) 95 °C for 20 seconds, iii) 58 °C for 20 seconds, iv) 72 °C for 20 seconds, 
v) repeat ii-iv 39 times. Subsequently, melt curves were generated by heating the 
reaction from 50-99 °C in 1 °C increments. These were inspected to confirm a single 
PCR product for each primer pair. The threshold cycle (Ct) was calculated at an Rn 
of 0.3 for all RT-qPCR reactions. 
RT-qPCR data were analysed using the 2-ΔΔCT method. First, data were averaged 
across the triplicates for each sample. Second, expression data were normalised to 
the internal control genes by calculating the geometric mean of the three 
housekeeping genes and subtracting this value from the Ct value for Setd1a for each 
sample. These ΔCt values were used for statistical analysis. Third, 2-ΔCT values were 
calculated and used to calculate fold-change expression for visualisation (2-ΔΔCT) by 
subtracting the average 2-ΔCT for the reference condition from the other conditions.  
Table 2.4. RT-qPCR primer sequences and target product sizes for Setd1a and three 
housekeeping genes (Hprt, Dynein, and B2m).  
Target Forward primer Reverse primer Product size (bp) 
Setd1a CCCTCCCGGTTCCTAAGTTT CATTGTCATTGAGCCTCGCA 90 
Hprt GCGATGATGAACCAGGTTATGA GCCTCCCATCTCCTTCATGA 146 
Dynein GACCTCAGGCTCAGACGAAGAC AAGACGCTCATGGCATCACA 116 
B2m TTCTGGTGCTTGTCTCACTGA CAGTATGTTCGGCTTCCCATTC 104 
 
2.4.5. Protein extraction 
Protein extraction was performed on ice to prevent protein degradation. Tissue was 
homogenised using Lysing Matrix D tubes (MP Biomedicals, UK) in an appropriate 
volume of sample buffer, comprising RIPA buffer (Sigma, UK) with one cOmpleteTM 
Mini Protease Inhibitor Cocktail tablet (Roche, Switzerland) per 10 mL of buffer. 
Homogenisation was performed three times for 10 seconds at 6 m/second in a Fast 
Prep 120 Homogeniser (Thermo Fisher Scientific, UK). Protein concentration was 
quantified in triplicate for each sample using a PierceTM BCA Protein Assay kit 
(Thermo Scientific, UK) according to manufacturer’s instructions. Samples were 
diluted to 1 μg/μL in sample buffer and treated with 1 % (v/v) Benzonase Nuclease 
(Millipore, UK) to digest nucleic acids. Samples were stored at -80 °C in 50 μL aliquots 
to reduce the number of freeze-thaw cycles. 
2.4.6. Western blotting 
Samples were defrosted on ice and an equal volume of 2X protein loading buffer (LI-
COR, UK) containing 0.05 % (v/v) 2-Mercaptoethanol (Sigma, UK) was added. 
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Samples were heated at 95 °C for 5 minutes to denature proteins. 20 μg of each 
protein sample and 5 μL Odyssey Protein Molecular Weight Marker (LI-COR, UK) 
were loaded onto a NuPAGETM 4-12 % Tris-Acetate gel (Invitrogen, UK). Proteins 
were separated by SDS-PAGE in NuPAGETM Tris-Acetate SDS Running Buffer 
(Invitrogen, UK) at 120 V for 2 hours at room temperature. Proteins were then 
transferred to a 0.45 μm pore size nitrocellulose membrane (Invitrogen, UK) at 70 V 
for 3 hours on ice in NuPAGETM Transfer Buffer (Invitrogen, UK) containing 10 % 
methanol (Fisher Scientific, UK). 
All incubation steps were performed with agitation. Following transfer, the membrane 
was stained for protein using a REVERTTM Total Protein Stain Kit (LI-COR, UK) and 
then blocked in Odyssey TBS Blocking Buffer (LI-COR, UK) for 60 minutes at room 
temperature. The membrane was incubated overnight at 4 °C in primary rabbit 
polyclonal Setd1a antibody (Bethyl Laboratories, USA), diluted 1:1,000 in blocking 
buffer containing 0.2 % (v/v) Tween 20 (Sigma, UK). Following primary antibody 
incubation, the membrane was washed four times in TBS-T (1M NaCl, 1M Tris-HCl 
pH 7.5, 0.2 % (v/v) Tween 20) for five minutes. The membrane was then incubated 
for one hour at room temperature in IRDye 800CW goat anti-rabbit secondary 
antibody (LI-COR, UK), diluted 1:10,000 in blocking buffer containing 0.2 % (v/v) 
Tween 20. Finally, four additional wash steps were performed in TBS-T.  
Membranes were imaged using an Odyssey CLx imaging system (LI-COR, UK). 
Average background-subtracted fluorescence was measured at 700 nm (total protein) 
and 800 nm (Setd1a) using Image Studio software (LI-COR, UK). Relative Setd1a 
protein abundance was quantified using total protein normalisation. The lane 
normalisation factor was calculated by dividing the total protein signal for each lane 
by the lane with the highest total protein signal. The normalised signal for Setd1a was 
calculated for each lane by dividing the signal for the Setd1a band (268 kDa) by the 
lane normalisation factor. These normalised values were used for analysis and 
calculating fold-change values for visualisation. 
2.5. Data analysis 
All data were analysed using IBM SPSS software (version 25) with the exception of 
the RNA-seq data (Chapter 4). Data are presented as mean and standard error of the 
mean (SEM) unless otherwise specified. Data were analysed using analysis of 
variance (ANOVAs) with the between-subjects factors of genotype and sex, with 
additional factors as required (see relevant chapters for details). 
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Chapter 3: Investigating transcriptomic changes in the developing brains of 
Setd1a+/- mice 
3.1. Introduction 
In this chapter, the regulatory role of Setd1a in the developing mouse brain was 
examined using RNA-seq. This work was conducted to assess the effects of Setd1a 
haploinsufficiency on biological processes during prenatal brain development that 
could be important for understanding pathogenic mechanisms. 
The neurodevelopmental hypothesis of schizophrenia posits that disrupted brain 
development is integral to pathogenesis (Murray & Lewis, 1987; Weinberger, 1987). 
Consistent with this, common variants for schizophrenia are highly expressed in the 
prenatal brain (Birnbaum et al., 2015; Clifton et al., 2019; Jaffe et al., 2018). Moreover, 
foetal brain expression quantitative trait loci are enriched for schizophrenia common 
variants (O’Brien et al., 2018). These findings suggest a degree of convergence of 
genetic risk for schizophrenia on biological processes taking place during early brain 
development. Dynamic regulation of histone modification, particularly H3K4 
methylation, is thought to be critical for the precise coordination of extensive changes 
in gene expression that are essential for cell-fate specification and migratory 
processes that occur during neurodevelopment (Roidl & Hacker, 2014; Shen, Shulha, 
Weng, & Akbarian, 2014). Indeed, mutations in several genes involved in the addition, 
reading, and removal of H3K4 methylation cause a range of neurodevelopmental 
disorders (Vallianatos & Iwase, 2015). Thus, one mechanism by which Setd1a loss 
of function could serve to increase risk for psychopathology is due to perturbed 
neurodevelopment as a result of aberrant H3K4 methylation and associated 
transcriptional dysregulation. 
A role for Setd1a in neurodevelopment has been reported previously. Specifically, 
knockdown of Setd1a has been shown to result in reduced proliferation of neuronal 
progenitor cells (NPCs) in vitro (Bledau et al., 2014), suggesting a role for Setd1a in 
maintenance of NPC pluripotency. Further evidence to support this is provided by in 
vivo evidence that Setd1a knockdown causes increased neurogenesis and a 
reduction in markers of NPC proliferation in the embryonic mouse brain (Li & Jiao, 
2017). These findings suggest that Setd1a loss of function may cause premature 
differentiation and, consequently, a depleted supply of NPCs. Adult Setd1a+/- mice 
have fewer pyramidal neurons in cortical layers 2 and 5 and reduced inhibitory 
neurons in layer 5 of the medial prefrontal cortex (Mukai et al., 2019). These changes 
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may be attributed to the aforementioned imbalance between proliferation and 
differentiation of NPCs that occurs as a result of Setd1a loss of function. 
Two previous studies have investigated the effects of Setd1a loss of function on the 
transcriptome in neural tissue. A 50 % reduction in Setd1a dosage has been shown 
to cause changes in expression of over 1,000 genes in a neuroblastoma cell line 
(Cameron et al., 2019). These transcriptional changes were enriched for 
schizophrenia common variants and gene annotations relating to metabolism, 
peptidase regulator activity, and cell adhesion. Interestingly, several of the 
differentially expressed genes (e.g., Dlx5 and Dcx) are known to play a role in 
neurodevelopment. In another study, approximately 300 differentially expressed 
genes were identified by RNA-seq of adult prefrontal cortex of Setd1a+/- mice (Mukai 
et al., 2019). However, the biological relevance of these changes and their overlap 
with other genetic variants for schizophrenia remains unclear. In addition, the effect 
of Setd1a loss of function on the transcriptome of the developing brain has not been 
investigated previously. 
The aim of this chapter was to assess transcriptomic changes in the developing brains 
of Setd1a+/- mice. The trajectory of Setd1a expression in the brain was examined 
across neurodevelopment (from E11.5 to P56), revealing highest expression around 
mid-gestation (section 3.3.1). Based on these results, RNA-seq was performed on 
E13.5 whole brain. This is a period of substantial neurogenesis, coinciding with the 
commencement of the formation of cortical layer 5 neurons (Finlay & Darlington, 
1995). Differentially expressed genes were assessed for enrichment of gene ontology 
(GO) annotations and schizophrenia common variants to investigate over-
representation in biological pathways and the degree of convergence with other 
molecular mechanisms conferring risk for schizophrenia, respectively. 
3.2 Methods 
3.2.1. Trajectory of Setd1a expression across neurodevelopment 
Timed-matings and dissections were conducted as described in Chapter 2.4.1. Whole 
brains (E11.5, E13.5 and E18.5) or hemibrains (P7, P23 and P56) were obtained from 
F1 progeny of C57BL/6J x C57BL/6NTac parents. Tissue was obtained from at least 
two separate litters per timepoint.  
RNA extraction, cDNA synthesis, and RT-qPCR were conducted as described in 
Chapter 2.4.2-2.4.3 to examine Setd1a mRNA expression levels (N = 6 per 
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timepoint). Protein extractions and Western blotting were conducted as described in 
Chapter 2.4.5-2.4.6 to examine SETD1A protein levels (N = 5 per timepoint). 
3.2.2. Generation of the model 
As described in Chapter 2.1.1, a “knock-out first” strategy was used to generate 
Setd1a heterozygous knockout mice. Although the tm1a allele disrupts gene function, 
it is necessary to remove the LacZ/neomycin cassette to eliminate potential 
confounding effects of these constructs (Coleman et al., 2015). Expression of LacZ 
in the central nervous system results in neuropathological changes and behavioural 
impairments (Reichel et al., 2016). Moreover, insertion of a neomycin cassette can 
disrupt expression of other genes more than 100 kb from the insertion (Pham, 
MacIvor, Hug, Heusel, & Ley, 1996). Therefore, mice heterozygous for the Setd1atm1c 
allele were crossed with a homozygous B6.C-Tg(CMV-cre)1Cgn/J line (referred to as 
'CMV-Cre'), purchased from The Jackson Laboratory. Cre recombinase is expressed 
constitutively in the CMV-Cre line under the control of the human cytomegalovirus 
promoter. This results in recombination and deletion of the floxed exon in all tissues 
(including germline cells), leading to a frameshift mutation in the deleted (tm1d) allele 
and loss of Setd1a function via nonsense mediated decay of the mutant transcript. 
Cre recombinase has been reported to have excitotoxic effects as a result of DNA 
damage (Loonstra et al., 2001), possibly arising from recombination at cryptic LoxP 
sites in the genome (Thyagarajan, Guimarães, Groth, & Calos, 2000). On this basis, 
a breeding strategy was devised that enabled elimination of the Cre transgene from 
experimental cohorts. F1 progeny from male Setd1atm1c and female CMV-Cre pairings 
were genotyped to identify animals that were positive for the tm1d (deleted) allele. 
Transgenic F1 males were then crossed with wild type C57BL/6J females purchased 
from Charles River. Since the Cre transgene is X-linked, all F2 male progeny were 
negative for the Cre transgene. Experimental cohorts were generated by pairing F2 
male Setd1a+/- mice with wild type C57BL/6J females to eliminate effects of Setd1a 
loss of function on maternal contributions to prenatal environment and maternal care.  
3.2.3. Model validation 
To confirm whether approximately 50 % knockdown of Setd1a had occurred in the 
constitutive heterozygous model, RT-qPCR (N = 16; 8 WT and 8 KO) was performed 
on cDNA derived from E13.5 whole brain (see Chapter 2.4.2-2.4.3). As described 
earlier, the tm1d allele is still transcribed following recombination by Cre recombinase. 
Therefore, a primer pair that included the deleted exon was designed in order to be 
sensitive to detect changes at the transcript level (i.e., the sequence of the reverse 
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primer was complementary to exon 4). In addition, SETD1A protein levels in E13.5 
whole brain (N = 10; 5 WT and 5 KO) were examined using Western blot (see Chapter 
2.4.5-2.4.6).  
3.2.4. RT-qPCR and Western blot data analysis 
The 2-ΔΔCT method was used to calculate ΔCt values (see Chapter 2.4.4). Normalised 
Western blot data were calculated as described in Chapter 2.4.6. To assess changes 
in Setd1a expression across neurodevelopment, between-subjects ANOVAs (age: 6 
levels) were used followed by Tukey post-hoc tests. Confirmation of Setd1a 
knockdown in Setd1a+/- mice was tested using independent t-tests. 
3.2.5. RNA-seq 
3.2.5.1. RNA extraction and quality control 
RNA was extracted from 16 (8 WT and 8 KO, balanced for sex) E13.5 whole brains 
using a Direct-zolTM RNA Miniprep kit (Zymo, UK). E13.5 was chosen based on the 
results of the developmental expression work, which showed highest expression 
levels at this timepoint (see section 3.3.1). RNA purity was assessed using a 
NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, UK). RNA 
concentration was quantified using a QubitTM RNA High Sensitivity Assay Kit and 
Qubit 2.0 Fluorometer (Invitrogen, UK). RNA integrity was assessed using a 
Bioanalyzer RNA 6000 Nano Assay (Agilent, UK) and 2100 Bioanalyzer system 
(Agilent, UK). All samples had an RNA Integrity Number of at least 9.7. 
3.2.5.2. Library preparations and sequencing 
Library preparations were performed using a KAPA mRNA Hyperprep kit (Roche, 
Switzerland) according to manufacturer’s instructions, with 1 µg total RNA as input. 
Following library amplification, fragment size (mean = 374.9, SD = 12.5) was 
determined using a High Sensitivity DNA kit (Agilent, UK). A QubitTM dsDNA High 
Sensitivity Assay Kit (Invitrogen, UK) was used to determine library concentration. 
Libraries were adjusted prior to pooling to achieve a final DNA molarity of 20 nM. 
Sequencing was performed on a HiSeq 4000 (Illumina, USA) with 75 bp paired-end 
reads at a read depth of 30 million reads. 
3.2.5.3. Analysis pipeline 
Reads were trimmed to remove adapters and low-quality bases using Trimmomatic 
(Bolger, Lohse, & Usadel, 2014) with default parameters. All samples passed quality 
control implemented in FastQC (Andrews, 2010). Reads were mapped to the mouse 
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reference genome (GRCm38) using STAR (Dobin et al., 2013). The mean number of 
reads mapped was 97.2 % (SD = 0.5 %). Read counts were generated using 
featureCounts (Liao, Smyth, & Shi, 2014) to allocate reads to genomic features using 
the mouse Ensembl gene annotation (GRCm.38.95). Coverage at exon 4 of Setd1a 
was substantially reduced in Setd1a+/- E13.5 brain, indicating that recombination had 
occurred (Figure 3.1). Differential expression analysis was performed using DEseq2 
(Love, Huber, & Anders, 2014) implemented in R (version 3.5.3). The Benjamini 
Hochberg correction was used to correct for multiple testing and identify genes that 
were differentially expressed in Setd1a+/- relative to WT (padj < .05), with sex included 
as a covariate. 
 
Figure 3.1. Read alignment at the critical exon of Setd1a. Screenshot from 
Integrative Genomics Viewer showing substantially more reads aligning to exon 4 in 
A) WTs compared to B) Setd1a+/- mice.  
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3.2.5.4. Gene ontology enrichment analysis 
GO term enrichment analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (Huang, Sherman, & Lempicki, 2009). Only 
protein-coding genes with entrez IDs (219 genes) were included in the differentially 
expressed gene-set. A custom background gene-set was created using all expressed 
genes in the dataset (12,295 genes). This was defined as any gene with a FPKM > 1 
across 8 samples (i.e., the number of biological replicates in each condition). 
3.2.5.5. Schizophrenia common variant gene set enrichment analysis 
The differentially expressed gene-set was filtered to include only genes with human 
entrez IDs (205 genes). This gene-set was assessed for enrichment of schizophrenia 
common variants using MAGMA (de Leeuw, Mooij, Heskes, & Posthuma, 2015) with 
GWAS summary data from 40,675 cases and 65,643 controls (Pardiñas et al., 2018). 
SNPs were filtered to include those with a minor allele frequency of greater than 0.01. 
Annotation of SNPs to genes was performed using an annotation window of 35 kb 
upstream and 10 kb downstream of each gene. The gene-set analysis function in 
MAGMA performs a linear regression, testing whether the association of the 
phenotype with genes in the gene-set is greater than with genes that are not in the 
gene-set (controlling for gene size, gene density, and linkage disequilibrium). 
3.3. Results 
3.3.1. Trajectory of Setd1a expression across neurodevelopment 
Analysis of the RT-qPCR data revealed a significant main effect of age (F(5, 30) = 
11.65, p < .001; Figure 3.2A). Post-hoc tests showed that expression levels were 
significantly higher at E11.5 than all other timepoints (all p < .002) except at E13.5 (p 
= .26). Expression levels at E13.5 were not significantly different from E18.5 (p = .32) 
or P7 (p = .08) but were significantly higher than at P23 (p = .003) and P56 (p = .02). 
There was no further significant decline in expression levels after E18.5 (all p > .33).  
Similar results were obtained at the protein level: a significant main effect of age was 
observed (F(5, 24) = 6.78, p < .001; Figure 3.2B), which reflected significantly 
increased expression at E11.5 and E13.5 relative to postnatal timepoints (all p <. 02). 
No significant difference was observed between E11.5 and E13.5 or E18.5 (both p > 
.60). Consistent with the RT-qPCR data, expression levels did not change after E18.5 
(all p > .17). Together, these data suggest that Setd1a expression levels are higher 
in the developing brain during (mid) gestation, followed by down-regulation in the 
postnatal brain. 
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Figure 3.2. Developmental trajectory of Setd1a expression in the brain. Mean 
(+/- SEM) fold-change expression (relative to E11.5) of A) Setd1a mRNA and B) 
SETD1A protein abundance across embryonic and postnatal brain development. 
3.3.2. Model validation 
Setd1a mRNA expression in E13.5 brain was reduced by 48.7 % in Setd1a+/- mice 
compared to WTs (t(14) = 9.19 p < .001; Figure 3.3A). Consistent with this, levels of 
SETD1A protein were reduced by 46.3 % (t(8) = 2.71 p = .03; Figure 3.3B). This 
magnitude of reduction is consistent with haploinsufficiency and confirms that Setd1a 
knockdown was successfully achieved.  
 
Figure 3.3. Confirmation of Setd1a haploinsufficiency in brains of Setd1a+/- mice 
at E13.5. Mean (+/- SEM) fold-change expression (relative to WT) of A) Setd1a 
mRNA and B) SETD1A protein abundance. 
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3.3.3. RNA-seq 
3.3.3.1. Differential expression 
Principal components analysis of differentially expressed genes showed that the 
samples clustered by genotype on principal component 1 (Figure 3.4A). This 
component accounted for the highest proportion of variance across samples (67.5%). 
There were 267 genes (Benjamini Hochberg padj < .05) that were differentially 
expressed (234 downregulated and 33 upregulated; Appendix 1) in brains of Setd1a+/- 
mice at E13.5 (Figure 3.4B). Modest changes in gene expression were observed, with 
log2 fold changes ranging from -0.63 to 1.19. Hierarchical clustering based on 
normalised read counts was performed using Morpheus 
(https://software.broadinstitute.org/morpheus) to produce a dendrogram (Figure 
3.4C). This showed that samples of the same genotype clustered together, 
suggesting similar patterns of gene expression changes within each group.  
3.3.3.2. Gene ontology enrichment analysis 
Results of the GO term enrichment analysis revealed that the differentially expressed 
gene-set was significantly enriched for the mitochondrion GO term 0005739 
(Benjamini Hochberg padj = .002). 16 nominally significantly (uncorrected p < .05) 
associations were observed that did not survive correction for multiple testing (Table 
3.1) but included annotations relating to other mitochondrial terms, cilium, and 
methylation. 
3.3.3.3. Schizophrenia common variant gene set enrichment analysis 
Gene-set enrichment analysis revealed that genes that were differentially expressed 
in Setd1a+/- E13.5 brain were not significantly enriched for schizophrenia common 
variant association (B = 0.004, SE = 0.088, p = .48). 
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Figure 3.4. Effects of Setd1a haploinsufficiency on transcriptional changes in 
E13.5 mouse brain. A) PCA plot of differentially expressed genes (Benjamini 
Hochberg padj < .05) showing separation of WT and KO samples along PC1, B) 
volcano plot of differentially expressed genes, and C) dendrogram showing clustering 
of differentially expressed genes according to genotype. 
 Table 3.1. Results of GO term enrichment analysis. 
Category GO term 
Gene 
count 
P value 
Benjamini 
Hochberg 
Cellular 
component 
Mitochondrion (GO: 0005739) 47 .00001 .002 
Cilium (GO: 005929) 10 .004 .35 
Ciliary basal body (GO: 0036064) 7 .005 .30 
Mitochondrial matrix (GO: 0005759) 8 .02 .74 
Integral component of mitochondrial inner membrane (GO: 0031305) 3 .04 .80 
Biological 
process 
Peptidyl-lysine deacetylation (GO: 0034983) 3 .006 .98 
Methylation (GO: 0032259) 8 .01 .99 
Cilium morphogenesis (GO: 0060271) 8 .01 .95 
Cell projection organization (GO: 0030030) 7 .02 .97 
Cilium assembly (GO: 0060271) 6 .04 1.0 
Nucleotide metabolic process (GO: 0009117) 3 .04 1.0 
Molecular 
Function 
Methyltransferase activity (GO: 0008168) 8 .009 .95 
Nucleic acid binding (GO: 0003676) 26 .01 .80 
NAD-dependent histone deacetylase activity (H3-K14 specific) (GO: 0032041) 3 .02 .82 
Transferase activity (GO: 0016740) 29 .02 .84 
Nucleotidyltransferase activity (GO: 0016779) 5 .03 .86 
Aspartate-tRNA ligase activity (GO: 0004815) 2 .03 .82 
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3.4. Discussion 
This chapter investigated the effects of Setd1a haploinsufficiency on the 
transcriptome of the developing mouse brain at E13.5. The number of differentially 
expressed genes was moderate (267 genes survived correction for multiple testing) 
and the magnitude of effect sizes were relatively modest. The majority of differentially 
expressed genes were downregulated, consistent with a loss of activating H3K4 
methylation following Setd1a loss of function (Shilatifard, 2012). The differentially 
expressed genes were enriched for mitochondrion annotations. No enrichment for 
schizophrenia common variant association was observed. 
The observation that Setd1a loss of function leads to differential expression of genes 
that are over-represented in the mitochondrion GO term is consistent with previous 
reports (Cameron et al., 2019; Hoshii et al., 2018). Mitochondrial dysfunction has 
been repeatedly implicated in the pathogenesis of schizophrenia (Ben-Shachar, 
2017; Flippo & Strack, 2017; Rajasekaran, Venkatasubramanian, Berk, & Debnath, 
2015). Further work is needed to determine whether this enrichment is a direct 
consequence of Setd1a loss of function or is attributable to increased cellular stress. 
No other GO terms survived correction for multiple testing. However, several 
nominally significant cilium-related GO terms were observed. Cilia play an essential 
role during neurodevelopment (Guemez-Gamboa, Coufal, & Gleeson, 2014) and 
knockdown of a range of neuropsychiatric risk genes affects cilia formation in vitro 
(Marley & von Zastrow, 2012). It would be interesting to explore whether Setd1a loss 
of function has similar effects in future work. 
The transcriptomic changes observed in Setd1a+/- E13.5 mouse brain were not 
enriched for schizophrenia common variant association. One interpretation of this 
finding is that Setd1a loss of function exerts pathogenic effects via molecular 
mechanisms that are distinct from common genetic variants. However, this is 
inconsistent with the results of a previous study conducted in a human neuroblastoma 
cell line (Cameron et al., 2019). Notably, substantially fewer differentially expressed 
genes were observed in the present study, which may be due to cellular heterogeneity 
of the E13.5 mouse brain. The number of differentially expressed genes observed 
here was similar to what has been reported in the prefrontal cortex of adult Setd1a+/- 
mice (Mukai et al., 2019). One explanation for why fewer changes were observed in 
mouse brain than in vitro is due to differences in gene-targeting approaches. That is, 
there is likely to be more opportunity for compensatory mechanisms to take place in 
vivo compared to an acute challenge of Setd1a knockdown in vitro since Setd1a+/- 
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mice are haploinsufficient from conception. Other explanations include differences in 
the transcriptomic effects of Setd1a loss of function in different cell types or in the 
regulatory role of Setd1a in mouse and human.  
Interestingly, Mukai et al. (2019) used Chip-seq to show that Setd1a target genes in 
WT mouse prefrontal cortex are enriched for schizophrenia common variants. 
However, very few of these target genes were differentially expressed in their RNA-
seq analysis, both of bulk prefrontal cortex and at the single-cell level. This suggests 
that the observed transcriptomic changes reflect effects downstream of Setd1a 
targets. It would be interesting in future work to assess differential H3K4 methylation 
in Setd1a+/- mice to explore the extent to which Setd1a haploinsufficiency results in 
altered H3K4 methylation of target genes that is not sufficient to cause transcriptional 
changes but increase vulnerability to transcriptional dysregulation following a second 
‘hit’ (e.g., stress).  
A limitation of the present experiment is that subtle gene expression changes may 
have been masked by the diverse cell types in E13.5 brain tissue. The whole brain 
transcriptome was assayed due to the lack of available data on cell-type and region 
specific expression of Setd1a in the developing mouse brain. However, it is possible 
that a stronger signal would be observed in the ventricular zone considering previous 
evidence demonstrating a role for Setd1a in neurogenesis (Bledau et al., 2014; Li & 
Jiao, 2017). It may be necessary in future work to generate homogeneous cell 
populations using primary neuron cultures or use single-cell RNA-seq to examine the 
cell-type specific effects of Setd1a loss of function. In addition, although Setd1a 
expression levels in the brain were highest at mid-gestation, robust expression was 
observed until adulthood. It would be informative to assess transcriptomic effects of 
Setd1a loss of function at other stages of neurodevelopment.  
Another limitation of the current design was a lack of power to detect sex-specific 
effects of Setd1a loss of function. When analysed separately, very few differentially 
expressed genes were identified in males (11 genes) and none survived correction 
for multiple testing in females. This likely reflects the fact that the magnitude of the 
changes in gene expression were relatively modest (log2 fold changes ranged from -
0.63 to 1.19). Sexually dimorphic effects of Setd1a loss of function have been 
observed in the placenta (Chapter 4) and in the effects of the atypical antipsychotic 
risperidone on the acoustic startle response (Chapter 6). Thus, further work is needed 
to determine whether the transcriptomic consequences of Setd1a loss of function in 
the developing brain are also moderated by sex.  
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In conclusion, this chapter demonstrated that Setd1a haploinsufficiency has a modest 
effect on the transcriptome of the developing mouse brain at E13.5. Gene-set 
enrichment analyses revealed that differentially expressed genes were enriched for 
mitochondrion annotations but not for association with schizophrenia common 
variants. Further work is needed to determine the cell-type specific effects of Setd1a 
loss of function at different stages of neurodevelopment.
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Chapter 4: Gestational compromise in Setd1a+/- mice and consequences for 
growth in the early post-weaning period 
4.1. Introduction 
Recent evidence highlights a role for the placenta in mediating genetic risk for 
schizophrenia (Ursini et al., 2018). This chapter explored whether the pathogenic 
effects of Setd1a haploinsufficiency may also be mediated by an effect in the placenta 
and how these effects translate into differences in foetal and postnatal growth. 
Many neurodevelopmental and neuropsychiatric disorders have their origins in early 
life. Epidemiological studies have identified several in utero risk factors that increase 
the likelihood of offspring developing schizophrenia, including prenatal diet (Brown & 
Susser, 2008; Xu et al., 2009), maternal stress (Khashan et al., 2008; van Os & 
Selten, 1998) and infection (Brown & Derkits, 2010; Khandaker et al., 2013), and 
obstetric complications (Cannon et al., 2002). These findings illustrate the 
susceptibility of the developing brain to prenatal adversity and are consistent with the 
neurodevelopmental hypothesis of schizophrenia (Birnbaum & Weinberger, 2017; 
Murray & Lewis, 1987; Weinberger, 1987). Further evidence is provided by animal 
models showing that many prenatal stressors recapitulate behavioural and 
neurobiological endophenotypes of schizophrenia (Meyer & Feldon, 2010). It has 
been suggested that the effects of prenatal insults on risk for neurodevelopmental 
disorders are mediated by the placenta, which acts as the interface between mother 
and foetus and is critically important for foetal development (Bronson & Bale, 2016; 
Jansson & Powell, 2007; Sandovici, Hoelle, Angiolini, & Constância, 2012). 
Placental defects in embryonically lethal transgenic mice are a strong predictor of 
abnormal brain morphology (Perez-Garcia et al., 2018), further suggesting that 
perturbed placental function has negative consequences for prenatal brain 
development. Recent evidence also suggests that common variant genetic risk for 
schizophrenia may be partially mediated by effects on placental function. Specifically, 
polygenic risk for schizophrenia is higher in the presence of early-life complications 
and pathway analysis of schizophrenia risk genes that are differentially expressed in 
the placenta following early-life complications has shown enrichment of metabolic and 
cellular stress pathways (Ursini et al., 2018). These findings raise the intriguing 
possibility that rare genetic variants for schizophrenia, such as Setd1a, may also exert 
pathogenic effects by influencing placental function. Preliminary evidence to support 
this hypothesis comes from a study showing that knockdown of Setd1a in embryonic 
stem cells causes transcriptomic changes that are enriched for placental 
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development (Fang et al., 2016). In addition, down-regulation of Setd1a expression 
in the placenta has been reported to occur following a prenatal high-fat diet (Gabory 
et al., 2012), which is also linked with schizophrenia-relevant behavioural alterations 
(Sullivan et al., 2015). However, the direct effects of Setd1a haploinsufficiency on 
placental phenotypes has not been examined previously. 
In eutherian mammals, the placenta plays an integral role in maternal-foetal nutrient 
and gas exchange, removal of foetal waste products, and endocrine signalling to 
maintain pregnancy (Watson & Cross, 2005). The mature mouse placenta is formed 
around mid-gestation and contains two foetally-derived regions (the junctional zone 
and labyrinth) and the maternally-derived decidua (Georgiades, Ferguson-Smith, & 
Burton, 2002) (Figure 4.1). The junctional zone is separated from the maternal 
decidua by a layer of parietal trophoblast giant cells (TGCs) (Simmons, Fortier, & 
Cross, 2007). It is a major endocrine compartment containing two trophoblast-derived 
lineages: the spongiotrophoblast and glycogen cells (Coan, Conroy, Burton, & 
Ferguson-Smith, 2006). The spongiotrophoblast, glycogen cells, and TGCs express 
several placental lactogen hormones (Simmons, Rawn, Davies, Hughes, & Cross, 
2008) that drive maternal physiological adaptations to sustain pregnancy 
(Bhattacharyya, Lin, & Linzer, 2002; Müller et al., 1999). Maternal-foetal exchange 
takes place in the labyrinth, which consists of foetal blood vessels surrounded by a 
trilaminar layer of trophoblast-derived cells comprising syncytiotrophoblast layers (I 
and II) and sinusoidal TGCs which are in contact with the maternal blood supply (John 
& Hemberger, 2012). Three additional trophoblast-derived cells line the maternal 
vasculature in the mouse placenta: spiral artery TGCs (in the maternal decidua), 
canal TGCs (in the junctional zone), and channel TGCs (beneath the decidua, the 
exit point of maternal blood) (Gasperowicz, Surmann-Schmitt, Hamada, Otto, & 
Cross, 2013; Rai & Cross, 2014).  
Although there are differences in the morphology and timing of development between 
the mouse and human placenta, there is considerable homology between the function 
of the different placental lineages and the molecular mechanisms underpinning their 
development (Cox et al., 2009; Georgiades et al., 2002). Consequently, the mouse is 
a widely accepted model system for studying the placenta. Several studies in 
transgenic mice have shown that genetic manipulations that cause a reduction in the 
size and/or changes in the cellular composition of the junctional zone or labyrinth are 
associated with intrauterine growth restriction (IUGR) (Woods, Perez-Garcia, & 
Hemberger, 2018). IUGR is a risk factor for neurodevelopmental disorders, including 
schizophrenia (Nielsen et al., 2013). Setd1a haploinsufficiency has been reported to 
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cause decreased fat mass with no effect on overall body weight by the International 
Mouse Phenotyping Consortium (IMPC). However, it is important to note that body 
weight measurements were not recorded at birth and were averaged across postnatal 
development from 3-8 weeks, which may mask IUGR and potential catch-up growth 
effects. 
 
Figure 4.1. Compartments and cell types in the mouse placenta. Taken from John 
and Hemberger (2012). 
The placenta has also been suggested to be an essential locus for the action of 
imprinted genes (John, 2017). Imprinted genes are expressed from one parental 
allele only as a result of epigenetic marks laid down during gametogenesis (Surani, 
1998). The parental conflict hypothesis posits that imprinted genes evolved as a result 
of viviparity in mammals and the coincident conflict between the maternal and 
paternal genomes (Moore & Haig, 1991). Imprinted genes are highly expressed in the 
placenta and are involved in regulating placental endocrine lineages in a manner 
consistent with the conflict hypothesis (John, 2017). Specifically, maternally-
expressed genes (e.g., Phlda2) restrict the development of endocrine lineages 
(Tunster, Creeth, & John, 2016), whereas paternally expressed genes (e.g., Peg3 
and Igf2) promote endocrine lineage expansion (Esquiliano, Guo, Liang, Dikkes, & 
Lopez, 2009; Tunster, Boqué-Sastre, et al., 2018). Interestingly, placental-specific 
knockout of Igf2 is sufficient to cause IUGR and neurobehavioural changes in 
adulthood (Mikaelsson, Constância, Dent, Wilkinson, & Humby, 2013), implicating 
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perturbations to the balance between placental supply and foetal demand in prenatal 
programming. 
H3K4 methylation has been postulated to influence both the establishment and 
maintenance of the epigenetic marks that are responsible for monoallelic imprinted 
gene expression (Kelsey & Feil, 2013; Sanli & Feil, 2015). Imprint acquisition occurs 
in the germline and involves the addition of DNA methylation at imprinting control 
regions (ICRs), leading to parent-of-origin specific differentially methylated regions 
(DMRs) (Barlow, 2011). This is dependent upon the action of the de novo DNA 
methyltransferase DNMT3A and its accessory protein DNMT3L (Bourc’his, Xu, Lin, 
Bollman, & Bestor, 2001; Hata, Okano, Lei, & Li, 2002). H3K4 methylation at ICRs 
prevents the DNMT3A/DNMT3L complex from binding to its target sequence 
(Henckel, Chebli, Kota, Arnaud, & Feil, 2012; Jia, Jurkowska, Zhang, Jeltsch, & 
Cheng, 2007; Ooi et al., 2007). Moreover, removal of H3K4 methylation by KDM1B 
is required for imprint acquisition in oocytes (Ciccone et al., 2009). 
Following imprint acquisition, DMRs at ICRs are maintained by DNMT1 during 
preimplantation development (Hirasawa et al., 2008), despite widespread 
demethylation in the genome of the developing zygote (Reik, Dean, & Walter, 2001). 
DNMT1 is also required for correct expression of imprinted genes in the embryo (Li, 
Beard, & Jaenisch, 1993) but is not involved in monoallelic expression of some 
imprinted genes in the placenta (Caspary, Cleary, Baker, Guan, & Tilghman, 1998; 
Lewis et al., 2004; Umlauf et al., 2004). Instead, imprint maintenance of these genes 
appears to involve histone modifications. Whether this extends to all imprinted genes 
in the placenta is unclear at present. Nevertheless, H3K4 dimethylation has been 
demonstrated to mark maternally-expressed genes in imprinting centre 2 (Lewis et 
al., 2004; Umlauf et al., 2004). Since Setd1a encodes a H3K4 methyltransferase 
subunit (Shilatifard, 2012), it is possible that it could influence placental function 
indirectly by affecting imprinted gene expression, either due to aberrant H3K4 
methylation during imprint establishment or imprint maintenance.  
The aim of this chapter was to conduct preliminary investigations into the role of 
Setd1a in the placenta. This was assessed by measuring placental weights, an 
indicator of placental efficiency (Fowden, Sferruzzi-Perri, Coan, Constancia, & 
Burton, 2009), and gene expression of placental lineage markers and three imprinted 
genes known to regulate placental endocrine function. Associated effects of placental 
changes on foetal and postnatal growth were also examined. 
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4.2. Methods 
4.2.1. Timed-matings, dissections, and assessment of embryonic and placental 
weights 
Timed-matings were conducted as described in Chapter 2.4.1. Placental and foetal 
wet weights were recorded at E13.5 for 5 litters (N = 46; Table 4.1). A foetal:placental 
weight ratio was calculated by dividing foetal wet weight by placental wet weight. 
Whole placentas and a foetal tissue biopsy were snap frozen using dry ice and stored 
at -80 °C until required. Genotyping was conducted using DNA extracted from the 
tissue biopsy to identify Setd1a+/- mice (Chapter 2.2.2) and determine embryonic sex 
(Chapter 2.2.3). 
Table 4.1. Sample characteristics for assessment of placental and foetal weights. 
 
KO WT Total 
Male 11 13 24 
Female 8 14 22 
Total  19 27 46 
 
4.2.2. Placental gene expression RT-qPCR 
RNA was extracted from placentas (N = 16, balanced for sex and genotype) and 
assessed for purity and concentration as described in Chapter 2.4.2. cDNA synthesis 
was performed as described in Chapter 2.4.3, diluted 1:100 in nuclease-free water 
and stored at -20 °C until required. 
Intron-spanning primers (annealing temperature = 60 °C) were designed for markers 
of the spongiotrophoblast (Prl8a8 and Prl3b1), glycogen cells (Prl7b1 and Pcdh12), 
TGCs (Prl2c and Ctsq), labyrinth zone (Flk1 and Dlx3), syncytiotrophoblast-I (Syna) 
and syncytiotrophoblast-II (Synb and Gcm1), 3 imprinted genes (Phlda2, Peg3, and 
Igf2), and two housekeeping genes (β-Actin and Gapdh; Table 4.2). Samples were 
run in triplicate on two separate runs and data were averaged across both runs. A 
nuclease-free water no-template control was included on each run. The contents of 
each 9.5 μL reaction comprised 2 uL cDNA and 7.5 μL RT-qPCR mastermix (Table 
4.3). Reactions were performed using a Quantstudio 5 PCR Machine with the 
following cycling conditions; i) 95 °C for 3 minutes, ii) 95 °C for 20 seconds, iii) 60 °C 
for 20 seconds, iv) 72 °C for 20 seconds, v) 75 °C for 20 seconds, vi) repeat ii-v 34 
times. Ct values were calculated using an Rn threshold of 1.5 x 104 for all reactions. 
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Data were prepared for analysis using the 2-ΔΔCT method (Chapter 2.4.4) and 
statistical analysis was performed on ΔCt values for each gene. 
Table 4.2. Primer sequences and product sizes for RT-qPCR of placental gene 
expression. 
Primer 
target Forward primer Reverse primer 
Product 
size 
(bp) 
Prl8a8  CCTGCATGTATGGCAGAAAA CCCTTATTTGGGGGATTTGT 244 
Prl3b1 AGCAGCCTTCTGGTGTTGTC TGTGACACCACAATCACACG 197 
Prl7b1 CAGCACATCAATAGCCTTGC TTGGTGATTTGAGTGGCAAA 162 
Pcdh12 ACTCTCCTCCTGTCCAGCAA CTGCTCTCAGCTGCCTTCTT 173 
Prl2c TCCAGAAAACAAGGAACAAGC TGTCTGTGGCTTTGGAGATG 161 
Ctsq TGGAAACGTGCACTTGGTAG GTGGGATCAGTTTGCCTGTT 196 
Flk1 GGCGGTGGTGACAGTATCTT GTCACTGACAGAGGCGATGA 183 
Dlx3 CGTTTCCAGAAAGCCCAGTA ACTGTTGTTGGGGCTGTGTT 169 
Syna CAGGGACACAAAGACCCCTA ACCAGAGGAGTTGAGGCAGA 180 
Synb CTGGCACTTCATTCCCATTT TGGCTGTAGGCTCTCAGGTT 163 
Gcm1 AGCCTGTGTTGAGCAGACCT TGTCGTCCGAGCTGTAGATG 173 
Phlda2 TCAGCGCTCTGAGTCTGAAA CAGCAAGCACGGGAATATCT 188 
Peg3 AAAACTCACCACTCCGTTGG GTCTCGAGGCTCCACATCTC 190 
Igf2 GTCGATGTTGGTGCTTCTCA AAGCAGCACTCTTCCACGAT 195 
β-Actin CCTGTATGCCTCTGGTCGTA CCATCTCCTGCTCGAAGTCT 260 
Gapdh CACAGTCAAGGCCGAGAATG TCTCGTGGTTCACACCCATC 242 
 
Table 4.3. Placental gene expression RT-qPCR reaction mix. 
Reagent Amount (μL) 
Nuclease-free water 6.25 
Buffer 1.0 
dNTPs 0.2 
Primer mix (25 μM forward and reverse) 0.4 
DreamTaqTM Hot Start DNA polymerase 
(ThermoFisher, UK) 0.065 
DyNAmo HS SYBR Green 
(ThermoFisher, UK) 0.08 
 
4.2.3. Postnatal growth 
Animals (N = 84; Table 4.4) were weighed at maternal separation (P28) and then 
every seventh day thereafter until P70. A subsample of these animals was used for 
the initial behavioural characterisation (Chapter 5). Thus, growth curves were 
assessed after maternal separation to eliminate potential effects of early-life stress 
induced by repeated handling on behaviour in adulthood.  
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Table 4.4. Sample characteristics for assessment of postnatal growth curves. 
 
KO WT Total 
Male 18 23 41 
Female 18 25 43 
Total  36 48 84 
 
4.2.4. Data analysis 
All data were analysed using a 2 x 2 between-subjects ANOVA with sex (male and 
female) and genotype (WT and KO), followed by Bonferroni-corrected post-hoc tests. 
One male KO was removed from the RT-qPCR experiment due to no signal being 
detected for all genes tested. The additional within-subjects factor age (7 levels) was 
included for analysis of postnatal weight data.  
4.3. Results 
4.3.1. E13.5 foetal and placental weight 
Foetal weight of Setd1a+/- mice at E13.5 was not significantly different from WT (F(1, 
42) = 0.42, p = .84; Figure 4.2A). There was no significant effect of sex (F(1, 42) = 
1.93, p = .17) or interaction between sex and genotype (F(1, 42) = 1.57, p = .22). 
Placental weights of Setd1a+/- mice were on average 8.9 % lighter than WTs (F(1, 42) 
= 8.36, p = .006; Figure 4.2B). In addition, placenta of male mice were significantly 
heavier than females (F(1, 42) = 4.46, p = .04) but there was no significant interaction 
between genotype and sex (F(1, 42) = 0.68, p = .41). There was no significant effect 
of genotype (F(1, 42) = 2.80, p = .10; Figure 4.2C) or sex F(1, 42) = 0.82, p = .78) 
and no significant genotype x sex interaction (F(1, 42) = 0.21, p = .65) for 
foetal:placental ratio. 
54 
 
Figure 4.2. Effects of Setd1a haploinsufficiency on placental and foetal weights 
at E13.5. Mean (+/- SEM) A) foetal weight, B) placental weight, and C) 
foetal:placental ratio, presented separately for males and females.  
4.3.2. Placental gene expression 
Effects of Setd1a haploinsufficiency on placental gene expression are summarised in 
Table 4.5. Analysis of the placental lineage markers (Figure 4.3A) revealed that the 
spongiotrophoblast marker Prl8a8 was significantly down-regulated in placenta of 
Setd1a+/- males (p = .01) but not females (p = .30). In addition, expression of the TGC 
marker Ctsq was also down-regulated in placenta of Setd1a+/- males (p = .01) but not 
females (p = .72). No other placental lineage markers were differentially expressed in 
placentas of Setd1a+/- mice (all p > .14). Analysis of the imprinted genes (Figure 4.3B) 
revealed that Peg3 expression was significantly reduced in male Setd1a+/- placenta 
(p = .02) but not in females (p = .48). There was no significant change in expression 
of Phlda2 (p = .09) or Igf2 (p = .18).
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 Table 4.5. Results of statistical analysis of RT-qPCR assessing effects of Setd1a haploinsufficiency on placental gene expression. 
Marker Gene Main effect genotype Main effect sex Genotype x sex 
Spongiotrophoblast Prl8a8 F(1,11) = 2.12, p = .17 F(1,11) = 4.62, p = .06 F(1,11) = 8.57, p = .01 Prl3b1 F(1,11) = 0.03, p = .87 F(1,11) = 0.06, p = .81 F(1,11) = 2.48, p = .14 
Glycogen cells Prl7b1 F(1,11) = 0.003, p = .95 F(1,11) = 2.53, p = .14 F(1,11) = 0.52, p = .49 Pcdh12 F(1,11) = 0.04, p = .84 F(1,11) = 2.51, p = .14 F(1,11) = 0.54, p = .48 
TGCs Prl2c F(1,11) = 0.15, p = .71 F(1,11) = 1.08, p = .32 F(1,11) = 1.56, p = .24 Ctsq F(1,11) = 6.46, p = .03 F(1,11) = 0.89, p = .37 F(1,11) = 4.20, p = .07 
Labyrinth Flk1 F(1,11) = 1.34, p = .27 F(1,11) = 0.06, p = .82 F(1,11) = 0.31, p = .59 Dlx3 F(1,11) = 0.36, p = .56 F(1,11) = 0.001, p = .98 F(1,11) = 0.03, p = .87 
Syncytiotrophoblast-I Syna F(1,11) = 1.04, p = .33 F(1,11) = 0.19, p = .68 F(1,11) = 0.22, p = .65 
Syncytiotrophoblast-II Synb  F(1,11) = 0.46, p = .51 F(1,11) = 0.69, p = .42 F(1,11) = 0.42, p = .53 Gcm1  F(1,11) = 0.68, p = .43 F(1,11) = 0.001, p = .97 F(1,11) = 0.26, p = .62 
Imprinted genes 
 
Phlda2 F(1,11) = 3.38, p = .09 F(1,11) = 2.39, p = .15 F(1,11) = 0.87, p = .37 
Peg3 F(1,11) = 6.19, p = .03 F(1,11) = 1.16, p = .31 F(1,11) = 2.20, p = .17 
Igf2 F(1,11) = 2.01, p = .18 F(1,11) = 1.01, p = .34 F(1,11) = 0.80, p = .39 
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Figure 4.3. Effects of Setd1a haploinsufficiency on placental gene expression. 
Mean (+/- SEM) fold-change expression (calculated separately for males and 
females) relative to WT for A) placental lineage markers and B) imprinted genes. 
Dotted line represents WT expression levels; ** p < .01; * p < .05. 
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4.3.3. General viability 
The median litter size across 18 litters was 7 (SD = 3.0). Genotype distributions did 
not deviate from Mendelian ratios (X2(1, N = 84) = 1.71, p > .05), suggesting that 
Setd1a haploinsufficiency did not cause embryonic lethality. All animals appeared in 
good general health and low pre-weaning mortality was observed (2.3 %).  
4.3.4. Postnatal growth curves 
Assessment of body weight from the point at which pups were separated from dams 
(P28) until P70 revealed that overall, there was no significant effect of genotype (F(1, 
80) = 1.71, p = .20). However, a significant interaction was observed between age 
and sex (F(2.26, 180.93) = 63.79, p < .001) and age and genotype (F(2.26, 180.93) 
= 11.43, p < .001). Post-hoc tests revealed that male Setd1a+/- mice were significantly 
lighter than their WT littermates at maternal separation (P28; p = .005, Figure 4.4A) 
and this effect was sustained one week later at P35 (p < .001). By P42, male Setd1a+/- 
and WT mice were of equivalent body weight (p = .06), indicating that catch-up growth 
had occurred. By contrast, in females, no significant effect of genotype was observed 
at any of the timepoints tested (all p > .20; Figure 4.4B). Similar findings were 
observed when analysing the percentage increase in body weight from P28 (Table 
4.6). Specifically, body weights of Setd1a+/- male (but not female) increased by 
significantly more than their WT littermates from P42 onwards, the age at which there 
was no longer a genotype effect on body weight. 
Table 4.6. Mean (SD) percentage increase in body weight from P28 at P35-P70 in 
Setd1a+/- and WT mice and Bonferroni corrected p values for effects of genotype, 
presented separately for males and females. 
 Male Female 
Age WT KO p WT KO p 
Body weight change at P35 
(%) 
35.9 
(10.0) 
44.3 
(11.6) .21 
31.8 
(9.3) 
33.0 
(9.9) .69 
Body weight change at P42 
(%) 
51.4 
(12.2) 
66.9 
(21.7) .005 
41.1 
(17.2) 
48.8 
(16.9) .15 
Body weight change at P49 
(%) 
62.2 
(14.4) 
82.1 
(25.5) .002 
48.9 
(17.9) 
58.6 
(20.0) .11 
Body weight change at P56 
(%) 
67.8 
(16.1) 
89.7 
(26.9) .001 
50.7 
(17.5) 
62.7 
(21.2) .06 
Body weight change at P63 
(%) 
71.0 
(16.4) 
94.4 
(31.0) .001 
56.0 
(19.5) 
67.0 
(23.0) .12 
Body weight change at P70 
(%) 
76.4 
(17.4) 
101.3 
(30.7) .001 
61.0 
(19.4) 
72.0 
(24.2) .12 
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Figure 4.4. Effect of Setd1a haploinsufficiency on postnatal growth curves. 
Mean (+/- SEM) body weight of Setd1a+/- mice and their WT littermates measured at 
maternal separation (P28) and every 7 days thereafter until P70 in A) males and B) 
females; *** p < .001, ** p < .01. 
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4.4. Discussion 
This chapter investigated the effects of Setd1a haploinsufficiency on measures of 
placental function and foetal and postnatal growth. Findings revealed that placental 
weight was reduced in Setd1a+/- embryos from WT dams. This was accompanied by 
sexually dimorphic changes in placental gene expression, with males showing 
reduced expression of two placental lineage markers (Prl8a8 and Ctsq) and imprinted 
genes known to play a role in regulating placental endocrine lineages (although only 
Peg3 was statistically significant). No differences were observed in foetal weight at 
E13.5. However, sexually dimorphic effects of Setd1a loss of function on postnatal 
growth were observed, with a reduction in body weight at P28 followed by catch-up 
growth by P42 in males but not females. 
The present findings provide initial evidence for a role for Setd1a in the placenta. The 
weight of placentas from Setd1a+/- mice were 8.9 % lighter than placenta from WTs. 
A similar magnitude of reduction has been reported following prenatal nutritional 
challenges that have functional consequences for placental efficiency (Sferruzzi-Perri 
& Camm, 2016). However, foetal:placenta ratio was not significantly affected, 
possibly suggesting that Setd1a haploinsufficiency exerts subtle effects on placental 
function. Future work should examine the effects of Setd1a haploinsufficiency on 
placental function (e.g., placental transport and endocrine signalling) to elucidate 
potential placental programming mechanisms that could influence prenatal brain 
development.  
Examination of placental gene expression revealed that foetal sex modulated the 
effects of Setd1a loss of function. Specifically, reduced expression of Prl8a8 was 
observed in male Setd1a+/- placenta. This placental lactogen hormone is exclusively 
expressed in the spongiotrophoblast (Simmons et al., 2008), which may suggest a 
reduced contribution of this lineage. Consistent with this, expression of the 
spongiotrophoblast marker Prl3b1 was also reduced, albeit non-significantly. The 
TGC marker Ctsq was downregulated in male Setd1a+/- placenta but there was no 
effect on Prl2c expression. Prl2c is ubiquitously expressed in all TGC subtypes 
(Simmons et al., 2008), whereas Ctsq is exclusively expressed in sinusoidal and 
channel TGCs (Gasperowicz et al., 2013; Simmons et al., 2007). This may indicate a 
relatively specific reduction of these TGC subtypes in male Setd1a+/- placenta. These 
findings should be confirmed histologically to rule out the possibility that these effects 
are due to changes in gene expression in the absence of morphological changes. 
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Placental expression of the imprinted gene Peg3 was also down-regulated in male, 
but not female, Setd1a+/- mice. Loss of Peg3 has been shown to result in a smaller 
spongiotrophoblast and reduced expression of spongiotrophoblast-expressed 
placental hormones (Tunster et al., 2018). This raises the possibility that the effects 
of Setd1a could be mediated through reduced Peg3 expression. However, Ctsq is not 
affected by Peg3 KO (Tunster et al., 2018), potentially suggesting a direct effect of 
Setd1a on placental function. However, reduced Ctsq expression could also be 
mediated by effects on imprinted genes not tested in the current experiment. For 
example, loss of imprinting centre 2 has been shown to cause a 50 % reduction in 
Ctsq expression (Tunster, Van de Pette, Creeth, Lefebvre, & John, 2018).  
Interestingly, two other imprinted genes (Phlda2 and Igf2) were also downregulated 
in male placenta but did not reach criteria for significance. This may suggest that 
Setd1a haploinsufficiency causes a general dysregulation of imprinting in male 
placenta. Further work is needed to investigate the effect of Setd1a loss of function 
on a wider repertoire of imprinted genes. More generally, the role of H3K4 methylation 
in mediating the correct expression of imprinted genes in the placenta is not well 
understood. Bidirectional interactions have been described between histone 
methylation and DNA methylation (Cedar & Bergman, 2009), making it unclear 
whether H3K4 methylation on the expressed allele plays a causal role in facilitating 
mono-allelic expression or is simply a marker of gene expression. Therefore, the 
mechanism underlying the effects of Setd1a loss of function on placental imprinted 
gene expression should be investigated in more detail. 
While there was no difference in foetal weight at E13.5, the sexually dimorphic effects 
on placental gene expression were mirrored by male-specific reduced body weight in 
Setd1a+/- mice between P28-P42. The lack of effect on foetal weight was surprising 
given evidence that a smaller spongiotrophoblast is linked with IUGR (Woods et al., 
2018). In addition, loss of Ctsq has also been linked with IUGR (Outhwaite, McGuire, 
& Simmons, 2015), an effect that is thought to be due to loss of placental hormones 
expressed in sinusoidal-TGCs (Simmons et al., 2008). It is possible that the effects 
of Setd1a loss of function on body weight emerge later in prenatal development as 
the effects of placental insufficiency accumulate, leading to low birth weight. Indeed, 
similar findings have been reported for Igf2 and Peg3, with reduced placental weight 
at around mid-gestation but no effect on foetal weight until later in gestation 
(Constância et al., 2002; Li et al., 1999; Tunster et al., 2018). An alternative 
explanation is that these effects arise postnatally in the pre-weaning period. This 
could occur as a consequence of foetal programming via the placenta, direct effects 
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on pup development, or abnormal interactions with the mother (e.g., by affecting pup 
ultrasonic vocalisations, which is known to influence maternal behaviour (Hashimoto, 
Saito, Furudate, & Takahashi, 2001)).  
The sexually dimorphic effects of Setd1a loss of function on placental gene 
expression and postnatal growth described in this chapter suggest that compensatory 
mechanisms in female placenta may be able to buffer the effects of Setd1a 
haploinsufficiency. This is consistent with several previous studies showing that 
increased susceptibility of males to prenatal insults is associated with sex-specific 
changes in placental function (Clifton, 2010; Kalisch-Smith, Simmons, Dickinson, & 
Moritz, 2017; Rosenfeld, 2015). Sex differences are also reported for schizophrenia 
liability, with higher incidence rates (Aleman, Kahn, & Selten, 2003; McGrath et al., 
2008), earlier onset (Ochoa, Usall, Cobo, Labad, & Kulkarni, 2012), and poorer 
prognosis (Grossman, Harrow, Rosen, Faull, & Strauss, 2008) in males. Interestingly, 
common variants for schizophrenia that are differentially expressed in the placenta 
after early-life complications are also more highly expressed in male than female 
placenta (Ursini et al., 2018). It has been suggested that the male bias in liability for 
neurodevelopmental disorders may be due, in part, to sex differences in placental 
expression of X-linked genes involved in histone methylation (Singh, Singh, & 
Schneider, 2019). No data is currently available on whether sex affects the 
penetrance of Setd1a loss of function in humans (Singh et al., 2016). However, the 
results reported here highlight that sex modulates the effects of Setd1a 
haploinsufficiency in the placenta with potentially important consequences for 
understanding sex differences in pathogenesis. 
In conclusion, this chapter provides evidence for sexually dimorphic effects of Setd1a 
loss of function on placental gene expression with concomitant effects on postnatal 
growth. Future work should investigate the effects of Setd1a haploinsufficiency on 
placental functioning to establish potential mechanisms that could contribute to 
abnormal prenatal brain development. 
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Chapter 5: Behavioural consequences of Setd1a haploinsufficiency in a 
constitutive knockout mouse 
5.1 Introduction 
5.1.1. Aims 
The aim of this chapter was to conduct an extensive characterisation of behavioural 
phenotypes arising from Setd1a haploinsufficiency. The rationale for this work was 
two-fold. First, behavioural tests were chosen that assay several schizophrenia-
relevant endophenotypes. Second, it was important to establish whether there were 
any potential confounding behavioural alterations (e.g., motoric problems) that 
needed to be considered when interpreting apparent cognitive phenotypes.  
5.1.2. Anxiety 
It is well documented that the prevalence of anxiety symptoms is higher in patients 
with schizophrenia compared to the general population (Karpov et al., 2016). Indeed, 
many patients meet diagnostic criteria for a range of comorbid anxiety disorders, 
including obsessive compulsive disorder, social phobia, generalised anxiety disorder, 
panic disorder, and post-traumatic stress disorder (Achim et al., 2011; Braga, 
Reynolds, & Siris, 2013; Buckley, Miller, Lehrer, & Castle, 2009). Cross-sectional 
studies have shown that anxiety symptoms correlate with severity of hallucinations 
and delusions (Hartley, Barrowclough, & Haddock, 2013). This may suggest that the 
increased prevalence of anxiety disorders observed in schizophrenia is a 
consequence of distress associated with the positive symptoms of schizophrenia. 
Alternatively, elevated anxiety levels may be a marker of general liability to 
psychopathology. Indeed, anxiety symptoms precede schizophrenia diagnosis in up 
to 50 % of cases (Pokos & Castle, 2006). However, while several studies have shown 
that anxiety disorders are common in individuals at high clinical risk for schizophrenia, 
the presence of an anxiety disorder does not predict transition to schizophrenia 
(Addington et al., 2017; McAusland et al., 2017). Although the precise relationship 
between anxiety and schizophrenia is poorly understood, it is clear that anxiety is an 
important aspect of psychopathology. 
The elevated-plus maze (EPM) and open field test (OFT) are widely used 
unconditioned behavioural tests for measuring anxiety-related behaviour in rodents 
(Belzung & Griebel, 2001). These tests rely on the conflict between a rodents’ natural 
tendency to explore novel environments and an aversion to open, unprotected spaces 
(Sartori, Landgraf, & Singewald, 2011). Anxiety-related behaviour is 
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indexed/quantified by measuring the propensity to explore the aversive regions of the 
arena (i.e., the open arms of the EPM and the central region of the OFT), although 
additional ‘ethobiological’ measures can also be considered, such as defecation, 
stretch-attend postures, and head dips (Harro, 2018). The construct and predictive 
validity of these tests is based on evidence that anxiolytic drugs, confirmed as such 
in people, increase the amount of exploration of the aversive areas, whereas 
avoidance behaviour is induced upon administration of anxiogenic substances 
(Carobrez & Bertoglio, 2005; Cryan & Holmes, 2005; Prut & Belzung, 2003). There is 
some evidence that different tests measure distinct aspects of anxiety-related 
behaviour (Ramos, 2008), which highlights the importance of convergent findings 
from multiple tasks. 
5.1.3. Locomotor activity 
Locomotor hyperactivity in rodent models of schizophrenia has been suggested to 
model ‘positive-like’ symptoms of the disorder (Jones, Watson, & Fone, 2011; Van 
Den Buuse, 2010). This is based on evidence that recapitulating the neurochemical 
changes observed in schizophrenia using in vivo model systems results in a 
hyperactive phenotype. The dopamine hypothesis of schizophrenia posits that 
elevated subcortical dopaminergic neurotransmission contributes to positive 
symptoms (Davis et al., 1991; Howes & Kapur, 2009). Evidence in rodents shows that 
basal activity levels are increased following administration of drugs that increase 
mesolimbic dopaminergic neurotransmission, such as cocaine (Uhl, Hall, & Sora, 
2002) and amphetamine (Salahpour et al., 2008). Moreover, increased extracellular 
dopamine as a result of knockout of the dopamine transporter also leads to 
hyperactivity (Gainetdinov, Jones, & Caron, 1999; Zhuang et al., 2002).  
Recent evidence suggests that hyperdopaminergic function may be downstream of 
the primary schizophrenia pathophysiology, with NMDA receptor hypofunction also 
being implicated (Grace, 2016; Howes, McCutcheon, & Stone, 2015). Administration 
of NMDA receptor antagonists, such as phencyclidine (PCP) (Mouri, Noda, Enomoto, 
& Nabeshima, 2007), ketamine (Chan, Chiu, Sou, & Chen, 2008; Wilson et al., 2007), 
and MK-801 (Irifune, Shimizu, Nomoto, & Fukuda, 1995; Nilsson, Carlsson, & 
Carlsson, 1997) also result in a hyperactive phenotype in rodents. Studies in humans 
have shown that sub-anaesthetic doses of these drugs induce psychotic-like 
symptoms in healthy controls (Krystal et al., 1994; Lahti et al., 2001). These findings 
support the proposition that locomotor hyperactivity can be used as an assay, 
operationally, of positive-like symptoms of schizophrenia in rodent models. 
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Another aspect of locomotor activity that can be assessed is habituation to a novel 
environment, whereby a decline in exploration occurs after prolonged exposure as 
the animal becomes familiar with the environment. Habituation is regarded as an 
elementary form of learning (Rankin et al., 2009) and is dependent on hippocampal 
function (Daenen, Van der Heyden, Kruse, Wolterink, & Van Ree, 2001; Daenen, 
Wolterink, Gerrits, & Van Ree, 2002). It can occur both within a session, as the animal 
learns about the environment, and between consecutive sessions, which relies on 
memory of the previous session (Leussis & Bolivar, 2006). Memory impairments are 
common in schizophrenia (Fioravanti, Bianchi, & Cinti, 2012) and many Setd1a loss 
of function carriers also present with learning disabilities (Singh et al., 2016). On this 
basis, habituation of locomotor activity was assessed during three test sessions to 
investigate basic learning impairments in Setd1a+/- mice. 
5.1.4. Motoric function abnormalities 
A wide variety of motor symptoms have been reported in schizophrenia patients, 
including catatonia, neurological soft signs (e.g., impaired motor coordination and 
sequencing), involuntary movements, and psychomotor slowing (Hirjak, Meyer-
Lindenberg, Kubera, Thomann, & Wolf, 2018; Walther & Strik, 2012). Widespread 
pathology in the motor system has been observed in schizophrenia, implicating 
morphological and neurochemical alterations in primary and supplementary motor 
cortices, cerebellum, and basal ganglia (Abboud, Noronha, & Diwadkar, 2017). Motor 
symptoms are present in antipsychotic naïve patients (Cortese et al., 2005; Peralta, 
Campos, De Jalón, & Cuesta, 2010), individuals at high clinical risk for schizophrenia 
(Callaway, Perkins, Woods, Liu, & Addington, 2014; Kindler et al., 2016), and 
unaffected relatives (Chan, Xu, Heinrichs, Yu, & Gong, 2010). These findings suggest 
that motor abnormalities are not simply a side-effect of medication and likely form part 
of the core pathophysiology of schizophrenia.  
The Rotarod performance test is the most widely used test for measuring motor 
system dysfunction in rodents (Brooks & Dunnett, 2009) and is sensitive to 
abnormalities arising from lesions to the cerebellum (Caston, Jones, & Stelz, 1995; 
Lalonde, Filali, Bensoula, & Lestienne, 1996) and nigrostriatal pathway (Heuer, 
Smith, Lelos, Lane, & Dunnett, 2012; Monville, Torres, & Dunnett, 2006). In this test, 
mice are placed on a rotating rod and must walk on the rod at the correct pace to 
maintain balance and avoid falling. The speed of rotation can either be fixed or 
accelerate over the trial. It is generally recommended that motor coordination be 
assessed at a range of fixed speeds to avoid confounding effects of fatigue that may 
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occur at longer latencies during accelerating trials (Monville et al., 2006). In addition, 
motor learning can be assessed by measuring the effect of repeated training on 
accelerating trials (Buitrago, Schulz, Dichgans, & Luft, 2004; Scholz, Niibori, 
Frankland, & Lerch, 2015). 
5.1.5. Sensorimotor gating 
Sensorimotor gating refers to the filtering and transmission of sensory information to 
the motor system and as such is often characterised as a form of low-level attentional 
functioning (Powell, Weber, & Geyer, 2012). In humans, sensorimotor gating is 
usually measured using electromyography to determine the degree to which a non-
startling auditory prestimulus inhibits the magnitude of the eyeblink response elicited 
by a closely following, and louder, auditory stimulus (Braff, Grillon, & Geyer, 1992). 
Reduced prepulse inhibition (PPI) of the startle response has been reliably observed 
in schizophrenia patients (Swerdlow, Braff, & Geyer, 2016; Swerdlow et al., 2018; 
Swerdlow, Weber, Qu, Light, & Braff, 2008) and is also reported in prodromal 
schizophrenia (Quednow et al., 2008) and unaffected relatives (Cadenhead, 
Swerdlow, Shafer, Diaz, & Braff, 2000), though PPI deficits are relatively non-specific 
being found across multiple psychopathologies (Swerdlow et al., 2016). Consistent 
with its role in filtering out irrelevant stimuli, deficient PPI correlates with symptoms of 
thought disorder (Perry & Braff, 1994) and distractibility (Karper et al., 1996). PPI is a 
cross-species phenomena, making it a viable endophenotype for in vivo modelling of 
neuropsychiatric disorders (Powell, Zhou, & Geyer, 2009).  
The neural circuitry of sensorimotor gating has been studied extensively in rodents 
(Swerdlow, Geyer, & Braff, 2001). The caudal pontine reticular nucleus plays a central 
role in mediating the acoustic startle response (ASR), receiving inputs from the 
primary auditory system and projecting to spinal motor neurons to generate a motor 
response (Koch, 1999). PPI of the ASR is mediated by a cortico-striato-pallido-
thalamic circuit, which influences the startle response through projections from the 
ventral pallidum to the caudal pontine reticular nucleus via the pedunculopontine 
nucleus (Swerdlow et al., 2016). Forebrain structures that project to the nucleus 
accumbens, such as the prefrontal cortex, hippocampus, and basolateral amygdala, 
are involved in regulating the properties of PPI (Swerdlow et al., 2001). 
Pharmacological studies have shown that PPI deficits can be induced in rodents using 
dopaminergic or 5-HT2 receptor agonists and NMDA receptor antagonists (Geyer, 
Krebs-Thomson, Braff, & Swerdlow, 2001), consistent, arguably, with neurochemical 
abnormalities in schizophrenia.  
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5.1.6. Learning and memory 
Cognitive impairments are a core aspect of schizophrenia psychopathology impacting 
on several domains of memory function (Fatouros-Bergman, Cervenka, Flyckt, 
Edman, & Farde, 2014; Fioravanti et al., 2012), particularly episodic memory 
(Schaefer, Giangrande, Weinberger, & Dickinson, 2013). Setd1a LoF is associated 
with learning difficulties in patients with schizophrenia and developmental delay in 
children with a range of neurodevelopmental disorders (Singh et al., 2016). Setd1a 
(KMT2F) is one of a family of KMT2 genes involved in H3K4 methylation (Shilatifard, 
2012). Knockout of KMT2A (Gupta et al., 2010; Kerimoglu et al., 2017) and KMT2B 
(Kerimoglu et al., 2013; Kerimoglu et al., 2017) are both associated with memory 
impairments, suggesting an important role for H3K4 methylation in memory formation. 
Consistent with this, KMT2A and KMT2B are involved in regulating the breadth of 
H3K4 trimethylation at learning-associated genes in the CA1 region of the 
hippocampus, leading to increased expression during memory formation (Collins et 
al., 2019). Moreover, KMT2A is essential for increased H3K4 trimethylation in the 
hippocampus and anterior cingulate cortex following memory reactivation (Webb et 
al., 2017), suggesting a role for H3K4 methylation in memory retrieval. These findings 
suggest that Setd1a haploinsufficiency might lead to similar learning and memory 
deficits by disrupting H3K4 methylation. 
The novel object recognition (NOR) memory test is the most widely used test of 
declarative memory in rodents (Grayson et al., 2015; Leger et al., 2013). In this task, 
rodents are exposed to two identical objects during encoding. Recognition memory is 
tested after a retention interval by replacing one of the objects with a novel object and 
measuring the amount of time spent exploring each of the objects. Intact recognition 
memory is indicated by increased exploration of the novel object relative to the 
familiar object. Performance on this task relies on hippocampal (Clark, Zola, & Squire, 
2000) and perirhinal cortex (Aggleton, Albasser, Aggleton, Poirier, & Pearce, 2010) 
function. One advantage of this test is that it is a one-trial test of memory performance 
that does not require extensive training, avoiding potential confounds of differential 
sensitivity to positive or negative reinforcement (Antunes & Biala, 2012). It is also 
possible to manipulate the interval between encoding and test in order to assay 
memory retention at short and long delays. 
5.1.7. Summary 
In this chapter, constitutive Setd1a+/- knockout mice and their wild type littermates 
were subjected to an extensive behavioural characterisation to examine 
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schizophrenia-relevant phenotypes; anxiety-related behaviour, locomotor activity, 
motor coordination, sensorimotor gating, and NOR memory. 
5.2. Methods 
5.2.1. Behavioural testing 
77 adult mice (39 male and 38 female) were included in behavioural experiments 
(Table 5.1). Behavioural testing started when animals were 8 weeks old and was 
conducted as described in Chapter 2.3. All mice completed the experiments in the 
following order: EPM, OFT, locomotor activity, sensorimotor gating, rotarod test, and 
NOR. 
Table 5.1. Genotype and sex information for Setd1a+/- mice included in behavioural 
experiments. 
 
KO WT Total 
Male 18 21 39 
Female 18 20 38 
Total  36 41 77 
 
5.2.2. Data analysis 
Multivariate ANOVAs were used to analyse data from the EPM and OFT. The four 
dependent variables included in each analysis were: distance moved, proportion of 
time spent in anxiogenic regions, latency of first entry into anxiogenic regions (log 
transformed to remove positive skew), and number of entries into anxiogenic regions.  
Locomotor activity data were analysed by a mixed ANOVA with day (3 levels) and 
quartile (4 levels) as within-subjects factors and genotype and sex as between-
subjects factors. Greenhouse-Geisser corrected results are reported due to violations 
of sphericity, indicated by a significant Mauchly's test.  
Weight-adjusted ASR data were analysed using a mixed ANOVA with pulse 
amplitude (80 dB, 90 dB, 100 dB, 110 dB, and 120 dB) as a within-subjects factor and 
genotype and sex as between-subjects factors. PPI data were analysed using a 
mixed ANOVA with prepulse amplitude (4 dB, 8 dB, and 16 dB) as a within-subjects 
factor and genotype and sex as between-subjects factors. Greenhouse-Geisser 
corrected results are reported where violations of sphericity occurred. Bonferroni 
corrected post-hoc tests were used to compare the effect of genotype on PPI at the 
different prepulse intensities, separately. 
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To assess motor learning in the rotarod performance test, the latency to fall data from 
the five accelerating runs were analysed by mixed ANOVA with run (5 levels) as a 
within-subjects factor and genotype and sex as between-subjects factors. Motor 
coordination was assessed by calculating the average latency to fall at each fixed 
speed for each mouse. These data were analysed using a mixed ANOVA with speed 
(10 levels) as a within-subjects factor and genotype and sex as between-subjects 
factors. Greenhouse-Geisser corrected results are reported due to violations of 
sphericity. 
NOR performance was assessed by calculating a discrimination ratio as the 
proportion of time the animal spent exploring the novel object relative to total time 
spent exploring either object (sum of novel and familiar). Data from one male WT 
mouse was missing due to a technical issue during the test session. Data were 
analysed using a mixed ANOVA with delay (30 minutes vs. 24 hours) as a within-
subjects factor and genotype and sex as between-subjects factors. 
5.3 Results 
5.3.1. Elevated plus maze 
MANOVA revealed a significant multivariate effect of genotype on indices of anxiety-
related behaviour in the EPM (F(4, 70) = 2.52, p = .049; Wilk's λ = 0.87). Follow-up 
analysis revealed a non-significant trend for Setd1a+/- mice taking longer than their 
WT littermates to enter one of the open arms (p = .057; Figure 5.1D). There were no 
significant effects of genotype on distance moved (p = .99; Figure 5.1A), the 
proportion of time spent on the open arms (p = .75; Figure 5.1C) or the number of 
entries into the open arms (p = .20; Figure 5.1B). There was no significant multivariate 
effect of sex (F(4, 70) = 1.39, p = .25; Wilk's λ = 0.93) and no interaction between 
genotype and sex (F(4, 70) = 1.33, p = .27; Wilk's λ = 0.93). 
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Figure 5.1. Effect of Setd1a haploinsufficiency on anxiety-related behaviour in 
the EPM. Mean (+/- SEM) A) distance moved, B) number of open arm entries, C) 
proportion of time on open arms, and D) log latency of first entry into an open arm. 
5.3.2. Open field test 
MANOVA revealed a significant multivariate effect of genotype on indices of anxiety-
related behaviour in the OFT (F(4, 70) = 3.43, p = .01; Wilk's λ = 0.84). Follow-up 
analysis revealed that Setd1a+/- mice made significantly fewer entries into the inner 
zone (p = .04; Figure 5.2B) and spent significantly less time in this region (p = .02; 
Figure 5.2C) than their WT littermates. There were no significant effects of genotype 
on distance moved (p = .11; Figure 5.2A) or log latency of first entry into the inner 
zone (p = .18; Figure 5.2D). There was no significant multivariate effect of sex (F(4, 
70) = 1.31, p = .27; Wilk's λ = 0.93) and no interaction between genotype and sex 
(F(4, 70) = 0.13, p = .97; Wilk's λ = 0.99). 
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Figure 5.2. Effect of Setd1a haploinsufficiency on anxiety-related behaviour in 
the OFT. Mean (+/- SEM) A) distance moved, B) number of inner zone entries, C) 
proportion of time in inner zone, and D) log latency of first entry into inner zone; * p < 
.05. 
5.3.3. Locomotor activity 
There was no significant main effect of genotype on locomotor activity levels (F(1, 73) 
= 0.46, p = .50). There was also no significant main effect of sex (F(1, 73) = 0.04, p = 
.84) and no significant interaction between sex and genotype (F(1, 73) = 2.45, p = 
.12). A significant main effect of day was observed (F(1.69, 123.09) = 28.63, p < .001; 
Figure 5.3A) and there was no significant interaction between day and genotype 
(F(1.69, 123.09) = 0.18, p = .80). This indicates that activity levels decreased by a 
similar amount in WT and Setd1a+/- mice across test days, suggesting normal 
habituation to a novel environment. Consistent with this, there was a significant main 
effect of quartile (F(1.74, 127.04) = 183.14, p < .001; Figure 5.3B) and no significant 
interaction between quartile and genotype (F(1.74, 127.04) = 1.41, p = .25). This 
shows that activity levels of WT and Setd1a+/- mice declined to the same degree 
during a session as they became more familiar with the environment. 
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Figure 5.3. Effect of Setd1a haploinsufficiency on locomotor activity levels. 
Mean (+/- SEM) beam breaks A) for each day, summed across a whole session and 
B) for each quartile, pooled across sessions; *** p < .001. 
5.3.4. Sensorimotor gating 
Analysis of the weight-adjusted ASR data (Figure 5.4) revealed a significant main 
effect of pulse (F(1.84, 134.58) = 293.21, p < .001), indicating an increased magnitude 
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of startle response at higher pulse intensities. There was a significant main effect of 
genotype (F(1, 73) = 8.44, p = .005), which was qualified by a significant interaction 
between genotype and pulse intensity (F(1.84, 134.58) = 8.15, p = .001). Post-hoc 
tests revealed that startle magnitude was significantly higher in Setd1a+/- than WT 
mice at 110 dB (p = .04) and 120 dB (p = .001) but not at 80 dB (p = .07), 90 dB (p = 
.55) or 100 dB (p = .12) The main effect of sex was not significant (F(1, 73) = 0.02, p 
= .88) and there was no significant interaction between sex and genotype (F(1, 73) = 
0.11, p = .74), showing that Setd1a+/- mice exhibited a greater startle response than 
WTs irrespective of sex. 
 
Figure 5.4. Effect of Setd1a haploinsufficiency on ASR. Mean (+/- SEM) weight-
adjusted ASR at 80-120 dB (above background); *** p < .001; * p < .05. 
Analysis of the PPI data (Figure 5.5) revealed a significant main effect of prepulse 
(F(1.64, 119.57) = 264.22, p < .001), indicating greater PPI with increasing prepulse 
intensity. There was also a significant main effect of genotype (F(1, 73) = 19.01, p < 
.001) and this was qualified by a significant interaction between genotype and 
prepulse (F(1.64, 119.57) = 8.37, p = .001). Post-hoc testing revealed that PPI was 
significantly reduced in Setd1a+/- mice at 8 dB (p < .001) and 16 dB (p < .001) but not 
at 4 dB (p = .26). There was no significant main effect of sex (F(1, 73) = 1.40, p = .24) 
and no interaction between sex and genotype (F(1, 73) = 1.84, p = .18). 
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Figure 5.5. Effect of Setd1a haploinsufficiency on PPI of the ASR. Mean (+/- 
SEM) PPI by a 4, 8, and 16 dB (above background) prepulse; *** p < .001. 
5.3.5. Rotarod performance test 
Analysis of the latency to fall on accelerating trials (Figure 5.6A) revealed a significant 
main effect of trial (F(2.97, 217.0), = 16.99, p < .001), indicating that latency to fall 
increased with training. There was no significant effect of genotype (F(1, 73) = 2.70, 
p = .11) and no significant interaction between genotype and trial (F(2.97, 217.0), = 
0.50, p = .68), suggesting that motor learning was not affected in Setd1a+/- mice. No 
significant sex differences were observed (F(1, 73) = 0.33, p = .57) and there was no 
significant interaction between sex and genotype (F(1, 73) = 0.001, p = .98). 
Analysis of the latency to fall on fixed speed trials (Figure 5.6B) revealed that the 
latency to fall was significantly shorter at higher speeds (F(5.62, 410.06) = 131.64, p 
< .001). There was no significant effect of genotype (F(1, 73) = 2.38, p = .13), 
indicating that motor coordination was equivalent between Setd1a+/- and WT mice. 
No significant sex differences were observed (F(1,73) = 8.25x10-8, p = .99) and there 
was no significant interaction between sex and genotype (F(1, 73) = 0.57, p = .45). 
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Figure 5.6. Effect of Setd1a haploinsufficiency on motoric function in the 
Rotarod test. Mean (+/- SEM) latency to fall A) on accelerating trials (5-50 rpm at 
0.15 rpm/s) and B) at fixed speeds increasing in 5 rpm increments from 5-50 rpm. 
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5.3.6. Novel object recognition 
Analysis of the acquisition time data revealed no significant effect of genotype on the 
time taken to achieve 40 seconds of object exploration (F(1, 72) = 0.09, p = .76) 
(Table 5.2). Raw exploration times at test are also shown in Table 5.2. Discrimination 
ratios were significantly higher at the 30 minute than 24 hour retention interval (F(1, 
72) = 19.61, p < .001). There was no significant effect of genotype (F(1, 72) = 0.05, p 
= .82) and no significant interaction between genotype and delay (F(1, 72) = 1.68, p 
= .20), indicating that short- and long-term object recognition memory was intact in 
Setd1a+/- mice. There was also no significant effect of sex (F(1, 72) = 0.32, p = .57) 
and no interaction between sex and genotype (F(1, 72) = 0.45, p = .51). 
Table 5.2. Mean (SD) acquisition time and object exploration at test for the 30 minute 
and 24 hour retention intervals. 
 30 mins 24 hours 
Dependent variable WT KO WT KO 
Acquisition time (mins) 6.9 (3.8) 7.3 (4.2) 7.1 (4.0) 6.9 (4.1) 
Novel object exploration time (s) 19.2 (9.0) 20.1 (11.0) 8.1 (5.2) 8.0 (5.4) 
Familiar object exploration time (s) 10.9 (8.7) 9.5 (6.8) 5.7 (4.0) 6.1 (3.6) 
 
 
Figure 5.7. Effect of Setd1a haploinsufficiency on object recognition memory. 
Mean (+/- SEM) discrimination ratios (%) in the NOR test after a 30 minute and 24 
hour retention interval. Dotted line shows chance performance. 
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5.4. Discussion 
In this chapter, behavioural consequences of constitutive Setd1a haploinsufficiency 
were examined. Findings revealed abnormal sensorimotor gating (increased ASR 
and reduced PPI) and mixed evidence for increased anxiety (increased anxiety in the 
OFT but no significant differences in the EPM). Conversely, locomotor activity, motor 
coordination, and object recognition memory were not affected by Setd1a loss of 
function. These results demonstrate that Setd1a haploinsufficiency leads to highly 
specific behavioural impairments in sensorimotor gating and anxiety without affecting 
general aspects of motoric function, habituation to a novel environment, or object 
recognition memory. 
At the time of conducting these experiments, there was no literature available on 
behavioural consequences of Setd1a haploinsufficiency. Subsequently, one study 
has shown that Setd1a loss of function results in working memory impairments (Mukai 
et al., 2019). The present findings extend our understanding of the functional 
consequences of Setd1a haploinsufficiency to reveal that sensorimotor gating and 
emotional reactivity are also affected. Consistent with the present results, Mukai et 
al. (2019) also showed normal locomotor activity levels and intact object recognition 
memory performance in heterozygous Setd1a mice. However, they report no 
difference in anxiety-related behaviour in the OFT, whereas the present results 
suggest that Setd1a loss of function leads to increased anxiety. A possible 
explanation for these divergent results is that the duration of the open field test used 
by Mukai et al. (2019) was considerably longer (60 minute trial) than the findings 
reported here (10 minute trial). It is likely that subtle anxiety phenotypes may have 
been masked by the longer session as the animals would have habituated to the 
arena after prolonged exposure. 
The reduced PPI observed in Setd1a+/- mice is reminiscent of pervasive PPI deficits 
observed in schizophrenia patients (Swerdlow et al., 2018). PPI deficits can be 
induced by dopaminergic or 5-HT2 receptor agonists and NMDA receptor antagonists 
in rodents (Geyer et al., 2001). This suggests that there are several mechanisms that 
could be responsible for the current findings. PPI deficits can be reversed with a 
variety of antipsychotics and this approach is often used as a screening tool for 
putative antipsychotics (Swerdlow et al., 2008). By comparing the effects of typical 
and atypical antipsychotics with different pharmacological profiles, this would shed 
light on underlying neurochemical changes in Setd1a+/- mice (see Chapter 6). It would 
also be interesting to explore whether other types of gating are impaired due to 
Setd1a haploinsufficiency. For example, latent inhibition is also impaired in 
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schizophrenia patients, which is thought to reflect cognitive gating mechanisms 
(Swerdlow, Braff, Hartston, Perry, & Geyer, 1996). 
The present findings suggest that Setd1a haploinsufficiency is associated with an 
increased anxiety phenotype. Specifically, Setd1a+/- mice spent less time in the 
central region of the open field and exhibited a greater ASR, another index of 
increased anxiety (Grillon, 2008). However, there was only weak evidence for 
increased anxiety in the EPM, with a non-significant trend for Setd1a+/- mice to take 
longer to enter the open arms than WTs. It is interesting to note that the average 
amount of time spent on the open arm was approximately 40 %. This is substantially 
higher than expected: other data from our laboratory from a similar hybrid C57BL/6J 
x C57BL/6NTac strain shows that WT animals usually spend only 30 % of the time 
on the open arms (T. Humby, personal communication). This suggests that the EPM 
task may not have been particularly aversive, which could explain why no differences 
in anxiety were observed. It has also been suggested that different tests of anxiety 
assay distinct, albeit overlapping, aspects of anxiety (Ramos, 2008). Consistent with 
this, factor analysis has shown that data from the EPM and OFT load onto different 
factors (Trullas & Skolnick, 1993). Future work could further characterise the anxiety 
phenotype of Setd1a+/- mice using other tests of anxiety (e.g., elevated zero maze 
and light-dark box).  
In our hands, there was no evidence for basic learning and memory impairments in 
Setd1a+/- mice. This was surprising given the link between Setd1a loss of function and 
learning disabilities (Singh et al., 2016) and the role of H3K4 methylation in memory 
formation (Collins, Greer, Coleman, & Sweatt, 2019). It is important to note that 
memory is multi-faceted; the present findings indicate normal novelty-based memory 
(intact object recognition and habituation of locomotor activity in a novel environment) 
and procedural memory (equivalent motor learning on the Rotarod). However, it 
remains to be tested whether other forms of memory, such as associative memory, 
are affected by Setd1a haploinsufficiency. This could be investigated using the object-
in-place task, which requires encoding of the relationship between objects and their 
location in the environment (Dix & Aggleton, 1999). 
In summary, the findings of this chapter show that constitutive haploinsufficiency of 
Setd1a causes impaired sensorimotor gating and a subtle anxiety phenotype, with 
spared motoric function and basic learning and memory. The results of this initial 
behavioural characterisation demonstrate functional consequences of Setd1a loss of 
function on behaviour that are of relevance to schizophrenia. These findings serve as 
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a foundation for further work into additional behavioural consequences of Setd1a loss 
of function and investigation of neurobiological mechanisms underlying behavioural 
phenotypes. 
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Chapter 6: Pharmacological modulation of sensorimotor gating deficits in 
Setd1a+/- mice using antipsychotics 
6.1. Introduction 
In this chapter, the effects of established antipsychotics on aberrant sensorimotor 
gating in Setd1a+/- mice were examined. The primary aim of this work was to test 
whether deficient prepulse inhibition (PPI) can be restored by antipsychotic treatment. 
In addition, the effects of two antipsychotics with different pharmacological profiles 
(haloperidol and risperidone) were compared to investigate underlying neurochemical 
changes. 
Deficient PPI is a robust endophenotype in schizophrenia (Swerdlow et al., 2018). 
Such deficits are influenced by antipsychotic medication, with patients currently taking 
antipsychotic medication showing higher levels of PPI than unmedicated patients, an 
effect that is more pronounced for atypical antipsychotics (Kumari, Soni, & Sharma, 
2002; Leumann, Feldon, Vollenweider, & Ludewig, 2002; Oranje, Van Oel, Gispen-
De Wied, Verbaten, & Kahn, 2002; Quednow et al., 2008). However, due to the cross-
sectional nature of these studies, it is possible that other confounding factors, such 
as heterogeneity in treatment history and severity of symptoms, may contribute to 
these effects. A few randomised controlled trials have been conducted but these have 
yielded mixed results and are difficult to interpret due to the lack of a placebo control 
group (Mackeprang, Kristiansen, & Glenthoj, 2002; Quednow et al., 2006; Wynn et 
al., 2007). Longitudinal studies have shown that several months treatment with the 
atypical antipsychotics risperidone or quetiapine leads to an increased level of PPI in 
schizophrenia patients relative to baseline (Aggernaes et al., 2010; Martinez-Gras et 
al., 2009). PPI is also enhanced by the atypical antipsychotics clozapine and 
quetiapine in individuals who normally show low levels of PPI in the absence of a 
psychiatric diagnosis (Swerdlow, Talledo, Sutherland, Nagy, & Shoemaker, 2006; 
Vollenweider, Barro, Csomor, & Feldon, 2006).  
Many studies have shown that PPI deficits in rodent models of schizophrenia can be 
reversed by treatment with antipsychotics (for reviews, see: Geyer, Krebs-Thomson, 
Braff, & Swerdlow, 2001; Swerdlow, Weber, Qu, Light, & Braff, 2008). This metric is 
often used in preclinical studies as a screening tool for novel antipsychotics, based 
on initial work demonstrating that the clinical potency of antipsychotic medication is 
strongly correlated with their ability to reverse apomorphine-induced PPI deficits in 
rats (Swerdlow, Braff, Taaid, & Geyer, 1994). There is some evidence to support a 
dissociation between the efficacy of typical and atypical antipsychotics in rescuing 
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PPI deficits induced by different pharmacological treatments. In general, both typical 
and atypical antipsychotics improve PPI deficits in D2 agonist models, whereas 
atypical antipsychotics tend to be more effective than typical antipsychotics in 
reversing PPI deficits in 5-HT receptor agonist and NMDAR antagonist models (Geyer 
et al., 2001).  
It is important to note that the division of antipsychotics into typical and atypical has 
been suggested to reflect their historical development rather than a pharmacological 
distinction (Cunningham Owens & Johnstone, 2018). D2 receptor blockade is 
common to all antipsychotics and is thought to be responsible for therapeutic effects 
(Creese et al., 1976; Kapur & Remington, 2001). This may also explain the ability of 
both typical and atypical antipsychotics to improve PPI deficits induced by D2 
agonists. Consistent with this, the ability to reverse apomorphine-induced PPI deficits 
correlates with D2 receptor affinity (Yamada, Harano, Annoh, Nakamura, & Tanaka, 
1999). Despite a large degree of heterogeneity in the pharmacological action of 
atypical antipsychotics (Miyamoto, Duncan, Marx, & Lieberman, 2005), some have 
argued that a higher relative affinity for 5-HT2A versus D2 receptors defines 
‘atypicality’ (Meltzer & Massey, 2011), which may explain the superiority of atypical 
antipsychotics in reversing PPI deficits induced by NMDAR antagonists and 5-HT2 
receptor agonists.  
In addition to causing NMDA receptor hypofunction, administration of the non-
competitive NMDA antagonists PCP (Hernandez, Auerbach, & Hoebel, 1988; Lillrank, 
O’Connor, Oja, & Ungerstedt, 1994; Martin, Carlsson, & Hjorth, 1998) and dizocilpine 
(Dall’Olio, Gaggi, Bonfante, & Gandolfi, 1999; Yan, Reith, Jobe, & Dailey, 1997) have 
been shown to cause serotonergic hyperactivity. Conversely, serotonin has been 
reported to influence glutamate release in the prefrontal cortex via its action at the 5-
HT2A receptor (Aghajanian & Marek, 1997). Attenuation of PCP-induced PPI deficits 
by antipsychotics correlates with their affinity for 5-HT2A receptors (Yamada et al., 
1999). Similar effects have been reported for PCP-induced hyperlocomotion, with 
antipsychotics that show a greater affinity for 5-HT2A relative to D2 receptors being 
more effective at normalising activity levels (Meltzer & Massey, 2011). In addition, 
dizocilpine-induced PPI deficits are rescued by the selective 5-HT2A antagonist 
M100907 (Varty, Bakshi, & Geyer, 1999) and selective 5-HT2A receptor antagonists 
block the PPI-reducing effect of the 5-HT2 receptor agonists DOI (Sipes & Geyer, 
1997) and LSD (Halberstadt & Geyer, 2010; Ouagazzal, Grottick, Moreau, & Higgins, 
2001). These findings illustrate the role of 5-HT2A receptor function in moderating 
PPI disruptions caused by NMDAR-antagonists and 5-HT2 receptor agonists. 
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The aim of this chapter was to assess whether deficient PPI in Setd1a+/- mice 
(Chapter 5.3.4) can be influenced, possibly rescued, by haloperidol or risperidone. 
Haloperidol is predominantly D2 selective, with a much higher affinity for D2 (Ki = 1.4 
nM) than 5-HT2A (Ki = 25 nM) receptors, whereas risperidone has a higher affinity 
for 5-HT2A (Ki = 0.16 nM) than D2 (Ki = 3.3 nM) receptors (Figure 6.1) (Kusumi, Boku, 
& Takahashi, 2015). Previous work in rodent models has shown that PPI deficits 
induced by D2 receptor agonists are reversed by both haloperidol and risperidone, 
whereas NMDAR antagonist induced deficits are generally insensitive to haloperidol 
but can be reversed by risperidone (Geyer et al., 2001; Swerdlow et al., 2008). Effects 
in 5-HT2 receptor agonist models are less well studied but there is some evidence 
that haloperidol is not able to rescue DOI- (Padich, McCloskey, & Kehne, 1996; Varty 
& Higgins, 1995) or LSD-induced PPI deficits (Ouagazzal et al., 2001), whereas 
risperidone enhances deficient PPI in DOI treated animals (Varty & Higgins, 1995).  
 
Figure 6.1. Receptor binding profiles of haloperidol and risperidone. Adapted 
from Cunningham Owens & Johnstone (2018). 
This work was conducted in three parts; first, two pilot studies were conducted to 
establish the feasibility of a within-subjects drug challenge by investigating stability of 
ASR and PPI over repeated sessions (Pilot study 1) and an appropriate dose range 
of each drug was identified (Pilot study 2). Second, the basic effects of Setd1a loss 
of function on increased ASR and decreased PPI described in Chapter 5.3.4 were 
replicated. Finally, the effects of haloperidol and risperidone on sensorimotor gating 
impairments in Setd1a+/- mice were compared. The rationale for this was two-fold; i) 
assess whether PPI deficits can be rescued by antipsychotics and ii) probe underlying 
neurochemical mechanisms. Considering the evidence reviewed above, it was 
hypothesised that if PPI deficits were rescued by both haloperidol and risperidone 
then this may indicate dopaminergic dysfunction. Conversely, if risperidone but not 
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haloperidol was effective in reversing PPI deficits then this may indicate the 
involvement of other neurotransmitter systems (e.g., glutamatergic or serotonergic).  
6.2. Methods 
6.2.1. Subjects 
6.2.1.1 Pilot work 
Two pilot studies were conducted with male mice (3 months old at the start of testing) 
on a similar genetic background (C57BL/6J) to the Setd1a+/- mice. 6 mice were 
included in Pilot study 1 to investigate the stability of ASR and PPI over repeated test 
sessions. In Pilot study 2, 34 mice were divided into two groups to identify an 
appropriate dose range of haloperidol (N = 17) and risperidone (N = 17) to use in the 
main experiment. 
6.2.1.2 Main experiment 
56 adult mice (26 male and 30 female) were tested in the main experiment (3 months 
old at the start of testing). First, all mice completed a pre-test session to replicate the 
basic effects. Then, mice were divided into two approximately equal groups (balanced 
for sex and genotype) and allocated to either the haloperidol or risperidone condition 
(see Table 6.1). 
Table 6.1. Sample characteristics for mice included in the main experiment and their 
allocation to drug condition. 
 Haloperidol Risperidone  
 
KO WT KO WT Total 
Male 5 8 5 8 26 
Female 7 9 6 8 30 
Total  12 17 11 16 56 
 
6.2.2 Apparatus and materials 
6.2.2.1 Testing apparatus 
The apparatus for measuring ASR and PPI are described in Chapter 2.3.4. Briefly, 
SR-Lab (San Diego Instruments, USA) sound attenuating chambers were used to 
present acoustic stimuli. Animals were placed in a clear Perspex tube (35 mm 
diameter) mounted on a plinth and the whole-body startle response was detected 
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using a piezoelectric sensor attached to the plinth. The average startle response 
(Vavg) was recorded in arbitrary startle units using SR-Lab software over the 65 ms 
period following stimulus onset. 
6.2.2.2 Drugs 
Each drug solution was prepared by dissolving either 1 mg haloperidol (Sigma, UK) 
or risperidone (Sigma, UK) in 2.5 μL 1M glacial acetic acid. This was transferred to 
an appropriate volume of 0.9 % saline (see Table 6.2), such that an equal volume 
(100 μL per g of body weight) of drug were administered for all dosages. A 0.025 % 
(v/v) glacial acetic acid in 0.9 % saline solution was used as vehicle. pH of all solutions 
were adjusted to 6.0 using 1 M sodium hydroxide.  
Table 6.2. Dilutions for the different dosages of drug solutions. 
Dosage (mg/kg) Volume 0.9 % saline (mL) 
1.0 10 
0.5 20 
0.1 100 
 
6.2.3 Design 
6.2.3.1 Test protocol 
In all experiments, ASR and PPI were assessed using a modified version of the 
protocol described in Chapter 2.3.4 using an identical trial structure. A 70 dB white 
noise background was presented throughout. Each session started with a 5 minute 
habituation period. Six 120 dB pulse alone trials were presented on consecutive trials, 
followed by an additional 7 pulse alone trials interspersed with 12 prepulse trials (8 
dB or 16 dB above background, 6 trials of each). Two no stimulus trials were 
presented at the beginning and end of the session. In the pre-test session, an 
additional range of pulse alone trials (80 – 120 dB in 10 dB increments, 3 trials of 
each) were presented at the end of the session, as in the previous experiment. 
6.2.3.2 Testing procedure 
In Pilot study 1, there were 8 sessions spaced 3-4 days apart performed under basal 
conditions. In Pilot study 2, each group completed a within-subjects dose-response 
experiment (vehicle, 0.1 mg/kg, 0.5 mg/kg and 1.0 mg/kg) for either haloperidol or 
risperidone. Order of dosage was counterbalanced and there were 7 days washout 
between each session.  
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In the main experiment, mice first completed a pre-test session to replicate the 
previous findings of elevated ASR and reduced PPI in Setd1a+/- mice (Chapter 5.3.4). 
Each group then completed 3 further sessions of either haloperidol or risperidone 
(vehicle, 0.5 mg/kg or 1.0 mg/kg) spaced 7 days apart. This dose range was chosen 
based on the results of Pilot study 2 (section 6.3.2). Dose order was counterbalanced 
across runs for vehicle and 0.5 mg/kg and all mice received the highest dose of each 
drug in the final session. 
All drugs were administered by intraperitoneal (IP) injection 30 minutes before the 
start of the session. The degree of sedation was rated on a scale from 1 (no sedation) 
to 5 (completely sedated) immediately prior to behavioural testing. Any animal scoring 
above 3 was excluded, which led to the removal of one animal at the 1 mg/kg dose 
of risperidone in Pilot study 2. 
6.2.4. Data analysis 
ASR data were weight-adjusted by dividing the average ASR by body weight. PPI 
was calculated as the percentage reduction in startle amplitude between prepulse 
and pulse alone trials (excluding the first 3 pulse-alone trials). Data were analysed 
using ANOVA, described below. 
 Pilot study 1: repeated measures ANOVA with session (8 levels) (ASR) and 
prepulse (8 & 16 dB) (PPI) 
 Pilot study 2: repeated measures ANOVA with dose (vehicle, 0.1 mg/kg, 0.5 
mg/kg, and 1.0 mg/kg) (ASR) and prepulse (8 & 16 dB) (PPI) 
 Pre-test: mixed ANOVAs with between-subjects factors genotype and sex and 
within-subjects factor pulse (5 levels) (ASR) or prepulse (8 & 16 dB) (PPI) 
 Main experiment: mixed ANOVA with between-subjects factors genotype and 
sex and within-subjects factor dose (vehicle, 0.5 mg/kg, 1.0 mg/kg) (ASR) and 
prepulse (8 & 16 dB) (PPI) 
Bonferroni corrected post-hoc tests were used to follow up main effects of dose. 
Where a significant 3-way interaction between dose, genotype, and sex was 
observed, simple main effects were examined using separate ANOVAs for each sex, 
followed by Bonferroni corrected post-hoc tests. 
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6.3. Results 
6.3.1. Pilot work 
6.3.1.1. Pilot study 1 
The aim of this study was to assess the stability of basal ASR and PPI in WT mice 
over repeated testing. There was no significant change in ASR (F(7, 35) = 1.96, p = 
.09; Figure 6.2A) or PPI (F(7, 35) = 2.22, p = .06; Figure 6.2B) measured across 8 
separate sessions spaced 3-4 days apart. These data show that these measures 
were robust over repeated test sessions. 
 
Figure 6.2. Robustness of sensorimotor gating measures over 8 test sessions. 
Mean (+/- SEM) A) ASR at 120 dB above background and B) PPI of ASR by an 8 and 
16 dB above background prepulse. 
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6.3.1.2. Pilot study 2 
The aim of this study was to test effects of haloperidol and risperidone in WT mice to 
identify an appropriate dose range for the main experiment. For haloperidol, there 
was no significant main effect of dose on magnitude of the ASR (F(3, 48) = 1.43, p = 
.25; Figure 6.3A). However, a significant main effect of dose was observed for PPI 
(F(3, 48) = 4.11, p = .01; Figure 6.3B). Post-hoc tests revealed that PPI was 
significantly greater than vehicle at 1.0 mg/kg (p = .04) but not at 0.5 mg/kg (p = .18) 
or 0.1 mg/kg (p = .99). 
  
Figure 6.3. Effects of haloperidol on sensorimotor gating in WT mice. Mean (+/- 
SEM) A) ASR at 120 dB above background and B) PPI of the ASR, pooled across 8 
and 16 dB above background prepulses. Data are presented following IP 
administration of vehicle, 0.1, 0.5 and 1.0 mg/kg haloperidol; * p < .05. 
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A significant main effect of risperidone dose was observed for ASR (F(3, 45) = 6.42, 
p = .001; Figure 6.4A). Post-hoc tests revealed a significantly reduced startle 
response at 1.0 mg/kg (p = .03) but not at 0.5 mg/kg (p = .10) or 0.1 mg/kg (p = .99). 
There was no significant main effect of dose on PPI (F(1.70, 25.51) = 2.12, p = .15; 
Figure 6.4B). 
 
Figure 6.4. Effects of risperidone on sensorimotor gating in WT mice. Mean (+/- 
SEM) A) ASR at 120 dB above background and B) PPI of the ASR, pooled across 8 
and 16 dB above background prepulses. Data are presented following IP 
administration of vehicle, 0.1, 0.5 and 1.0 mg/kg risperidone; * p < .05. 
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The results of Pilot study 2 showed that 0.5 mg/kg was the highest dose of haloperidol 
and risperidone tested that did not have significant effects on basal sensorimotor 
gating in WT mice. Thus, in the main experiment, all mice were tested at this dosage 
in the first instance to explore drug effects on sensorimotor gating in Setd1a+/- mice 
in the absence of non-specific effects.  
6.3.2. Main experiment 
6.3.2.1. Pre-test session 
This experiment investigated whether the sensorimotor gating deficits reported in 
Chapter 5.3.4 could be replicated in an independent sample of Setd1a+/- mice and 
their WT littermates. Consistent with the previous results, a significant main effect of 
genotype on ASR (F(1, 52) = 16.36, p < .001; Figure 6.5) was observed. There was 
also a significant interaction between genotype and pulse (F(1.77, 91.88) = 10.46, p 
< .001). Post hoc tests revealed that startle magnitude was significantly greater in 
Setd1a+/-  mice at 100 dB (p = .003), 110 dB (p = .004), and 120 dB (p < .001) but not 
at 80 dB (p = .75) or 90 dB (p = .88). There was a non-significant trend for greater 
startle magnitude in males (F(1, 52) = 3.89, p = .05) but no significant interaction 
between sex and genotype was observed (F(1, 52) = 2.10, p = .15).  
 
Figure 6.5. Replication of increased ASR in Setd1a+/- mice. Mean (+/- SEM) ASR 
at 80-120 dB (above background) in 10 dB increments; *** p < .001, ** p < .01. 
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The effects of Setd1a haploinsufficiency on PPI were also replicated in this 
experiment; a significant reduction in PPI was observed in Setd1a+/- mice (F(1, 52) = 
19.79, p < .001; Figure 6.6). There was no significant main effect of sex (F(1, 52) = 
0.42, p = .52) or interaction between sex and genotype (F(1, 52) = 2.37, p = .13). 
 
Figure 6.6. Replication of decreased PPI in Setd1a+/- mice. Mean (+/- SEM) PPI 
of the ASR at 120 dB (above background) by an 8 and 16 dB (above background) 
prepulse; *** p < .001. 
6.3.2.2. Drug challenge 
6.3.2.2.1 Haloperidol  
Analysis of the ASR data revealed that Setd1a+/- mice showed an elevated startle 
response (F(1, 25) = 14.01, p = .001; Figure 6.7). This effect was maintained at all 
doses tested (genotype x dose interaction: F(2, 50) = 1.72, p = .19). The main effect 
of dose was not significant (F(2, 50) = 3.17, p = .05). There was no significant effect 
of sex (F(1, 25) = 3.83, p = .06) and no significant sex x genotype interaction (F(1, 
25) = 0.02, p = .90). There was also no significant 3 way interaction between dose, 
sex and genotype (F(2, 50) = 1.22, p = .29), suggesting equivalent drug effects across 
genotypes in both sexes.  
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Figure 6.7. Effect of haloperidol on ASR in Setd1a+/- and WT mice. Mean (+/- 
SEM) ASR at 120 dB (above background) following IP administration of vehicle, 0.5 
or 1.0 mg/kg haloperidol, presented separately for males and females. 
Analysis of the PPI data revealed a significant main effect of genotype (F(1, 25) = 
21.92, p < .001; Figure 6.8). However, this effect was qualified by a significant 
interaction between genotype and sex (F(1, 25) = 9.16, p = .01). Post hoc tests 
revealed that the effect of genotype was significant in females (p < .001) but not in 
males (p = .28). In addition, WT females showed greater PPI than WT males (p = .02) 
but there was no significant sex difference in Setd1a+/- mice (p = .08). The main effect 
of dose was not significant (F(2, 50) = 3.08, p = .06) but indicated a trend for a dose-
related increase in PPI. There was also no significant interaction between dose and 
genotype (F(2, 50) = 0.02, p = .98) or between dose, genotype and sex (F(2, 50) = 
1.20, p = .31), indicating that the non-significant enhancement of PPI occurred in all 
groups and did not reflect a reversal of PPI deficits in Setd1a+/- mice by haloperidol. 
V 0.5 1.0 V 0.5 1.0 V 0.5 1.0 V 0.5 1.0
93 
 
Figure 6.8. Effect of haloperidol on PPI in Setd1a+/- and WT mice. Mean (+/- SEM) 
PPI of the ASR at 120 dB (above background) pooled across 8 and 16 (dB above 
background) prepulses following IP administration of vehicle, 0.5 or 1.0 mg/kg 
haloperidol, presented separately for males and females. 
6.3.2.2.2 Risperidone 
Analysis of the weight-adjusted ASR data revealed that startle magnitude was 
significantly higher in Setd1a+/- mice (F(1, 23) = 63.38, p < .001; Figure 6.9). There 
was no significant effect of sex (F(1, 23) = 2.82, p = .11) and no significant sex x 
genotype interaction (F(1, 23) = 1.41, p = .25). A significant main effect of dose was 
observed (F(2, 46) = 25.25, p < .001) but this effect was qualified by a significant 
three-way interaction with sex and genotype (F(2, 46) = 5.51, p = .01). In males, 
simple main effects analyses revealed that the main effect of dose (F(2, 22) = 7.32, p 
= .004) was qualified by a significant dose x genotype interaction (F(2, 22) = 6.26, p 
= .01). Post-hoc tests showed that startle magnitude was dose dependently reduced 
in WT males (relative to vehicle: p = .05 at 0.5 mg/kg and p = .01 at 1.0 mg/kg) but 
not in Setd1a+/- males (relative to vehicle: p = .62 at 0.5 mg/kg and p = .42 at 1.0 
mg/kg). Conversely, in females there was a significant main effect of dose (F(2, 24) 
= 23.10, p < .001) but no significant dose x genotype interaction (F(2, 24) = 1.32 p = 
.29), indicating an equivalent risperidone-induced reduction in startle magnitude in 
female WT and Setd1a+/- mice (relative to vehicle: p = .002 at 0.5 mg/kg and p < .001 
at 1.0 mg/kg). These findings suggest an insensitivity to risperidone in Setd1a+/- males 
but not females. 
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Figure 6.9. Effect of risperidone on ASR in Setd1a+/- and WT mice. Mean (+/- 
SEM) ASR at 120 dB (above background) following IP administration of vehicle, 0.5 
or 1.0 mg/kg risperidone, presented separately for males and females; *** p < .001, 
** p < .01. 
Analysis of the PPI data revealed that Setd1a+/- mice showed significantly less PPI 
than WTs (F(1, 23) = 6.36, p = .02 Figure 6.10). There was no main effect of sex (F(1, 
23) = 0.13, p = .73) and the effect of genotype was consistent for males and females 
(sex x genotype: F(1, 23) = 0.24, p = .63). The main effect of dose was not significant 
(F(2, 46) = 2.71, p = .08) and there was no significant interaction between dose and 
genotype (F(2, 46) = 1.38, p = .26). Although the genotype effect in females appeared 
to be normalised at 1.0 mg/kg (Figure 6.10), there was no significant 3-way interaction 
between dose, genotype and sex (F(2, 46) = 0.50, p = .61). In addition, a paired 
samples t-test performed on data from female Setd1a+/- mice revealed that PPI at 1.0 
mg/kg was not significantly different from vehicle (t(5) = 1.56, p = .18). Thus, this 
apparent normalisation is probably due to greater variability in this group at the high 
dose. These results show that risperidone did not reverse PPI deficits in Setd1a+/- 
mice. 
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Figure 6.10. Effect of risperidone on PPI in Setd1a+/- and WT mice. Mean (+/- 
SEM) PPI of the ASR at 120 dB (above background) pooled across 8 and 16 (dB 
above background) prepulses following IP administration of vehicle, 0.5 or 1.0 mg/kg 
risperidone, presented separately for males and females. 
6.4. Discussion 
This chapter examined whether PPI deficits in Setd1a+/- mice are reversed by 
haloperidol or risperidone. First, the effects of Setd1a haploinsufficiency on 
sensorimotor gating (i.e., increased startle magnitude and reduced PPI) described in 
Chapter 5.3.4 were replicated in a separate cohort under basal conditions. However, 
genotype effects on PPI were more pronounced in females than males in the drug 
challenge experiment. Neither haloperidol nor risperidone were able to rescue PPI 
deficits at dosages that had effects on WT sensorimotor gating in pilot work. 
Unexpectedly, a sexually dimorphic effect of risperidone on startle magnitude was 
observed, whereby Setd1a+/- males (but not females) showed an insensitivity to the 
startle-reducing effect of the drug. 
Both haloperidol and risperidone have previously been shown to reverse PPI deficits 
in several rodent models of schizophrenia (Geyer et al., 2001; Swerdlow et al., 2008). 
Therefore, the inability to enhance PPI in Setd1a+/- mice is not due to a general 
insensitivity of PPI to these drugs. Rather, it suggests that the neurobiological 
changes that cause deficient PPI in Setd1a+/- mice are not appropriately targeted by 
haloperidol or risperidone. It is possible that a particular combination of receptor 
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binding and/or targeting additional receptor types may be necessary. For example, it 
would be interesting to test the efficacy of olanzapine, quetiapine, or clozapine. These 
atypical antipsychotics have mixed receptor-binding profiles with varying affinities for 
additional receptors (i.e., muscarinic acetylcholine M1 and histaminergic H1 
receptors) that are not bound by haloperidol or risperidone at therapeutic doses 
(Miyamoto et al., 2005). In addition, putative antipsychotics could be tested in the 
Setd1a+/- model. For example, co-agonists of the glycine site on the NMDA receptor, 
such as glycine (Le Pen et al., 2003) and D-serine (Kanahara et al., 2008), and the 
DAO inhibitor sodium benzoate (Matsuura, Fujita, Iyo, & Hashimoto, 2015) have been 
reported to reverse PPI deficits in other rodent models of schizophrenia. Interestingly, 
a recent study has shown that inhibition of the histone demethylase LSD1 with either 
tranylcypromine (TCP) or ORY-1001 rescues the effects of Setd1a haploinsufficiency 
on aberrant axon-branching in vitro and working memory deficits in vivo (Mukai et al., 
2019). Future work should test whether LSD1 inhibition is also effective for improving 
sensorimotor gating impairments in Setd1a+/- mice. 
Despite the inability of haloperidol or risperidone to modify PPI deficits in Setd1a+/- 
mice, an interesting dissociation was observed in their effects on the startle response. 
Specifically, the magnitude of startle response was dose-dependently reduced by 
risperidone in all groups except for Setd1a+/- males. Conversely, all groups responded 
equally to haloperidol. Since risperidone binds preferentially to 5-HT2A receptors 
(Miyamoto et al., 2005), this finding may suggest that, in males, Setd1a 
haploinsufficiency causes abnormal 5-HT2A receptor functioning. Indeed, reduced 
expression of 5-HT2A receptors has been reported in schizophrenia patients (Burnet 
et al., 1996; Harrison, 1999c). However, risperidone also has moderate to high affinity 
for several other receptors (i.e., D2, D3, 5-HT2C, 5-HT7, and alpha-1 and alpha-2 
adrenergic receptors), and D2 receptor occupancy is increased at higher doses 
(Kusumi et al., 2015). Thus, further work is needed to determine the extent to which 
this effect is caused by 5-HT2A receptor dysfunction, such as examining 5-HT2A 
receptor gene expression levels in the brain and testing propensity for head-twitch 
responses following administration of 2,5-Dimethoxy-4-iodoamphetamine (DOI), 
which is known to depend on 5-HT2A receptor activation (Willins & Meltzer, 1997). 
Nevertheless, it is interesting to note that sexually dimorphic effects of Setd1a loss of 
function on placental gene expression were also observed in males but not females 
(see Chapter 4). 
Although PPI deficits in Setd1a+/- mice were replicated in the pre-test session, the 
genotype effect on PPI was not sustained in males allocated to the haloperidol drug 
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challenge. This is likely due to reduced statistical power in combination with the fact 
that male WTs showed a low level of PPI. Indeed, PPI in WT males was significantly 
lower than WT females, whereas Setd1a+/- males showed a similar level of PPI to 
Setd1a+/- females. Therefore, the “low-gating” WT males may have masked a 
genotype effect in males in the haloperidol group. An alternative possibility is that the 
effects of Setd1a haploinsufficiency on PPI are stronger in females. Interestingly, 
evidence from humans suggests that PPI is more impaired in females with 
schizophrenia than males (Swerdlow et al., 2014). While this cannot be ruled out, it 
is unlikely to be the case here since no significant sex differences in the effect of 
Setd1a on PPI were observed at baseline or in a larger sample (Chapter 5.3.4). 
In conclusion, PPI deficits in Setd1a+/- mice were not rescued by haloperidol or 
risperidone, two established antipsychotics that have both been used successfully in 
previous preclinical studies. Further work is needed to assess the efficacy of other 
established and putative antipsychotic compounds. Unexpectedly, male (but not 
female) Setd1a+/- mice showed an insensitivity to the inhibitory effects of risperidone 
on the ASR. This indicates sexually dimorphic effects of Setd1a haploinsufficiency on 
brain function, potentially implicating abnormal 5-HT2A receptor functioning.  
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Chapter 7: Isolating the contribution of Setd1a haploinsufficiency in the 
nervous system to behavioural phenotypes using a conditional Setd1a KO 
mouse model 
7.1. Introduction 
The aim of this chapter was to generate and characterise a conditional knockout 
mouse model of Setd1a haploinsufficiency confined to the (central and peripheral) 
nervous system. This work was conducted to examine the extent to which behavioural 
consequences of Setd1a loss of function have their origin in effects solely on the 
nervous system. 
Conditional mutagenesis involves spatially and/or temporally restricted genetic 
modification (Gavériaux-Ruff & Kieffer, 2007). This approach enables investigation of 
the nervous system function of genes that are widely expressed in several tissues, 
whereby constitutive inactivation is associated with deficits arising in multiple systems 
(Deussing, 2013). Constitutive Setd1a haploinsufficiency has been reported to cause 
immune and metabolic phenotypes by the IMPC, including decreased leukocyte and 
B cell number, increased CD8+ T cell number, decreased circulating (HDL and LDL) 
cholesterol levels, decreased total body fat, and decreased circulating alkaline 
phosphatase and alanine transaminase levels. It is possible that these phenotypes 
could exert effects on behaviour that are independent of the nervous system role of 
Setd1a. Therefore, it is necessary to constrain Setd1a loss of function to the nervous 
system to isolate the biological mechanisms underlying behavioural phenotypes. 
The Cre/LoxP system is the most widely used tool for creating conditional knockout 
mouse models (Lewandoski, 2001). Cre recombinase is an enzyme that catalyses 
DNA recombination between two LoxP sites (Heldt, 2009). A Cre driver line that 
expresses Cre recombinase under the control of a promoter known to be expressed 
in the target cell types is crossed with a line in which the critical exon of the gene of 
interest is 'floxed' (i.e., flanked by LoxP sites). This results in excision or inversion of 
the floxed exon only in cells that express Cre recombinase, leading to tissue-specific 
disruption of gene function.  
Several Cre lines are available that drive recombination in the nervous system, many 
of which result in brain region or cell-type specific recombination (Morozov, 
Kellendonk, Simpson, & Tronche, 2003). Nestin-Cre mice were chosen to create the 
Setd1a conditional knockout line because this driver results in widespread loss of 
function in neuronal and glial progenitors throughout the developing brain. These 
mice express Cre recombinase in neural stem cells under the control of the rat Nestin 
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promoter and nervous system-specific enhancer (Tronche et al., 1999). 
Recombination occurs from E11.5, which coincides with the peak Setd1a expression 
levels reported in Chapter 3. Therefore, effects of Setd1a loss of function on 
neurodevelopmental processes that have downstream effects on later brain function 
should be recapitulated in this model. 
Findings from Chapter 5 revealed that constitutive Setd1a haploinsufficiency causes 
increased anxiety in the open field test (OFT) and altered sensorimotor gating 
(elevated acoustic startle response (ASR) and reduced prepulse inhibition (PPI)), with 
normal locomotor activity levels, motoric function, and object recognition memory. 
The aim of this chapter was to explore the extent to which these behavioural effects 
are caused by Setd1a loss of function in the nervous system. To this end, conditional 
KO mice were subjected to an identical behavioural testing pipeline to enable 
comparison with results from the constitutive KO model.  
7.2. Methods 
7.2.1. Generation of the model 
Heterozygous Setd1a floxed mice were crossed with a hemizygous B6.Cg-Tg(Nes-
cre)1Kln/J line (referred to as 'Nes-Cre'), purchased from The Jackson Laboratory. 
This generated mixed litters comprising conditional KO (referred to as ‘cKO’) mice 
and three littermate control groups (WT, Nes-cre and floxed). These were included in 
all experiments to assess potential confounding effects of other constructs involved 
in generating the cKO mouse line (i.e., Cre transgene and LoxP sites). 
To establish that Setd1a knockdown was achieved in the cKO model, Setd1a mRNA 
and SETD1A protein levels were assessed in whole brain tissue using RT-qPCR (N 
= 5 per group) and Western blot (N = 4 per group), respectively. To demonstrate that 
Setd1a knockdown was specific to the nervous system, a PCR for the deleted Setd1a 
allele (see Chapter 2.2.2) was performed on DNA extracted from several brain 
regions (frontal cortex, hippocampus, striatum, midbrain, and cerebellum) and other 
non-nervous system tissue (testis, kidney, liver, heart, lung, pancreas, thymus, large 
intestine, muscle, and spleen) in adulthood (approximately 7 months old). 
7.2.2. Animals  
77 adult mice (45 male and 32 female) were included in behavioural experiments 
(Table 7.1). Behavioural testing started when the animals were 8 weeks old and was 
conducted in the order described in Chapter 2.3 (i.e., EPM, OFT, locomotor activity, 
sensorimotor gating, rotarod, and novel object recognition). 
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Table 7.1. Genotype and sex information for mice included in behavioural 
experiments. 
 
cKO WT Nes-Cre Floxed Total 
Male 15 11 11 8 45 
Female 7 7 10 8 32 
Total  22 18 21 16 77 
 
7.2.3. Data analysis 
RT-qPCR and Western blot data were prepared for analysis as described in Chapter 
2. ΔCT values (RT-qPCR) and normalised fluorescence (Western blot) were analysed 
using a one-way ANOVA with genotype as the between-subjects factor, followed by 
Dunnett post-hoc tests to compare all groups with WT. 
Multivariate ANOVAs were used to analyse data from the EPM and OFT. One female 
WT mouse was identified as a multivariate outlier in the OFT (Mahalanobis distance 
p < .001) and was excluded from the analysis. The four dependent variables included 
in each analysis were: distance moved, proportion of time spent in anxiogenic 
regions, latency of first entry into anxiogenic regions (log transformed to remove 
positive skew), and number of entries into anxiogenic regions. Where a significant 
multivariate result was observed, separate between-subjects ANOVAs were 
conducted for each dependent variable. Dunnett post-hoc tests were conducted for 
significant main effects of genotype to identify which genotypes were significantly 
different from WT. 
Locomotor activity data were analysed by a mixed ANOVA with day (3 levels) and 
quartile (4 levels) as within-subjects factors and genotype and sex as between-
subjects factors. Greenhouse-Geisser corrected results are reported due to violations 
of sphericity, indicated by a significant Mauchly's test. Significant interactions were 
followed up with simple main effects analyses and Bonferroni corrected post-hoc 
tests.  
Weight-adjusted ASR data were analysed using a mixed ANOVA with pulse 
amplitude (80 dB, 90 dB, 100 dB, 110 dB, and 120 dB) as a within-subjects factor and 
genotype and sex as between-subjects factors. PPI data were analysed using a 
mixed ANOVA with prepulse amplitude (4 dB, 8 dB, and 16 dB) as a within-subjects 
factor and genotype and sex as between-subjects factors. Greenhouse-Geisser 
corrected results are reported where violations of sphericity occurred. 
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To assess motor learning in the Rotarod performance test, the latency to fall data 
from the five accelerating runs were analysed with a mixed ANOVA with run (5 levels) 
as a within-subjects factor and genotype and sex as between-subjects factors. Motor 
coordination was assessed by calculating the average latency to fall at each fixed 
speed for each mouse. These data were analysed using a mixed ANOVA with speed 
(10 levels) as a within-subjects factor and genotype and sex as between-subjects 
factors. Greenhouse-Geisser corrected results are reported due to violations of 
sphericity. Bonferroni-corrected pairwise comparisons were conducted to examine 
significant interactions.  
Data from the NOR test were analysed using a mixed ANOVA with delay (30 minutes 
vs. 24 hours) as a within-subjects factor and genotype and sex as between-subjects 
factors. 
7.3. Results 
7.3.1. Model validation 
A significant main effect of genotype on Setd1a mRNA expression in E13.5 brain 
tissue was observed (F(3, 16) = 3.78, p = .03; Figure 7.1A). Dunnett’s post-hoc tests 
showed that expression levels of Setd1a were reduced by approximately 30 % in cKO 
brain relative to WT (p = .04). As expected, Setd1a expression levels in Nes-cre and 
floxed groups were similar to WT (both p > .99), suggesting intact Setd1a expression 
in these control groups. Analysis of the Western blot data showed that while the main 
effect of genotype was not statistically significant (F(3, 12) = 1.03, p = .41), a 30 % 
reduction was also observed for Setd1a protein levels in cKO mice (Figure 7.1B). This 
demonstrates that Setd1a expression levels were reduced in E13.5 brain tissue. 
However, the magnitude of reduction achieved was less than the 50 % reduction that 
would be predicted to occur due to haploinsufficiency. 
Figure 7.1C shows an example PCR for the deleted Setd1a allele performed on 
several brain regions and other non-nervous system tissues. As was expected, the 
deleted allele (174 bp) was only present in brain tissue. Only the floxed allele (259 
bp) was observed in all other non-nervous system tissues. This shows that Setd1a 
haploinsufficiency was specific to the nervous system. However, the floxed allele was 
also observed in all brain regions, indicating the presence of residual non-recombined 
floxed allele in some cells. 
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Figure 7.1. Confirmation of brain-specific knockdown of Setd1a in the cKO 
model. Mean (+/- SEM) fold-change in expression of A) Setd1a mRNA and B) 
SETD1A protein abundance relative to WT. C) Example PCR for the deleted (174 bp) 
and floxed (259 bp) alleles in brain and non-nervous system tissue.  
7.3.2. Elevated plus maze 
There was no significant multivariate effect of genotype on indices of anxiety-related 
behaviour (F(12, 174.91) = 1.36, p = .19; Wilk's λ = 0.79; Figure 7.2). A significant 
multivariate main effect of sex was observed (F(4, 66) = 3.21, p = .02; Wilk's λ = 0.84; 
Table 7.2). Follow-up analysis revealed that males took significantly longer than 
females to enter one of the open arms (F(1, 69) = 11.10, p = .001). There were no 
significant sex differences observed for distance moved (p = .23), proportion of time 
spent on the open arm (p = .27), or number of entries into the open arm (p = .11). 
There was also no significant interaction between genotype and sex (F(12, 174.91) = 
0.94, p = .51; Wilk's λ = 0.85). 
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Figure 7.2. Effects of conditional knockdown of Setd1a on anxiety-related 
behaviour in the EPM. Mean (+/- SEM) A) distance moved, B) number of open arm 
entries, C) proportion of time on open arms, and D) log latency of first entry into an 
open arm. 
Table 7.2. Mean (SD) indices of anxiety-related behaviour in the EPM in males and 
females pooled across genotypes. 
Dependent variable Males Females 
Distance moved (cm) 1232.6 (287.3) 1304.5 (253.1) 
Number of entries into open arms 17.5 (7.5) 20.3 (9.5) 
Proportion of time spent on open arms (%) 26.8 (16.2) 30.1 (15.3) 
Log latency of first entry into open arm 1.2 (0.3) 1.0 (0.2) 
 
7.3.3. Open field test 
There was a significant multivariate main effect of genotype on anxiety-related 
behaviour in the OFT (F(12, 172.27) = 2.15, p = .01; Wilk's λ = 0.68). Follow-up 
ANOVAs revealed a significant main effect of genotype for distance travelled (F(3,68) 
= 4.21, p = .01; Figure 7.3A), number of entries into the inner zone (F(3,68) = 5.64, p 
= .002; Figure 7.3B), proportion of time spent in the inner zone (F(3,68) = 4.46, p = 
.01; Figure 7.3C), and log latency of first entry into the inner zone (F(3,68) = 3.60, p 
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= .02; Figure 7.3D). Dunnett post-hoc tests revealed Setd1a cKO mice displayed 
increased anxiety-related behaviour relative to WTs, indicated by a significant 
reduction in distance moved (p = .046), making significantly fewer entries into the 
inner zone (p = .046), and spending significantly less time in the inner zone (p = .04). 
However, there was no significant difference in log latency of first entry into the inner 
zone (p = .48). In addition, Nes-Cre mice showed a similar pattern of elevated anxiety 
related behaviour, evidenced by a significant reduction in overall distance travelled (p 
= .02), significantly fewer entries into the inner zone (p = .01), a significantly lower 
proportion of time in the inner zone (p = .01) and a significantly longer latency of first 
entry into the inner zone (p = .03). There were no significant differences between WT 
and floxed animals for any of the measures of anxiety (all p > .09). 
 
Figure 7.3. Effects of conditional knockdown of Setd1a on anxiety-related 
behaviour in the OFT. Mean (+/- SEM) A) distance moved, B) number of inner zone 
entries, C) proportion of time in inner zone, D) and log latency of first entry into inner 
zone; **p < .01, * p < .05. 
There was also a significant multivariate main effect of sex on anxiety-related 
behaviour in the OFT (F(4, 65) = 3.38, p = .01; Wilk's λ = 0.83; Table 7.3). Follow-up 
testing revealed that males travelled significantly less distance (F(1, 68) = 6.46, p = 
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.013), made significantly fewer entries (F(1, 68) = 12.91, p = .001) and spent 
significantly less time (F(1, 68) = 7.99, p = .01) in the inner zone relative to females. 
However, there was no significant sex difference in log latency of first entry into the 
inner zone (F(1, 68) = 0.02, p = .90). In addition, there was no significant multivariate 
interaction between sex and genotype (F(12, 172.27) = 1.04, p = .16; Wilk's λ = 0.83).  
Table 7.3. Mean (SD) indices of anxiety-related behaviour in the OFT in males and 
females, pooled across genotypes. 
Dependent variable Males Females 
Distance moved (cm) 4270.3 (1017.6) 4839.0 (1263.4) 
Number of entries into inner zone 20.6 (7.6) 26.9 (11.5) 
Proportion of time spent in inner zone (%) 10.3 (5.3) 13.3 (5.6) 
Log latency of first entry into inner zone 1.2 (0.7) 1.2 (0.6) 
7.3.4. Locomotor activity 
There was no significant effect of genotype on number of beam breaks (F(3, 69) = 
1.08, p = .36), suggesting that overall activity levels were equivalent across groups 
(Figure 7.4). Activity levels of females were significantly greater than males (F(1, 69) 
= 13.90, p < .001; Table 7.4). However, there was no significant interaction between 
sex and genotype (F(3, 69) = 1.85, p = .15).  
Table 7.4. Mean (SD) total beam breaks for each day in males and females, pooled 
across genotypes. 
Number of beam breaks Males Females 
Day 1 1952.6 (813.3) 2716.2 (1298.0) 
Day 2 1506.9 (852.2) 2467.0 (1587.7) 
Day 3 1281.4 (811.2) 2404.7 (1627.9) 
 
A significant main effect of day was observed (F(1.81, 125.13) = 27.68, p < .001), 
which was qualified by a significant interaction between day and genotype (F(5.44, 
125.13) = 2.91, p = .01; Figure 7.4A). Simple main effects analyses revealed a 
significant effect of day for WTs (F(2, 68) = 15.56, p < .001) and floxed mice (F(2, 68) 
=  6.91, p = .002), indicating the expected reduction in activity levels across the test 
days as the animals habituated to the testing environment. However, there was no 
significant effect of day for Setd1a cKOs (F(2, 68) = 1.56, p = .22) or Nes-Cre mice 
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(F(2, 68) = 1.91, p = .16), suggesting that these groups did not habituate to the testing 
environment across consecutive test days.  
 
Figure 7.4. Effects of conditional knockdown of Setd1a on locomotor activity 
levels. Mean (+/- SEM) beam breaks A) for each day, summed across a whole 
session and B) for each quartile, pooled across sessions; *** p < .001, ** p < .01. 
A significant main effect of quartile was observed (F(2.01, 138.42) = 92.56, p < .001), 
which was also qualified by a significant interaction with genotype (F(6.02, 138.42) = 
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2.41, p = .03; Figure 7.4B). Simple main effects analyses revealed a significant effect 
of quartile for all four groups (all p < .001). Post-hoc pairwise comparisons revealed 
that all four groups made significantly fewer beam breaks in the second quartile 
relative to the first quartile (all p < .001). However, while there was a significant 
reduction in activity levels between the second and third quartile for WTs (p = .002) 
and floxed mice (p = .009), no significant difference was observed in Setd1a cKOs (p 
= .44) or Nes-Cre mice (p = .57). No further significant decline in activity levels 
between the third and fourth quartile was observed in any of the groups (all p > .36). 
This suggests that habituation of activity levels within a test session was also blunted 
in Setd1a cKO and Nes-Cre mice.  
7.3.5. Sensorimotor gating 
Analysis of the weight-adjusted ASR data revealed a significant main effect of pulse 
amplitude (F(1.54, 106.02) = 186.68, p < .001; Figure 7.5), indicating that startle 
magnitude was greater on trials with a louder pulse stimulus. However, there was no 
significant effect of genotype (F(3, 69) = 0.61, p = .61). There was also no significant 
effect of sex (F(1, 69) = 1.28, p = .26) or interaction between sex and genotype (F(3, 
69) = 1.24, p = .30). 
 
Figure 7.5. Effect of conditional knockdown of Setd1a on ASR. Mean (+/- SEM) 
weight-adjusted ASR at 80-120 dB (above background).  
Analysis of the PPI data revealed that louder prepulse stimuli elicited significantly 
greater PPI (F(2, 138) = 278.37, p < .001; Figure 7.5B). However, there was no 
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significant main effect of genotype on the magnitude of PPI (F(3, 69) = 2.25, p = .09). 
There was no significant main effect of sex (F(1, 69) = 1.24, p = .27) or interaction 
between sex and genotype (F(3, 69) = 0.38, p = .77). 
 
Figure 7.6. Effect of conditional knockdown of Setd1a on PPI of the ASR. Mean 
(+/- SEM) PPI by a 4, 8, and 16 dB (above background) prepulse. 
7.3.6. Rotarod performance test 
Analysis of the latency to fall on accelerating trials revealed a significant main effect 
of run (F(3.09, 213.3) = 24.42, p < .001; Figure 7.7A), indicating that the latency to 
fall was significantly increased by training. There was no significant main effect of 
genotype (F(3, 69) = 1.23, p = .31) or sex (F(1, 69) = 0.10,  p = .75). A significant 
interaction was observed between genotype and sex (F(3, 69) = 3.13, p = .03). Post-
hoc tests revealed that no genotype pairwise comparisons within each sex were 
significantly different from WT (all p > .41). However, across trials, the latency to fall 
was significantly longer in female cKOs (mean = 155.7, SEM = 12.80) compared with 
male cKOs (mean = 211.43, SEM = 18.71; p = .02). No significant sex differences 
were observed for the other genotypes (data not shown; all p > .10). Importantly, there 
were no significant interactions between run and genotype (F(9.27, 213.31) = 0.74, p 
= .68), run and sex (F(3.09, 213.31) = 0.99, p = .40), and no three-way interaction 
between run, sex, and genotype (F(9.27, 213.31) = 0.70, p = .71) indicating equivalent 
motor learning across groups.  
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Figure 7.7. Effect of conditional Setd1a knockdown on motoric function in the 
Rotarod test. Mean (+/- SEM) latency to fall A) on accelerating trials (5-50 rpm at 
0.15 rpm/s) and B) at fixed speeds increasing in 5 rpm increments from 5-50 rpm. 
Analysis of the latency to fall on fixed-speed trials revealed latency to fall was 
significantly shorter at higher speeds (F(4.12, 284.23) = 110.82, p < .001; Figure 
7.7B). There was no significant main effect of genotype (F(3, 69) = 1.38, p = .26) or 
sex (F(1, 69) = 0.001, p = .97). However, a significant three-way interaction between 
speed, sex, and genotype was observed (F(12.36, 284.23) = 1.86, p = .04). Post-hoc 
analysis revealed that no genotype pairwise comparisons within each sex were 
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significantly different from WT (all p > .13), indicating equivalent motor coordination 
across genotypes. Sex differences were observed at some speeds but no consistent 
pattern was observed across genotypes (Table 7.5).  
Table 7.5. Mean (SD) latency to fall (s) on fixed-speed Rotarod trials for each 
genotype, stratified by sex.  
 WT cKO Nes-cre Floxed 
 Male Female Male Female Male Female Male Female 
Latency to 
fall at 5 
rpm (s) 
119.82 
(0.60) 
120.0 
(0.00) 
120.0 
(0.00) 
120.0 
(0.00) 
120.0 
(0.00) 
116.20 
(12.17) 
120.0 
(0.00) 
120.0 
(0.00) 
Latency to 
fall at 10 
rpm (s) 
115.95 
(13.41) 
119.29 
(1.89) 
118.43 
(4.22) 
120.0 
(0.00) 
120.0 
(0.00) 
119.95 
(0.16) 
120.0 
(0.00) 
120.0 
(0.00) 
Latency to 
fall at 15 
rpm (s) 
117.91 
(6.93) 
114.14 
(15.49) 
118.53 
(3.01) 
120.0 
(0.00) 
111.55 
(15.40) 
117.90 
(6.64) 
120.0 
(0.00) 
117.81 
(4.92) 
Latency to 
fall at 20 
rpm (s) 
112.41 
(13.02) 
113.00 
(13.15) 
102.07 
(18.47) 
116.57 
(9.07) 
114.72 
(13.40) 
116.20 
(12.02) 
115.56 
(10.18) 
120.00 
(0.00) 
Latency to 
fall at 25 
rpm (s) 
109.63 
(23.07) 
97.50 
(24.77) 
92.57 
(29.59) 
120.0 
(0.00) 
107.86 
(25.17) 
116.65 
(6.99) 
107.81 
(24.80) 
111.94 
(17.83) 
Latency to 
fall at 30 
rpm (s) 
84.32 
(36.76) 
116.21 
(7.86) 
75.20 
(37.30) 
111.71 
(14.98) 
93.50 
(32.73) 
92.55 
(28.71) 
107.94 
(30.28) 
80.63 
(28.97) 
Latency to 
fall at 35 
rpm (s) 
78.45 
(34.72) 
92.79 
(22.23) 
63.97 
(39.53) 
89.64 
(30.21) 
82.68 
(30.92) 
82.15 
(36.99) 
102.75 
(30.34) 
56.56 
(19.00) 
Latency to 
fall at 40 
rpm (s) 
62.68 
(36.22) 
69.79 
(28.69) 
53.10 
(42.81) 
63.86 
(27.12) 
64.68 
(33.58) 
76.05 
(37.50) 
86.94 
(28.77) 
57.38 
(21.96) 
Latency to 
fall at 45 
rpm (s) 
58.64 
(45.53) 
53.71 
(44.72) 
42.50 
(41.07) 
34.71 
(19.40) 
48.45 
(35.15) 
48.80 
(28.94) 
81.38 
(25.04) 
60.94 
(39.69) 
Latency to 
fall at 50 
rpm (s) 
62.41 
(42.41) 
68.00 
(34.75) 
29.43 
(26.87) 
34.00 
(33.66) 
59.32 
(52.96) 
38.50 
(16.80) 
89.56 
(26.55) 
52.63 
(35.72) 
Emboldened cells show significant sex difference (Bonferroni-corrected p < .05). 
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7.3.7. Novel object recognition 
Analysis of the acquisition data revealed no effect of genotype on the time taken to 
achieve 40 seconds of object exploration (F(3, 69) = 0.72, p = .54; Table 7.6). Table 
7.6 also shows raw object exploration times at test. Analysis of the discrimination 
ratios revealed a significant main effect of delay (F(1, 69) = 4.57, p = .04; Figure 7.8), 
indicating better object recognition memory at 30 minutes compared to 24 hours. 
There was no significant effect of genotype (F(3, 69) = 0.92, p = .44) and no significant 
interaction between genotype and delay (F(3, 69) = 0.20, p = .89). There was also no 
significant effect of sex (F(1, 69) = 0.05, p = .82) and no significant interaction between 
sex and genotype (F(3, 69) = 0.22, p = .88). 
Table 7.6. Mean (SD) acquisition time and object exploration at test for the 30 minute 
and 24 hour retention intervals. 
 30 mins 24 hours 
Dependent 
variable 
WT cKO Nes-cre Floxed WT cKO Nes-cre Floxed 
Acquisition 
time (mins) 
8.89 
(3.87) 
7.50 
(3.71) 
9.64 
(4.40) 
8.38 
(3.58) 
7.06 
(2.94) 
8.30 
(3.83) 
8.86 
(3.75) 
8.13 
(3.45) 
Novel object 
exploration 
time (s) 
20.58 
(9.99)  
17.18 
(9.32) 
14.65 
(7.87) 
18.40 
(9.91) 
6.53 
(3.84) 
8.81 
(4.97) 
9.41 
(5.50) 
7.97 
(4.86) 
Familiar 
object 
exploration 
time (s) 
9.31 
(2.12) 
8.71 
(3.38) 
7.60 
(4.58) 
9.62 
(5.99) 
4.08 
(2.52) 
6.75 
(3.17) 
5.70 
(2.92) 
6.08 
(3.61) 
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Figure 7.8. Effect of conditional Setd1a knockdown on object recognition 
memory. Mean (+/- SEM) discrimination ratios (%) after a 30 minute and 24 hour 
retention interval. Dotted line shows chance performance. 
7.4. Discussion 
This chapter investigated the extent to which increased anxiety-related behaviour in 
the OFT and aberrant sensorimotor gating (increased ASR and reduced PPI) 
identified in constitutive Setd1a KO mice is due to effects of Setd1a loss of function 
in the nervous system. Consistent with the results reported in Chapter 6, mice with 
conditional Setd1a loss of function constrained to the nervous system under a Nestin-
Cre promoter showed; i) an increased anxiety phenotype in the OFT despite no 
difference in anxiety-related behaviour in the EPM, ii) normal motor coordination and 
motor learning, and iii) intact object recognition memory. In contrast to the constitutive 
KO, there were no significant effects on ASR or PPI. In addition, an impairment in 
habituation of activity levels in a novel environment was observed in conditional KOs, 
a finding that was not observed in constitutive KOs.  
It is important to note that Nestin-Cre control mice also showed evidence of increased 
anxiety in the OFT and impaired habituation of activity levels in a novel environment. 
Since the conditional KO mice also carry the Nestin-Cre transgene, it is possible that 
this transgene may have exerted confounding effects on behaviour in the conditional 
KO mice. Although this possibility cannot be conclusively eliminated, this is unlikely 
to be the case for the anxiety phenotype because convergent findings are observed 
in the constitutive KO line that does not carry a Cre transgene. In contrast, impaired 
habituation was not observed in the constitutive KO mice, which may suggest that the 
habituation impairments observed in conditional KO mice are attributable to the 
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Nestin-Cre transgene. Future studies could investigate whether the observed effects 
are due to Setd1a loss of function using alternative Cre drivers, such as the BAF53b-
cre line which results in neuron-specific recombination (Zhan et al., 2015). 
The present findings underline the importance of including a Cre control group for 
behavioural phenotyping of conditional KO mice using the Cre/LoxP system (Harno, 
Cottrell, & White, 2013). A previous study has reported that Nestin-Cre mice display 
a mild increase in anxiety-related behaviour on the EPM but not in the OFT (Giusti et 
al., 2014). It is possible that differences in the experimental set-up and background 
strain may explain the differing results of the present experiments, whereby increased 
anxiety was observed in the OFT but not the EPM. Nevertheless, the present findings 
are consistent with a subtle anxiety phenotype in Nestin-Cre mice that should be 
considered when interpreting behavioural experiments using this Cre driver. 
Moreover, the observation of impaired habituation to a novel environment in Nestin-
Cre mice in the present experiments may contribute to previously reported deficits in 
contextual-conditioning of fear (Giusti et al., 2014) and could suggest some mild 
spatial learning impairments. These behavioural alterations may be, in part, due to 
excitotoxic effects of Cre recombinase (Naiche & Papaioannou, 2007) leading to 
compromised neurodevelopment (Forni et al., 2006) and/or the presence of human 
growth hormone minigene in the Nestin-Cre transgene (Declercq et al., 2015).  
In contrast to constitutive Setd1a KO mice, conditional KO mice did not show 
evidence of an increased ASR and the effects on PPI were not statistically significant. 
There are several explanations for these discrepant findings. First, the absence of 
significant effects on PPI may be due to a lack of statistical power due to the inclusion 
of additional control groups. Consistent with this, relative to WTs, conditional KO mice 
showed a non-significant reduction in PPI at all prepulse amplitudes. Another 
possibility is that Setd1a expression levels were not sufficiently reduced in the 
conditional KO model. In the constitutive KO, the deleted Setd1a allele is inherited, 
causing a 50 % reduction in Setd1a expression from conception. In the conditional 
KO, recombination of the floxed allele commences at E11.5 (Tronche et al., 1999), 
which means that neurodevelopmental processes prior to this will not be affected by 
Setd1a loss of function. In addition, only a 30 % reduction in Setd1a expression was 
observed in E13.5 brain tissue. This is less than would be expected to occur as a 
result of haploinsufficiency and may be because recombination using a Nestin-Cre 
driver has been reported to only occur in post-mitotic neurons (Liang, Hippenmeyer, 
& Ghashghaei, 2012). Another possibility is that the effects of Setd1a loss of function 
on sensorimotor gating are not directly mediated by effects in the brain; rather, they 
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could be indirect consequences of effects in other tissues that contribute to 
neurodevelopment and/or adult brain function (see General Discussion).  
In this chapter, a conditional KO mouse model of Setd1a has been generated and 
subjected to an extensive behavioural characterisation to investigate behavioural 
consequences of Setd1a haploinsufficiency in the nervous system. Consistent with 
results of the constitutive KO described in Chapter 5, conditional KO mice displayed 
elevated anxiety-related behaviour in the OFT and no differences in motoric function 
or object recognition memory. In contrast to the constitutive KO, no significant effects 
on sensorimotor gating were observed in the conditional KO. In addition, confounding 
effects of Cre recombinase on behaviour were identified (i.e., increased anxiety in the 
OFT and reduced habituation in a novel environment). This highlights the importance 
of adequately designed experiments in conditional KO studies to prevent erroneous 
interpretation.  
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Chapter 8: General Discussion 
8.1. Overview 
Translating genetic findings into mechanistic insights regarding neuropsychiatric 
disorder pathogenesis remains a major challenge for neuroscience. Exome 
sequencing studies are beginning to identify highly damaging loss of function (LoF) 
variants in protein-coding genes that are promising candidates for disease modelling. 
In particular, LoF variants in the Setd1a gene were the first rare variants to be 
identified for schizophrenia (Singh et al., 2016; Takata et al., 2014). This thesis aimed 
to investigate the functional consequences of Setd1a haploinsufficiency using a 
mouse model to recapitulate the predicted effects of LoF variants on gene function in 
human carriers. The primary aims and key findings from each experimental chapter 
are summarised in Table 8.1. 
8.2. Setd1a haploinsufficiency causes neuropsychiatric endophenotypes that 
cannot be rescued by antipsychotic treatments 
In depth behavioural phenotyping of the constitutive Setd1a+/- model (Chapter 5) 
revealed behavioural effects that resemble specific endophenotypes of schizophrenia 
and neurodevelopmental disorders, rather than a general impairment of functioning. 
Specifically, Setd1a+/- mice displayed increased anxiety-related behaviour in the OFT 
but not in the EPM. The reasons for these inconsistent findings are unclear but may 
be because the EPM was not as aversive as the OFT, reflected by high levels of open 
arm exploration in the EPM. Nevertheless, Setd1a+/- mice also displayed an 
exaggerated ASR, providing to an extent convergent evidence for an increased 
anxiety phenotype. Moreover, PPI of the ASR was markedly reduced in Setd1a+/- 
mice, a robust endophenotype of schizophrenia and neurodevelopmental disorders 
(Swerdlow et al., 2006; Swerdlow et al., 2018). There were no effects of Setd1a 
haploinsufficiency on locomotor activity levels, motoric functioning, or object 
recognition memory. These findings provide the first evidence that Setd1a 
haploinsufficiency causes heightened emotional reactivity and abnormal 
sensorimotor gating in a model system.  
The effects of Setd1a haploinsufficiency on sensorimotor gating were replicated in a 
separate cohort (Chapter 6) and could not be rescued by haloperidol (primarily 
selective for the D2 receptor) or risperidone (high 5-HT2A receptor affinity). Both 
antipsychotics have previously been shown to improve PPI deficits in 
pharmacological and transgenic models (Geyer et al., 2001; Swerdlow et al., 2008). 
These findings demonstrate that the neurobiological mechanisms of deficient PPI in 
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Setd1a+/- mice are not corrected by haloperidol or risperidone. Further work is needed 
to establish the pathophysiological mechanisms underlying the effects of Setd1a 
haploinsufficiency on sensorimotor gating impairments. This would inform future 
pharmacological studies investigating the effects of other validated antipsychotics 
with different pharmacological profiles (e.g., clozapine, quetiapine, and olanzapine) 
and putative antipsychotics, such as DAO inhibitors which have the potential to 
normalise NMDA receptor function (Verrall et al., 2010). Another possibility includes 
treatment with histone demethylase inhibitors (TCP and ORY-1001) that have 
recently been shown to improve working memory deficits in Setd1a+/- mice (Mukai et 
al., 2019).
  
 
Table 8.1. Primary aims and key findings from each experimental chapter, associated limitations, and suggestions for future work. 
Aims Key findings Limitations Future work 
Assess transcriptomic 
effects of Setd1a 
haploinsufficiency in the 
developing mouse brain 
 Peak Setd1a expression in embryonic 
brain 
 Modest changes in gene expression:  267 
differentially expressed genes with fold 
changes -0.67 – 1.19 
 Significantly enriched for mitochondrion 
and nominal enrichment for cilium 
 No enrichment for schizophrenia common 
variant association 
 Whole brain may have 
masked subtle region- and 
cell-type specific effects 
 Lack of power to detect 
sexually dimorphic effects 
 Assess enrichment for 
CNVs associated with 
schizophrenia and 
neurodevelopmental 
disorders 
 Single-cell RNA-seq to 
assess cell-type specific 
effects across 
development 
Investigate effects of 
Setd1a loss of function on 
placental phenotypes and 
growth curves 
 8.9 % reduction in placental weight but no 
effect on foetal weight at E13.5 
 Sexually dimorphic changes in placental 
gene expression in males but not females 
 Reduced body weight at maternal 
separation (P28) in males but not females 
 No histological 
assessment of placental 
morphological changes 
 Lack of assessment of 
foetal weight later in 
gestation, birth weight, 
and early postnatal growth 
 Developmental 
assessment of pup and 
placental weights 
 Histology to confirm 
morphological changes 
 Assessment of placental 
transport and endocrine 
functions 
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Aims Key findings Limitations Future work 
Perform behavioural 
characterisation of 
Setd1a+/- mice 
 Increased anxiety in OFT but not EPM 
 Increased ASR and decreased PPI 
 No effects on locomotor activity, motoric 
function, or novel object recognition 
 Inconsistent findings from 
EPM and OFT 
 Limited assessment of 
cognitive function 
 Assess other measures of 
anxiety (e.g., elevated zero 
maze and light-dark box) 
 Cognitive testing of 
associative memory and 
attentional processing 
(e.g., 5-choice serial 
reaction time task) 
Rescue PPI impairments 
in Setd1a+/- mice using 
antipsychotics and 
investigate neurochemical 
changes 
 Neither haloperidol nor risperidone 
rescued deficient PPI 
 Males (but not females) showed 
insensitivity to startle-inhibiting effects of 
risperidone, suggesting 5-HT2A receptor 
dysfunction 
 Lack of genotype effect in 
males allocated to 
haloperidol challenge, 
possibly due to small 
sample size 
 Replicate findings in larger 
sample 
 Assess expression of 5-
HT2A receptor in the brain 
 Test effects of other 
validated and putative 
antipsychotics 
Isolate contribution of 
effects of Setd1a LoF in 
the nervous system to 
behavioural phenotypes 
using a conditional KO 
 Increased anxiety in OFT but not EPM 
 No effect on ASR and non-significant 
reduction in PPI 
 Impaired habituation to a novel 
environment 
 Confounding effects of 
Nestin-cre 
 Only 30 % reduction in 
Setd1a dosage at E13.5 
 Inducible and/or brain-
region specific conditional 
knockout 
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8.3. Potential mechanisms underlying pathogenic effects of Setd1a 
haploinsufficiency 
8.3.1. Disrupted transcriptome of the developing brain 
H3K4 methylation is essential for transcriptional regulation during neurodevelopment 
(Roidl & Hacker, 2014). Previous studies have shown that Setd1a plays an important 
role in regulating embryonic neurogenesis (Bledau et al., 2014; Li & Jiao, 2017; Qiao 
et al., 2018). On this basis, Setd1a LoF could perturb neurodevelopment with 
downstream consequences for adult brain function. Consistent with this, intellectual 
disability is common in Setd1a LoF carriers (Singh et al., 2016), potentially indicating 
a general effect on neurodevelopmental robustness, although an increased burden 
of LoF variants is also observed in individuals with schizophrenia who do not have 
intellectual disability (Singh et al., 2017).  
Despite the aforementioned evidence implicating a role for Setd1a in the developing 
brain, pathway analysis of transcriptomic changes occurring in E13.5 Setd1a+/- brain 
did not strongly implicate effects on neurodevelopment (Chapter 3). There was 
nominally significant enrichment for cilium-related annotations but the only GO term 
to survive correction for multiple testing was the mitochondrion. This finding is 
consistent with previous studies (Cameron et al., 2019; Hoshii et al., 2018) and 
mitochondrial dysfunction has been implicated in schizophrenia pathogenesis (Ben-
Shachar, 2017; Flippo & Strack, 2017; Rajasekaran et al., 2015). Nevertheless, the 
extent to which this reflects a primary cause or downstream consequence of Setd1a 
haploinsufficiency remains to be tested. One possibility is that this enrichment is a 
surrogate marker of increased cellular stress during neurodevelopment but the 
precise biological mechanisms and associated functional consequences for the 
developing brain are unclear.  
Gene-set enrichment analysis revealed that the genes that were differentially 
expressed in Setd1a+/- E13.5 brain were not enriched for schizophrenia common 
variant association. This was surprising given previous work showing enrichment in 
a human cell line (Cameron et al., 2019). Other work has shown that although Setd1a 
target genes identified by Chip-seq are enriched for schizophrenia common variants, 
only 10 % of these genes are differentially expressed in adult mouse prefrontal cortex 
(Mukai et al., 2019). Common variants for schizophrenia are dynamically expressed 
during neurodevelopment, with high expression in foetal brain (Birnbaum et al., 2015; 
Clifton et al., 2019; Jaffe et al., 2018). Moreover, functional genomics approaches 
strongly implicate convergence of common variant risk on foetal brain development 
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(de la Torre-Ubieta et al., 2018; Hannon et al., 2016; Li et al., 2018; O’Brien et al., 
2018; Pidsley et al., 2014; Won et al., 2016) and an enrichment for particular brain 
cell-types (Skene et al., 2018). Further work is needed to investigate the degree of 
molecular convergence between Setd1a haploinsufficiency and other genetic variants 
for schizophrenia and neurodevelopmental disorders at different stages of 
development and consideration of potential cell-type and brain region specific effects. 
8.3.2. Prenatal programming by the placenta: preliminary evidence for sexually 
dimorphic effects of Setd1a haploinsufficiency 
Several lines of evidence converge on the placenta as contributing to 
neuropsychiatric disorder pathogenesis (Bronson & Bale, 2016; Jansson & Powell, 
2007; Sandovici et al., 2012). In particular, common variant genetic risk for 
schizophrenia is, in part, mediated by effects on the placenta (Ursini et al., 2018). 
These findings raise the possibility that rare variants, such as Setd1a, may also exert 
pathogenic effects via the placenta (Chapter 4). Consistent with this hypothesis, 
placentas of Setd1a+/- mice were found to be 8.9 % lighter than WT placentas at 
E13.5. This reduction in placental weight is suggestive of placental insufficiency 
during prenatal development. Prenatal programming by placental dysfunction has 
been shown to have long-lasting effects on offspring neurobehavioural outcomes 
(Mikaelsson et al., 2013). Further work is needed to investigate the effects of Setd1a 
haploinsufficiency on placental function (e.g., nutrient transfer and endocrine 
signalling) to determine mechanisms by which it may influence prenatal brain 
development. 
Notably, the effects of Setd1a haploinsufficiency on placental gene expression were 
moderated by foetal sex. That is, expression of markers of the spongiotrophoblast 
(Prl8a8 and to a lesser extent Prl3b1) (Simmons et al., 2008) were reduced in 
Setd1a+/- male but not female placenta. Moreover, male Setd1a+/- placenta showed 
reduced expression of Ctsq, a marker of (channel and sinusoidal) TGCs lining the 
maternal vasculature (Gasperowicz et al., 2013; Simmons et al., 2007). These 
findings may indicate morphological changes in the spongiotrophoblast and TGC 
lineages in male Setd1a+/- placenta, with effects on endocrine signalling and placental 
transfer, respectively. Similarly, Setd1a haploinsufficiency was also associated with 
reduced expression of the imprinted gene Peg3 (and non-significant reductions in 
Phlda2 and Igf2) in male but not female placenta. These findings are the first 
demonstration of effects of Setd1a on placental expression of imprinted genes, which 
are known to play essential roles in placental function (John, 2017). More generally, 
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they provide novel insights into potential sexually dimorphic mechanisms by which 
Setd1a LoF increases risk for psychopathology. This notion is consistent with recent 
evidence implicating sex differences in genetic pathways underlying schizophrenia 
risk (Tiihonen et al., 2019). 
Table 8.2. Summary of sexually dimorphic effects of Setd1a haploinsufficiency. 
Measures Males Females 
Placental Prl8a8 expression ↓ ↔ 
Placental Ctsq expression ↓ ↔ 
Placental Peg3 expression ↓ ↔ 
Postnatal weight ↓ ↔ 
Effect of risperidone on ASR ↓ ↔ 
 
Sexual dimorphism was also observed in the effects of Setd1a haploinsufficiency in 
postnatal life (Table 8.2). Specifically, while no differences were observed in foetal 
weight at E13.5, male (but not female) Setd1a+/- mice were significantly smaller at 
maternal separation (Chapter 4). Although there are several potential explanations 
for this finding (including placental programming, direct effects on pup development, 
and effects on maternal interactions), all are consistent with sexually dimorphic effects 
of Setd1a haploinsufficiency. Moreover, the effects of risperidone on the ASR 
dissociated between Setd1a+/- males and females, whereby males showed 
insensitivity to its startle-inhibiting effects (Chapter 6), potentially indicating 5-HT2A 
receptor dysfunction. This hypothesis is consistent with observations of decreased 5-
HT2A receptor expression in post-mortem brains of schizophrenia patients (Burnet et 
al., 1996; Eastwood et al., 2001; Harrison, 1999c). It is also worth mentioning that the 
placenta expresses several 5-HT receptor subtypes and is a source of serotonin 
influencing prenatal brain development (Bonnin et al., 2011). Although the effects of 
Setd1a expression on 5-HT2A receptor dysfunction in the brain require confirmation, 
it may also be informative in future work to assess the effects of Setd1a 
haploinsufficiency on the placental serotonin system. 
8.3.3. Nervous system specific mechanisms 
To explore the contribution of nervous system specific effects of Setd1a 
haploinsufficiency to behavioural phenotypes, a heterozygous conditional KO was 
created using a Nestin-Cre driver (Chapter 7). While the constitutive KO model more 
closely resembles the consequences of LoF mutations in human carriers, the 
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conditional KO was used as an experimental tool to examine the direct effects of 
Setd1a haploinsufficiency on the brain. This was necessary to eliminate potentially 
confounding effects of Setd1a haploinsufficiency on metabolic and immune 
phenotypes previously reported by the IMPC and effects on the placenta described 
earlier (section 8.4.2). Some convergence was observed in the behavioural effects of 
nervous system specific Setd1a LoF (Table 8.3). Consistent with the constitutive LoF 
model, increased anxiety was observed in the OFT but not the EPM and there were 
no effects on motoric function or object recognition memory. Conversely, the 
increased ASR observed in the constitutive LoF model was not recapitulated by 
conditional Setd1a knockdown. Although the conditional LoF model exhibited 
reduced PPI, this effect was not statistically significant. Moreover, the conditional LoF 
model had an additional impairment in habituation of locomotor activity, which was 
likely due to the confounding effect of Cre recombinase. Similarly, the Nestin-Cre 
control group also displayed increased anxiety in the OFT and (non-significantly) 
impaired PPI, which complicates interpretation of these results. 
Table 8.3. Summary of behavioural phenotypes in the constitutive and conditional 
heterozygous Setd1a knockout models. 
Behaviour Test 
Constitutive 
KO 
Conditional 
KO 
Anxiety-related 
behaviour 
EPM ↔ ↔ 
OFT ↑ ↑* 
Motoric function 
Basal locomotor activity levels ↔ ↔ 
Rotarod ↔ ↔ 
Sensorimotor 
gating 
ASR ↑ ↔ 
PPI ↓ NS ↓* 
Learning and 
memory 
Habituation of activity levels ↔ ↓* 
NOR ↔ ↔ 
*Confounded by Nestin-Cre control group 
The convergent findings between the constitutive and conditional models regarding 
increased anxiety and decreased PPI (albeit non-significant in the conditional model) 
suggest that these findings are likely due to effects of Setd1a LoF in the nervous 
system. Nevertheless, the confounding effect of Nestin-Cre should be highlighted as 
an important caveat to this interpretation. Moreover, the effect on PPI was not 
statistically significant in the conditional model, which may be attributable to a lack of 
statistical power or because only a 30 % reduction in Setd1a dosage was achieved 
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in this model. Conversely, the dissociation in effects on ASR, which was increased in 
the constitutive model whereas no effect was observed in the conditional model, 
suggest that this effect may be due to Setd1a LoF in other systems with indirect 
effects on the brain. One possibility includes perturbed brain development via the 
placenta. In addition, constitutive Setd1a LoF causes reduced circulating LDL 
cholesterol, a major component of myelin, potentially leading to white matter 
abnormalities which are known to be widespread in schizophrenia and other 
neurodevelopmental disorders (Fields, 2008). Increased CD8+ T cell number and 
decreased leukocyte and B cell number have also been reported in Setd1a+/- mice, 
which may be relevant given recent evidence supporting a role for the immune system 
in schizophrenia pathogenesis (Carter, Bullmore, & Harrison, 2014; Network and 
Pathway Analysis Subgroup of Psychiatric Genomics Consortium, 2015; Sekar et al., 
2016). Although speculative, it is biologically plausible that these peripheral effects of 
Setd1a could play a role in pathogenic mechanisms since constitutive LoF occurs in 
human carriers. 
The Nestin-Cre driver used to generate the heterozygous conditional Setd1a 
knockout results in recombination from E11.5 in the mouse brain (Tronche et al., 
1999). Therefore, the observed effects on behaviour could either be attributable to 
effects on neurodevelopment and/or adult brain function. Indeed, reinstatement of 
Setd1a expression in adult Setd1a+/- mice results in a partial reversal of working 
memory deficits (Mukai et al., 2019). This suggests that the residual impairment may 
be attributable to neurodevelopmental effects of Setd1a LoF. It would be informative 
to explore whether similar findings are observed for heightened emotional reactivity 
and impairments of sensorimotor gating, as this would shed light on underlying 
pathogenic mechanisms. 
8.3.4. Summary 
The findings presented in this thesis implicate diverse mechanisms that could underlie 
neuropsychiatric endophenotypes associated with Setd1a haploinsufficiency, ranging 
from effects on the placenta to transcriptomic changes in the developing brain and 5-
HT2A receptor dysfunction in the adult brain. While the precise contributions of these 
effects to the emergence of psychopathology remains unclear, they serve as a 
starting point for further investigations to be undertaken in the context of the working 
model outlined in Figure 8.1. 
 
 126 
 
 
Figure 8.1. Working model of pathogenic mechanisms underlying effects of 
Setd1a haploinsufficiency. A) Setd1a LoF has direct effects on brain development 
via transcriptional dysregulation during neurodevelopment with downstream 
consequences for adult brain function. B) Indirect effects on brain development due 
to effects on placental function, potentially leading to sexually dimorphic placental 
programming of neurobehavioural outcomes. C) Setd1a haploinsufficiency disrupts 
adult brain function due to aberrant H3K4 methylation, which contributes to synaptic 
plasticity and learning and memory. 
8.4. Limitations 
Specific limitations have been acknowledged and discussed throughout this thesis 
and are summarised in Table 8.1. More generally, a potential limitation of the work 
presented herein is that the models used were intercrosses of two C57BL/6 
substrains. This was necessary because founder animals harbouring the floxed 
Setd1a allele were generated in C57BL/6NTac mouse ESCs by EUCOMM, whereas 
commercially available Cre driver lines were produced on the C57BL/6J substrain. 
Phenotypic and genomic differences have been reported between these two 
substrains, albeit to a considerably lesser degree than between mice from entirely 
different strains (Simon et al., 2013; Vanden Berghe et al., 2015). To address this, 
littermate controls were used in all experiments to ensure that the relative contribution 
of each genetic background was equal in Setd1a knockouts and controls. However, 
residual heterozygosity at other loci may have introduced additional variability. 
Despite this, robust genotype effects were observed for several phenotypes. Another 
potential concern is the possibility of passenger mutations flanking the Setd1a gene 
that are co-inherited with the knockout allele. The closest identified variant to Setd1a 
is approximately 500 kb upstream (occurring in the Zp2 gene, which is not known to 
have neurobehavioural effects) and all other variants are at least 1.5 Mb from Setd1a 
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(Vanden Berghe, 2015; Simon, 2013). While the probability of passenger mutations 
over this genomic distance is unlikely, it may be necessary to conduct sequencing in 
order to conclusively rule out this possibility. 
It is important to note that the main aim of this thesis was to investigate the functional 
consequences of Setd1a haploinsufficiency to identify pathogenic mechanisms that 
might contribute to the association between Setd1a LoF and risk for psychopathology. 
This haploinsufficiency models the predicted effects of the heterozygous LoF 
mutations on gene function observed in human carriers (Singh et al., 2016). 
Nevertheless, a potential limitation of this approach is that the model used does not 
reflect the precise risk variant(s) observed in people (i.e., exon 4 is deleted in the 
mouse model, leading to haploinsufficiency via nonsense-mediated decay, whereas 
LoF mutations in human carriers are distributed throughout the SETD1A gene). It has 
been proposed that such ‘humanised’ genetic mouse models provide greater 
construct validity for interrogating pathogenic mechanisms of genetic risk for 
neuropsychiatric disorders (Harrison et al., 2012). Considering this, it would be 
interesting in future work to generate a model of the recurrent two-base pair deletion 
at the exon 16 splice acceptor site, which was observed in 7 out of 16 carriers by 
Singh et al. (2016). 
8.5. Future directions 
The findings of this thesis provide several avenues for future experiments aimed at 
investigating pathogenic mechanisms associated with Setd1a haploinsufficiency 
(summarised in Table 8.1). The working model outlined in Figure 8.1 has been 
proposed as a preliminary framework for conducting further studies that is by no 
means exhaustive and can be refined as additional pathogenic mechanisms and 
associated neurobehavioural effects are identified. In the first instance, further 
behavioural testing of the Setd1a+/- model is necessary to explore as yet unidentified 
effects of Setd1a haploinsufficiency on other neuropsychiatric endophenotypes, such 
as cognitive function (e.g., 5-choice serial reaction time task, associative learning) 
and hedonics (e.g., lick cluster analysis, progressive ratio task). Such studies would 
serve as the basis for investigating whether dissociable pathogenic mechanisms 
contribute to distinct endophenotypes using conditional knockout approaches that 
target Setd1a LoF to particular cell types at specific stages of development. The 
details of this work would be informed by further interrogation of the direct effects of 
Setd1a LoF in the developing brain (e.g., single-cell RNA-seq across development, 
Figure 8.1A) and the effects of Setd1a LoF on placental function (e.g., placental 
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transport and endocrine signalling, Figure 8.1B). Moreover, an inducible knockout 
system could be used to dissociate the effects of Setd1a LoF on adult brain function 
(Figure 8.1C) from downstream effects of perturbed neurodevelopment. Together, 
these studies would provide a comprehensive understanding of the causal roles of 
pathogenic mechanisms associated with Setd1a haploinsufficiency. 
8.6. Concluding remarks 
Recent advances in understanding the genetic architecture of schizophrenia and 
related neurodevelopmental disorders are providing opportunities to investigate 
pathophysiology with the hope that this may one day lead to more effective 
treatments. Using a model system to recapitulate Setd1a haploinsufficiency, the first 
highly damaging LoF variant to be identified for schizophrenia, this thesis has 
provided novel insights into its role in pathogenesis that warrant further investigation 
to delineate the pathophysiological contributions of Setd1a LoF in the developing 
brain, placenta, and adult brain function. 
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Appendix 1. Differentially expressed genes (Benjamini Hochberg padj < .05) in E13.5 Setd1a+/- brain. 
Ensembl gene ID Entrez gene ID Gene name Gene biotype log2 fold change SE p value padj 
ENSMUSG00000033233 229644 Trim45 Protein coding -0.34921 0.048286 4.76E-13 8.83E-09 
ENSMUSG00000034371 225913 Tkfc Protein coding -0.29257 0.045843 1.75E-10 1.36E-06 
ENSMUSG00000029524 75387 Sirt4 Protein coding -0.36778 0.05842 3.06E-10 1.36E-06 
ENSMUSG00000078867 NA Gm14418 Protein coding 0.888915 0.141821 3.66E-10 1.36E-06 
ENSMUSG00000044475 69090 Ascc1 Protein coding -0.28519 0.045503 3.67E-10 1.36E-06 
ENSMUSG00000024869 NA Gm49405 Protein coding -0.40202 0.064596 4.86E-10 1.42E-06 
ENSMUSG00000097048 72012 1600020E01Rik lncRNA -0.30576 0.049246 5.34E-10 1.42E-06 
ENSMUSG00000022685 74108 Parn Protein coding -0.21464 0.035198 1.07E-09 2.49E-06 
ENSMUSG00000014606 67863 Slc25a11 Protein coding -0.19498 0.03301 3.49E-09 7.20E-06 
ENSMUSG00000034032 68925 Rpap1 Protein coding -0.23763 0.040532 4.56E-09 7.71E-06 
ENSMUSG00000024871 60425 Doc2g Protein coding -0.44336 0.075631 4.57E-09 7.71E-06 
ENSMUSG00000007777 66050 0610009B22Rik Protein coding -0.31995 0.05478 5.20E-09 8.05E-06 
ENSMUSG00000039048 235169 Foxred1 Protein coding -0.30068 0.05166 5.87E-09 8.39E-06 
ENSMUSG00000013622 381629 Atraid Protein coding -0.26682 0.04627 8.09E-09 1.06E-05 
ENSMUSG00000059540 21400 Tcea2 Protein coding -0.31618 0.054924 8.57E-09 1.06E-05 
ENSMUSG00000073096 243371 Lrrc61 Protein coding -0.40306 0.071239 1.53E-08 1.78E-05 
ENSMUSG00000078864 626802 Gm14322 Protein coding 0.692545 0.122871 1.74E-08 1.84E-05 
ENSMUSG00000025188 192236 Hps1 Protein coding -0.30295 0.053796 1.79E-08 1.84E-05 
ENSMUSG00000037363 270035 Letm2 Protein coding -0.34534 0.06152 1.98E-08 1.94E-05 
ENSMUSG00000041881 66416 Ndufa7 Protein coding -0.16476 0.029509 2.36E-08 2.19E-05 
ENSMUSG00000025142 68938 Aspscr1 Protein coding -0.16641 0.030017 2.96E-08 2.61E-05 
ENSMUSG00000052369 380967 Tmem106c Protein coding -0.29373 0.053938 5.16E-08 4.35E-05 
ENSMUSG00000045211 213484 Nudt18 Protein coding -0.38152 0.070713 6.84E-08 5.52E-05 
ENSMUSG00000048920 243853 Fkrp Protein coding -0.25413 0.047172 7.15E-08 5.53E-05 
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Ensembl gene ID Entrez gene ID Gene name Gene biotype log2 fold change SE p value padj 
ENSMUSG00000039795 66361 Zfand1 Protein coding -0.21884 0.041165 1.06E-07 7.86E-05 
ENSMUSG00000042404 229541 Dennd4b Protein coding -0.21019 0.039593 1.10E-07 7.88E-05 
ENSMUSG00000003423 68845 Pih1d1 Protein coding -0.1898 0.03592 1.26E-07 8.52E-05 
ENSMUSG00000018554 53422 Ybx2 Protein coding -0.30843 0.058405 1.29E-07 8.52E-05 
ENSMUSG00000007783 78070 Cpt1c Protein coding -0.1701 0.032363 1.47E-07 9.43E-05 
ENSMUSG00000028158 17777 Mttp Protein coding -0.34283 0.065566 1.71E-07 0.000104 
ENSMUSG00000027259 75894 Adal Protein coding -0.29732 0.056944 1.78E-07 0.000104 
ENSMUSG00000030301 67015 Ccdc91 Protein coding -0.28969 0.055546 1.84E-07 0.000104 
ENSMUSG00000002910 70807 Arrdc2 Protein coding -0.42196 0.080919 1.84E-07 0.000104 
ENSMUSG00000001100 67811 Poldip2 Protein coding -0.14768 0.028424 2.04E-07 0.000111 
ENSMUSG00000035595 69770 1600002K03Rik Protein coding -0.62757 0.121327 2.31E-07 0.000122 
ENSMUSG00000027737 26570 Slc7a11 Protein coding 0.562082 0.110346 3.51E-07 0.000181 
ENSMUSG00000109274 NA Gm45133 TEC -0.26569 0.052398 3.97E-07 0.000199 
ENSMUSG00000033021 69080 Gmppa Protein coding -0.22587 0.044654 4.23E-07 0.000207 
ENSMUSG00000026792 227738 Lrsam1 Protein coding -0.25453 0.05075 5.29E-07 0.000252 
ENSMUSG00000028047 21827 Thbs3 Protein coding -0.16946 0.03389 5.73E-07 0.000266 
ENSMUSG00000018570 70419 2810408A11Rik Protein coding -0.44198 0.089262 7.36E-07 0.000333 
ENSMUSG00000032952 67489 Ap4b1 Protein coding -0.24184 0.049047 8.19E-07 0.000362 
ENSMUSG00000068264 69596 Ap5s1 Protein coding -0.32959 0.066939 8.49E-07 0.000366 
ENSMUSG00000026356 226414 Dars Protein coding -0.1531 0.031143 8.83E-07 0.000373 
ENSMUSG00000017188 52469 Coa3 Protein coding -0.19849 0.040498 9.52E-07 0.000393 
ENSMUSG00000022339 55960 Ebag9 Protein coding -0.30065 0.061424 9.85E-07 0.000397 
ENSMUSG00000016940 70382 Kctd2 Protein coding -0.20458 0.042126 1.20E-06 0.000472 
ENSMUSG00000022828 74197 Gtf2e1 Protein coding -0.18528 0.038362 1.37E-06 0.000529 
ENSMUSG00000042632 53357 Pla2g6 Protein coding -0.3047 0.063312 1.49E-06 0.000564 
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ENSMUSG00000047921 76510 Trappc9 Protein coding -0.15541 0.032329 1.53E-06 0.000569 
ENSMUSG00000002781 70209 Tmem143 Protein coding -0.34756 0.072579 1.68E-06 0.000609 
ENSMUSG00000116138 223665 C030006K11Rik Protein coding -0.36807 0.076916 1.71E-06 0.000609 
ENSMUSG00000034757 72053 Tmub2 Protein coding -0.17567 0.036761 1.76E-06 0.000617 
ENSMUSG00000097287 NA D130017N08Rik lncRNA -0.33992 0.071196 1.80E-06 0.00062 
ENSMUSG00000046463 NA 5930403N24Rik lncRNA 0.279275 0.059386 2.57E-06 0.000861 
ENSMUSG00000039246 226791 Lyplal1 Protein coding -0.37695 0.080194 2.60E-06 0.000861 
ENSMUSG00000028085 229487 Gatb Protein coding -0.25471 0.054254 2.67E-06 0.000869 
ENSMUSG00000078866 628308 Zfp970 Protein coding 0.381367 0.08134 2.75E-06 0.000881 
ENSMUSG00000042642 319945 Flad1 Protein coding -0.23795 0.051193 3.35E-06 0.001049 
ENSMUSG00000051007 213350 Gatd1 Protein coding -0.31046 0.06683 3.39E-06 0.001049 
ENSMUSG00000105053 NA Gm43064 Protein coding -0.24188 0.052163 3.54E-06 0.00106 
ENSMUSG00000003308 50868 Keap1 Protein coding -0.16419 0.035412 3.54E-06 0.00106 
ENSMUSG00000002280 67563 Narfl Protein coding -0.23162 0.050033 3.67E-06 0.00106 
ENSMUSG00000053111 66930 Fank1 Protein coding -0.58497 0.126541 3.79E-06 0.00106 
ENSMUSG00000031641 234309 Cbr4 Protein coding -0.2725 0.058961 3.81E-06 0.00106 
ENSMUSG00000034121 380718 Mks1 Protein coding -0.27606 0.059734 3.81E-06 0.00106 
ENSMUSG00000073684 67513 Faap20 Protein coding -0.20789 0.044991 3.82E-06 0.00106 
ENSMUSG00000021913 239017 Ogdhl Protein coding -0.28956 0.062749 3.94E-06 0.001075 
ENSMUSG00000094786 NA Gm14403 Protein coding 0.837328 0.182417 4.43E-06 0.001191 
ENSMUSG00000078656 28084 Vps25 Protein coding -0.19941 0.04356 4.70E-06 0.001246 
ENSMUSG00000033111 218734 3830406C13Rik Protein coding -0.27783 0.060801 4.89E-06 0.001278 
ENSMUSG00000031158 21855 Timm17b Protein coding -0.18384 0.040267 4.98E-06 0.00128 
ENSMUSG00000020287 268395 Mpg Protein coding -0.24293 0.053236 5.03E-06 0.00128 
ENSMUSG00000051154 12238 Commd3 Protein coding -0.18249 0.040233 5.73E-06 0.001425 
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ENSMUSG00000011382 71755 Dhdh Protein coding -0.35505 0.078288 5.76E-06 0.001425 
ENSMUSG00000027281 74243 Slx4ip Protein coding -0.4188 0.092754 6.33E-06 0.001535 
ENSMUSG00000105345 NA BC030343 lncRNA -0.51934 0.115054 6.37E-06 0.001535 
ENSMUSG00000045039 269878 Megf8 Protein coding -0.16501 0.03666 6.76E-06 0.001608 
ENSMUSG00000019864 170728 Rtn4ip1 Protein coding -0.24567 0.054671 7.01E-06 0.001646 
ENSMUSG00000006850 71983 Tmco6 Protein coding -0.30185 0.067788 8.47E-06 0.001966 
ENSMUSG00000078877 100039123 Gm14295 Protein coding 0.381522 0.085733 8.58E-06 0.001967 
ENSMUSG00000006010 226499 Odr4 Protein coding -0.2035 0.0458 8.86E-06 0.002006 
ENSMUSG00000009281 71660 Rarres2 Protein coding -0.38378 0.086558 9.26E-06 0.00207 
ENSMUSG00000026709 226539 Dars2 Protein coding -0.29535 0.067053 1.06E-05 0.00234 
ENSMUSG00000021902 71838 Phf7 Protein coding -0.28201 0.06448 1.22E-05 0.002668 
ENSMUSG00000040586 237222 Ofd1 Protein coding -0.17755 0.040871 1.40E-05 0.003018 
ENSMUSG00000032565 75686 Nudt16 Protein coding -0.31388 0.072514 1.50E-05 0.003203 
ENSMUSG00000017286 67201 Glod4 Protein coding -0.13644 0.031557 1.53E-05 0.003235 
ENSMUSG00000061046 68977 Haghl Protein coding -0.25549 0.05919 1.59E-05 0.003297 
ENSMUSG00000007216 243372 Zfp775 Protein coding -0.27751 0.064342 1.61E-05 0.003297 
ENSMUSG00000021792 70564 Prxl2a Protein coding -0.21665 0.050247 1.62E-05 0.003297 
ENSMUSG00000001755 71743 Coasy Protein coding -0.23088 0.053591 1.65E-05 0.003297 
ENSMUSG00000039701 99526 Usp53 Protein coding 0.293955 0.068245 1.65E-05 0.003297 
ENSMUSG00000032067 19286 Pts Protein coding -0.18906 0.044044 1.77E-05 0.003489 
ENSMUSG00000015542 66176 Nat9 Protein coding -0.30798 0.072183 1.98E-05 0.003838 
ENSMUSG00000085615 NA A330035P11Rik lncRNA -0.4127 0.096728 1.99E-05 0.003838 
ENSMUSG00000020289 17168 Nprl3 Protein coding -0.16804 0.039424 2.02E-05 0.003864 
ENSMUSG00000024253 213575 Dync2li1 Protein coding -0.2472 0.058021 2.04E-05 0.003864 
ENSMUSG00000095677 100040531 Dynlt1f Protein coding -0.2102 0.04941 2.10E-05 0.003933 
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ENSMUSG00000013997 27045 Nit1 Protein coding -0.14112 0.033204 2.14E-05 0.003964 
ENSMUSG00000003344 208198 Btbd2 Protein coding -0.15313 0.036112 2.23E-05 0.004104 
ENSMUSG00000021013 76260 Ttc8 Protein coding -0.19918 0.047022 2.28E-05 0.004144 
ENSMUSG00000038838 68915 Vars2 Protein coding -0.17722 0.041876 2.32E-05 0.004174 
ENSMUSG00000059851 232811 Kmt5c Protein coding -0.2241 0.05311 2.45E-05 0.004358 
ENSMUSG00000018669 80280 Cdk5rap3 Protein coding -0.16083 0.038128 2.46E-05 0.004358 
ENSMUSG00000001751 27419 Naglu Protein coding -0.38673 0.09207 2.66E-05 0.004665 
ENSMUSG00000020752 170472 Recql5 Protein coding -0.20338 0.048459 2.70E-05 0.004691 
ENSMUSG00000024666 72982 Tmem138 Protein coding -0.20587 0.049147 2.80E-05 0.004817 
ENSMUSG00000048755 223722 Mcat Protein coding -0.27658 0.066121 2.88E-05 0.004899 
ENSMUSG00000048550 208967 Thnsl1 Protein coding -0.29015 0.069417 2.92E-05 0.004923 
ENSMUSG00000110949 66387 Nudt8 Protein coding -0.31167 0.074852 3.13E-05 0.005234 
ENSMUSG00000078519 NA 2310026L22Rik lncRNA -0.57117 0.137348 3.20E-05 0.005285 
ENSMUSG00000035722 27403 Abca7 Protein coding -0.21145 0.050863 3.22E-05 0.005285 
ENSMUSG00000023939 68463 Mrpl14 Protein coding -0.26355 0.063422 3.25E-05 0.005285 
ENSMUSG00000024958 107173 Gpr137 Protein coding -0.22844 0.055034 3.31E-05 0.005347 
ENSMUSG00000108555 NA Gm18310 TEC -0.29977 0.072255 3.34E-05 0.005348 
ENSMUSG00000018733 103737 Pex12 Protein coding -0.20043 0.04842 3.48E-05 0.005526 
ENSMUSG00000024592 77422 C330018D20Rik Protein coding -0.27096 0.065501 3.52E-05 0.005543 
ENSMUSG00000107040 NA Gm43791 lncRNA -0.21331 0.051628 3.60E-05 0.005617 
ENSMUSG00000016344 66496 Ppdpf Protein coding -0.20984 0.051185 4.14E-05 0.006384 
ENSMUSG00000003731 16650 Kpna6 Protein coding 0.121994 0.029767 4.16E-05 0.006384 
ENSMUSG00000078570 68920 1110065P20Rik Protein coding -0.21352 0.052298 4.45E-05 0.006772 
ENSMUSG00000053870 75540 Fpgt Protein coding -0.19725 0.048339 4.49E-05 0.00678 
ENSMUSG00000020747 71947 Tmem94 Protein coding -0.14658 0.035991 4.65E-05 0.006959 
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ENSMUSG00000024325 19763 Ring1 Protein coding -0.20048 0.049414 4.97E-05 0.007375 
ENSMUSG00000110611 NA Gm20163 lncRNA -0.36493 0.090044 5.06E-05 0.007458 
ENSMUSG00000037773 319513 Pced1a Protein coding -0.14904 0.036873 5.30E-05 0.007748 
ENSMUSG00000046567 68281 4930430F08Rik Protein coding -0.24653 0.061266 5.72E-05 0.0083 
ENSMUSG00000034744 56174 Nagk Protein coding -0.23652 0.058853 5.85E-05 0.008415 
ENSMUSG00000110980 NA Gm47204 lncRNA -0.41824 0.104117 5.89E-05 0.008417 
ENSMUSG00000060380 NA C030014I23Rik lncRNA -0.42397 0.105792 6.13E-05 0.008691 
ENSMUSG00000041936 11603 Agrn Protein coding -0.17229 0.043035 6.24E-05 0.008744 
ENSMUSG00000108461 NA AV356131 lncRNA -0.60935 0.152239 6.27E-05 0.008744 
ENSMUSG00000066829 235050 Zfp810 Protein coding -0.18767 0.04704 6.62E-05 0.009168 
ENSMUSG00000051977 213389 Prdm9 Protein coding -0.31508 0.079112 6.81E-05 0.00937 
ENSMUSG00000043251 277978 Exoc3l Protein coding -0.27556 0.069295 6.99E-05 0.009539 
ENSMUSG00000074158 208111 Zfp976 Protein coding 0.237299 0.059742 7.13E-05 0.009656 
ENSMUSG00000029782 72649 Tmem209 Protein coding -0.22904 0.05793 7.69E-05 0.010347 
ENSMUSG00000021918 23955 Nek4 Protein coding -0.16928 0.042902 7.95E-05 0.010623 
ENSMUSG00000096990 NA Gm26790 lncRNA -0.17106 0.043441 8.22E-05 0.010853 
ENSMUSG00000024959 12015 Bad Protein coding -0.19586 0.049746 8.24E-05 0.010853 
ENSMUSG00000034903 319876 Cobll1 Protein coding 0.264273 0.067209 8.42E-05 0.011006 
ENSMUSG00000087523 NA Gm12319 lncRNA -0.48619 0.123944 8.76E-05 0.011314 
ENSMUSG00000037151 216011 Lrrc20 Protein coding -0.27095 0.069083 8.78E-05 0.011314 
ENSMUSG00000025500 72000 Lmntd2 Protein coding -0.37699 0.096301 9.05E-05 0.011588 
ENSMUSG00000029713 14693 Gnb2 Protein coding -0.16081 0.041208 9.52E-05 0.012059 
ENSMUSG00000048100 99730 Taf13 Protein coding -0.24306 0.062295 9.55E-05 0.012059 
ENSMUSG00000032842 224814 Abcc10 Protein coding -0.19074 0.048912 9.64E-05 0.012069 
ENSMUSG00000030380 109889 Mzf1 Protein coding -0.31017 0.079566 9.69E-05 0.012069 
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ENSMUSG00000046947 57869 Adck2 Protein coding -0.16379 0.042047 9.80E-05 0.01213 
ENSMUSG00000022022 211253 Mtrf1 Protein coding -0.30697 0.07898 0.000102 0.012474 
ENSMUSG00000030649 75430 Anapc15 Protein coding -0.24667 0.063486 0.000102 0.012474 
ENSMUSG00000055660 76781 Mettl4 Protein coding -0.18127 0.046757 0.000106 0.012802 
ENSMUSG00000057181 70591 5730455P16Rik Protein coding -0.17376 0.04483 0.000106 0.012802 
ENSMUSG00000073647 NA Gm10557 Processed pseudogene 0.288825 0.074668 0.00011 0.013136 
ENSMUSG00000054931 544922 Zkscan4 Protein coding -0.31046 0.080693 0.000119 0.0142 
ENSMUSG00000039623 231855 Ap5z1 Protein coding -0.18033 0.046888 0.00012 0.0142 
ENSMUSG00000024799 73166 Tm7sf2 Protein coding -0.17738 0.046196 0.000123 0.014288 
ENSMUSG00000041354 19732 Rgl2 Protein coding -0.15137 0.039436 0.000124 0.014288 
ENSMUSG00000096983 NA 2010015M23Rik lncRNA -0.42533 0.110852 0.000125 0.014288 
ENSMUSG00000022558 223658 Mroh1 Protein coding -0.19825 0.051676 0.000125 0.014288 
ENSMUSG00000031534 102032 Smim19 Protein coding -0.21539 0.056176 0.000126 0.014288 
ENSMUSG00000073609 98314 D2hgdh Protein coding -0.22051 0.057519 0.000126 0.014288 
ENSMUSG00000018405 217038 Mrm1 Protein coding -0.32512 0.084813 0.000126 0.014288 
ENSMUSG00000015013 59005 Trappc2l Protein coding -0.21088 0.05503 0.000127 0.014288 
ENSMUSG00000032579 69536 Hemk1 Protein coding -0.27837 0.072896 0.000134 0.014998 
ENSMUSG00000117055 NA Gm9805 Processed pseudogene 0.716735 0.187948 0.000137 0.015232 
ENSMUSG00000038593 654470 Tctn1 Protein coding -0.1134 0.029763 0.000139 0.015355 
ENSMUSG00000087687 100503890 Pet100 Protein coding -0.26837 0.070603 0.000144 0.015819 
ENSMUSG00000021376 22017 Tpmt Protein coding -0.21988 0.057879 0.000145 0.015871 
ENSMUSG00000074220 233060 Zfp382 Protein coding 0.307904 0.081283 0.000152 0.016481 
ENSMUSG00000019577 27273 Pdk4 Protein coding 0.542745 0.143586 0.000157 0.016796 
ENSMUSG00000033467 57914 Crlf2 Protein coding -0.47617 0.125995 0.000157 0.016796 
ENSMUSG00000024169 106633 Ift140 Protein coding -0.15185 0.040181 0.000157 0.016796 
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ENSMUSG00000033728 223664 Lrrc14 Protein coding -0.21042 0.055907 0.000167 0.017705 
ENSMUSG00000051224 245695 Tceanc Protein coding -0.25192 0.066946 0.000168 0.017705 
ENSMUSG00000027366 66552 Sppl2a Protein coding 0.106947 0.028454 0.000171 0.017922 
ENSMUSG00000055991 22757 Zkscan5 Protein coding -0.16965 0.045171 0.000173 0.018033 
ENSMUSG00000003762 76889 Coq8b Protein coding -0.16852 0.044901 0.000175 0.018111 
ENSMUSG00000023873 66931 1700010I14Rik Protein coding -0.49306 0.131604 0.000179 0.018435 
ENSMUSG00000078878 668030 Gm14305 Protein coding 0.246224 0.065732 0.00018 0.018435 
ENSMUSG00000078878 100043387 Gm14305 Protein coding 0.246224 0.065732 0.00018 0.018435 
ENSMUSG00000020621 105014 Rdh14 Protein coding -0.23661 0.063204 0.000181 0.018502 
ENSMUSG00000006463 70605 Zdhhc24 Protein coding -0.21869 0.058651 0.000193 0.01953 
ENSMUSG00000034667 73192 Xpot Protein coding 0.103968 0.027963 0.000201 0.020248 
ENSMUSG00000074519 626848 Zfp971 Protein coding 0.307206 0.082939 0.000212 0.021294 
ENSMUSG00000110424 75479 1700012D14Rik lncRNA -0.29807 0.080514 0.000214 0.021343 
ENSMUSG00000057729 19152 Prtn3 Protein coding -0.35034 0.094708 0.000216 0.021374 
ENSMUSG00000022940 56176 Pigp Protein coding -0.17073 0.046157 0.000216 0.021374 
ENSMUSG00000043257 230801 Pigv Protein coding -0.256 0.069493 0.00023 0.022572 
ENSMUSG00000007122 12372 Casq1 Protein coding 0.575813 0.156425 0.000232 0.02266 
ENSMUSG00000035048 69010 Anapc13 Protein coding -0.25425 0.069089 0.000233 0.02266 
ENSMUSG00000097718 NA Gm26896 lncRNA -0.27462 0.074734 0.000238 0.023023 
ENSMUSG00000026203 56812 Dnajb2 Protein coding -0.17459 0.047542 0.00024 0.023114 
ENSMUSG00000032657 68521 Fam189b Protein coding -0.28548 0.077967 0.000251 0.02399 
ENSMUSG00000029101 71729 Rgs12 Protein coding -0.16731 0.045757 0.000256 0.024341 
ENSMUSG00000041966 75763 Dcaf17 Protein coding -0.15339 0.042004 0.00026 0.024663 
ENSMUSG00000022472 28075 Desi1 Protein coding -0.13418 0.036762 0.000262 0.024709 
ENSMUSG00000062944 100043133 9130023H24Rik Protein coding -0.17711 0.048541 0.000264 0.024712 
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ENSMUSG00000059142 240041 Zfp945 Protein coding 0.146552 0.040257 0.000272 0.02539 
ENSMUSG00000024319 224705 Vps52 Protein coding -0.14174 0.038963 0.000275 0.025528 
ENSMUSG00000020056 67282 Washc3 Protein coding -0.22261 0.061502 0.000295 0.027251 
ENSMUSG00000034673 18515 Pbx2 Protein coding -0.20887 0.057727 0.000297 0.027256 
ENSMUSG00000015474 54397 Ppt2 Protein coding -0.16003 0.044264 0.0003 0.0274 
ENSMUSG00000051705 71599 Senp8 Protein coding -0.24519 0.067837 0.000301 0.0274 
ENSMUSG00000107336 NA Gm43461 TEC -0.4366 0.120873 0.000304 0.027503 
ENSMUSG00000097439 NA Gm16754 lncRNA -0.19052 0.052822 0.00031 0.02793 
ENSMUSG00000021661 68558 Ankra2 Protein coding -0.25906 0.071854 0.000312 0.027956 
ENSMUSG00000006019 71723 Dhx34 Protein coding -0.19496 0.054105 0.000314 0.028023 
ENSMUSG00000040374 19302 Pex2 Protein coding -0.21951 0.060937 0.000316 0.028023 
ENSMUSG00000035829 241289 Ppp1r26 Protein coding -0.16423 0.045662 0.000322 0.028484 
ENSMUSG00000023923 72238 Tbc1d5 Protein coding -0.18742 0.052195 0.00033 0.029001 
ENSMUSG00000043140 66690 Tmem186 Protein coding -0.17507 0.048944 0.000348 0.030447 
ENSMUSG00000025486 64384 Sirt3 Protein coding -0.19837 0.055627 0.000362 0.031582 
ENSMUSG00000030861 66885 Acadsb Protein coding 0.111857 0.031405 0.000368 0.031882 
ENSMUSG00000038312 108687 Edem2 Protein coding -0.16048 0.045065 0.000369 0.031882 
ENSMUSG00000072772 14790 Grcc10 Protein coding -0.17513 0.04925 0.000377 0.032359 
ENSMUSG00000015468 18132 Notch4 Protein coding -0.19895 0.05618 0.000398 0.03405 
ENSMUSG00000007033 15482 Hspa1l Protein coding -0.30457 0.086218 0.000412 0.035045 
ENSMUSG00000097174 NA Gm4890 lncRNA -0.37506 0.106326 0.00042 0.035568 
ENSMUSG00000007682 13371 Dio2 Protein coding 1.197192 0.339726 0.000425 0.035629 
ENSMUSG00000040795 230767 Iqcc Protein coding -0.16082 0.045655 0.000427 0.035629 
ENSMUSG00000068250 232566 Amn1 Protein coding -0.20026 0.056864 0.000429 0.035629 
ENSMUSG00000002846 76916 Timmdc1 Protein coding -0.17235 0.048947 0.00043 0.035629 
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ENSMUSG00000024579 240334 Pcyox1l Protein coding -0.20715 0.058842 0.000431 0.035629 
ENSMUSG00000098597 102465227 Mir6418 miRNA -0.14987 0.04258 0.000432 0.035629 
ENSMUSG00000019813 103268 Cep57l1 Protein coding -0.21386 0.060866 0.000442 0.036307 
ENSMUSG00000035898 231380 Uba6 Protein coding 0.134961 0.038533 0.000461 0.037497 
ENSMUSG00000031079 245368 Zfp300 Protein coding 0.28019 0.080014 0.000462 0.037497 
ENSMUSG00000039059 99296 Hrh3 Protein coding -0.37335 0.106626 0.000463 0.037497 
ENSMUSG00000028876 230735 Epha10 Protein coding -0.46956 0.134145 0.000465 0.037497 
ENSMUSG00000046603 382117 Tcaim Protein coding -0.23144 0.066296 0.000481 0.038616 
ENSMUSG00000101225 629159 1700008J07Rik lncRNA -0.2734 0.078334 0.000483 0.038616 
ENSMUSG00000048410 240476 Zfp407 Protein coding 0.1936 0.05552 0.000488 0.038694 
ENSMUSG00000004698 79221 Hdac9 Protein coding 0.151772 0.043535 0.00049 0.038694 
ENSMUSG00000068130 668923 Zfp442 Protein coding 0.379337 0.108842 0.000492 0.038694 
ENSMUSG00000074807 NA Gm10762 lncRNA -0.2259 0.064817 0.000492 0.038694 
ENSMUSG00000040771 106821 Oard1 Protein coding -0.2411 0.069403 0.000513 0.039968 
ENSMUSG00000078630 791260 Tomt Protein coding -0.2162 0.062242 0.000514 0.039968 
ENSMUSG00000014850 17686 Msh3 Protein coding 0.127811 0.036801 0.000515 0.039968 
ENSMUSG00000035285 269854 Nat14 Protein coding -0.29898 0.086227 0.000526 0.040537 
ENSMUSG00000111080 100504586 Gm20300 lncRNA -0.28311 0.081658 0.000526 0.040537 
ENSMUSG00000026154 68002 Sdhaf4 Protein coding -0.37553 0.108363 0.000529 0.040607 
ENSMUSG00000015095 30839 Fbxw5 Protein coding -0.13437 0.038806 0.000535 0.040843 
ENSMUSG00000035206 73218 Sppl2b Protein coding -0.16119 0.046683 0.000555 0.042006 
ENSMUSG00000042066 68875 Tmcc2 Protein coding -0.1897 0.054953 0.000556 0.042006 
ENSMUSG00000111977 NA Gm47163 lncRNA -0.29357 0.085047 0.000557 0.042006 
ENSMUSG00000052566 170833 Hook2 Protein coding -0.1902 0.055128 0.00056 0.04211 
ENSMUSG00000040502 216438 March9 Protein coding -0.25584 0.074188 0.000564 0.0422 
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ENSMUSG00000047507 545192 Baiap3 Protein coding -0.2922 0.084942 0.000582 0.04315 
ENSMUSG00000021038 104799 Vipas39 Protein coding -0.11517 0.033484 0.000583 0.04315 
ENSMUSG00000022671 72083 Mzt2 Protein coding -0.2012 0.058501 0.000583 0.04315 
ENSMUSG00000064364 NA mt-Th Mt_tRNA 0.634031 0.184602 0.000593 0.043718 
ENSMUSG00000060261 14886 Gtf2i Protein coding -0.07321 0.021373 0.000614 0.045026 
ENSMUSG00000031755 67378 Bbs2 Protein coding -0.2195 0.064192 0.000628 0.045683 
ENSMUSG00000008855 15184 Hdac5 Protein coding -0.1389 0.040621 0.000628 0.045683 
ENSMUSG00000030811 233902 Fbxl19 Protein coding -0.15385 0.045054 0.000638 0.046282 
ENSMUSG00000002797 110175 Ggct Protein coding 0.296215 0.086824 0.000646 0.046633 
ENSMUSG00000056753 NA C330011M18Rik lncRNA -0.28651 0.084105 0.000658 0.047342 
ENSMUSG00000090290 212728 Tarbp1 Protein coding 0.180664 0.0531 0.000668 0.047808 
ENSMUSG00000021773 69156 Comtd1 Protein coding -0.28442 0.083612 0.00067 0.047808 
ENSMUSG00000112880 100504661 Gm20337 lncRNA -0.579 0.170289 0.000674 0.047906 
ENSMUSG00000022664 74102 Slc35a5 Protein coding -0.22951 0.067575 0.000683 0.048372 
ENSMUSG00000039577 260305 Nphp4 Protein coding -0.16984 0.050052 0.000691 0.048649 
ENSMUSG00000027163 76501 Commd9 Protein coding -0.15681 0.046217 0.000692 0.048649 
ENSMUSG00000033065 18642 Pfkm Protein coding -0.14205 0.041894 0.000697 0.04882 
ENSMUSG00000073415 NA Gm10501 lncRNA -0.2775 0.081929 0.000707 0.049304 
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